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Abstract
Each year 3500 people in Switzerland are diagnosed with colorectal cancer, approximately 51.8
and 34.3 per 100’000 inhabitants for males and females, respectively. Those patients with a
familial risk ie. they have 2 or more first or second degree relatives with colorectal cancer,
account for approximately 20 percent of all affected patients, whereas roughly 5 to 10 percent of
the total annual burden of colorectal cancer is mendelian in nature – that is, it is inherited in an
autosomal dominant manner. This thesis has focused on genotype-phenotype correlations in two
hereditary colorectal cancer syndromes, hereditary nonpolyposis colorectal cancer (HNPCC) and
familial adenomatous polyposis (FAP) in an attempt to optimise the selection criteria for affected
individuals, to establish the sensitivity and specificity of different screening methods, to
investigate a relatively new gene associated with a multiple colorectal adenoma and carcinoma
phenotype and to assess the role of a modifier gene locus on chromosome 1p33-36.
Since only limited data are available which detail the value of the different HNPCC referral
criteria in combination with microsatellite instability (MSI) testing and various mutation
screening methods, 222 unrelated Swiss patients were studied in order to (i) assess the phenotypic
and molecular differences between patients belonging to different referral criteria groups, and (ii)
determine the diagnostic accuracy of the criteria and screening procedures employed in
identifying individuals with mismatch repair (MMR) gene alterations. The Bethesda Guidelines
(BG) proved to be of superior sensitivity and diagnostic accuracy compared to Amsterdam
Criteria I/II (AC I/II) alone, in identifying patients with MMR gene alterations. Based on the
evaluation of the different screening techniques employed in this study, it is suggested that MSI
analysis combined with immunohistochemistry testing and subsequent mutational analysis of the
positively scored individuals encompassing both a DNA and a mRNA-based technique, should be
conducted for optimal rates of mutation detection.
Investigations subsequently continued in attempts to further characterise the phenotype of Swiss
HNPCC patients by comparing 46 MMR gene mutation carriers to 84 gene alteration negative
individuals in order to ultimately aid the identification of HNPCC individuals and MMR gene
mutation carriers. Ninety-four percent of the mutation positive patients were classified by referral
criteria (AC or BG) compared to only 76% of mutation negative individuals. Mutation positive
patients were also younger at the time of their CRC diagnosis, had more often proximally located
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CRCs, a higher prevalence of syn-/metachronous CRCs and more frequently extracolonic
manifestations. Using such phenotypic differences to distinguish mutation positive from mutation
negative individuals, clinicians may be aided in their preselection of patients for genetic
surveillance, mutation screening and subsequently, genetic counselling.
In light of results from recent studies, implicating germline mutations in MYH with a multiple
colorectal adenoma and carcinoma phenotype, it was the purpose of this study to  further correlate
MYH germline mutations with Swiss APC-negative individuals (n=65) and establish any
genotype-phenotype correlations to aid in the optimisation of clinical screening and prevention
strategies. An optimised protocol for the rapid and sensitive mutation analysis of MYH via high
performance liquid chromatography (DHPLC) was established. Thirteen (20%) individuals were
identified as MYH mutation carriers, 7 (54%) of which had biallelic mutations. Aside from
previously reported mutations, 3 apparently novel gene alterations were established in 3 patients
with a multiple adenoma phenotype. The phenotypical characteristics of all patients investigated
were similar, with no statistically significant correlations to genotype, hence, clinicians and
counsellors are advised to screen for MYH mutations in patients displaying tens to hundreds of
colorectal adenomas, and a family history consistent only with recessive inheritance.
FAP patients typically display considerable inter- and intra-familial phenotypic heterogeneity,
which represents a major problem in genetic counselling of APC mutation carriers. The Min
mouse model indicated a putative disease modifier locus on chromosome 4, which is syntenic to
human chromosome 1p35-36. Furthermore, germline mutations in the base-excision repair gene
MYH, which maps to the 1p33-34 region, have been described in patients with multiple
adenomas, pointing to a possible role as disease modifier in FAP. Here, the re-assessment of one
of the largest FAP kindreds published, which was previously used in linkage mapping of 1p35-
36, is documented. Using the latest available clinical information, additional mutation carriers
and polymorphic markers, fine-mapping of the critical region as well as mutation analysis of the
MYH gene were performed. These investigations significantly excluded (i) the 1p33-36 region as
a modifier locus and (ii) MYH as a modifier gene for extracolonic disease in this FAP kindred.
The results indicate that linkage analysis of further putative candidate regions is necessary to
identify a disease modifier locus in FAP.
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General Introduction
Colorectal Cancer Incidence:
Today’s global population is approximately 6.1 billion people, with 133 million
being born and 52 million dying each year. World-wide, about 8 million people
develop cancer each year. Approximately 876 000 of these are diagnosed with
colorectal cancer, the third most frequently occurring cancer after that of lung and
stomach (http://home.swipnet.se/crc/crc.htm). The lifetime risk in the general
population for developing colorectal cancer is 5%, but this figure rises
dramatically with age and by 70 years, almost half the Western population will
have developed an adenoma. In general, the incidence of colorectal cancer is
high in developed countries (Jemel et al., 2002). However, incidence rates vary
up to 20-fold between low- and high-risk geographical areas throughout the
world, probably due to environmental and dietary factors (Lothe et al., 1993).
Each year 3500 people in Switzerland are diagnosed with colorectal cancer,
approximately 51.8 and 34.3 per 100’000 inhabitants for males and females,
respectively (Swiss Cancer Registries’ Association Database, 2003).
Since only 37% of cancers are detected in the early, most treatable stages
(Dukes A or B), almost 50% of the patients with a new diagnosis of colorectal
cancer are expected to die within 5 years of diagnosis (Jass et al., 1992).
Figure 1: The colon and examples of an adenoma and carcinoma
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Colorectal Carcinogenesis:
It is a common understanding that cancer cells are derived from normal stem
cells. Only such stem cells have the natural capacity for extensive proliferation
and the ability to differentiate along several directions, factors that define cancer
(Campbell et al., 1998). Detailed morphological, biochemical and physiological
studies have provided clear evidence for the existence of stem cells near the
base of the crypts (Sancho et al., 2003). The progeny of stem cells migrate up
the crypts, continuously dividing, until they reach the mid-section. Here, the
migrating epithelial cells cease to divide and subsequently differentiate to mature
cells, the majority being mucous-secreting globlet cells and absorptive epithelial
cells. On reaching the top of the crypt, the differentiating cells undergo apoptosis
and are engulfed by stromal cells or shed into the lumen (Brittan et al., 2002).
However, in the initial stages of tumorigenesis, dysplastic cells are commonly
found at the luminal surface of the crypts and are found to be mutant clones,
genetically unrelated to the cells at the base of the crypt. This dysplastic
eptithelium, forming the top portion of the crypt, proliferates in a manner identical
to that observed in advanced neoplasms (Schon, 2003). In addition, the
dysplastic epithelium harbours such genetic alterations at the APC locus that are
associated with functional changes in beta-catenin expression and localisation
(Michor et al., 2004). These histologic, biochemical and genetic features are
virtually always detected, in almost every crypt of every small adenoma
investigated and suggest that adenomatous polyp development proceeds via a
top-bottom mechanism (Vogelstein et al., 1998). The genetically altered cells
spread laterally and downward to form new crypts that primarily attach
themselves to pre-existing normal crypts and subsequently replace them.
By the time the cancer cell and its progeny have divided 30 times, the resulting
tumour could contain 1 billion cells and weigh about 1 gram, and it could be
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detectable by X-rays or endoscopy. However, the growth rate of a tumour is
greatly affected by cell death, in the form of apoptosis or necrosis.
Additional mutations in oncogenes and tumour suppressor genes give rise to
clonal expansion and the adenoma gaining the ability to invade surrounding
tissue and metastasize to other organs as adenocarcinoma (see Figure 2,
Vogelstein et al., 1993, 1998). It is thought that at least 4 sequential genetic
changes are necessary to ensure colorectal cancer evolution. One oncogene
(KRAS) and three tumour suppressor genes (APC, SMAD4 and TP53) are the
primary targets for these genetic changes (Weinberg, 1994). The dominant and
recessive nature of these genes predicts that at least 7 mutations are required:
one oncogenic mutation at KRAS and six further mutations to inactivate both
alleles of the APC, SMAD4 and TP53 tumour suppressor genes. Tumour
suppressor gene mutations are determined in the majority of tumours, however
KRAS mutations are found in approximately 50-60% of cases (Lipton et al.,
2003).
Figure 2: Histopathology and genetic hits in the progression of normal epithelial
cells to carcinoma (taken from Nature Reviews: Cancer, October 2001, Vol 1).
 Intestinal epithelial 
crypts 
Aberrant crypt focus             
            Adenoma 
            
               Carcinoma 
APC 
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Other Oncogenes? 
SMAD2/SMAD4 
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Genetic Factors of Colorectal Cancer:
Colorectal cancer usually arises sporadically due to environmental or dietary
factors, but can also stem from a hereditary pre-disposition.
Approximately 80% of patients with colorectal cancer appear to have sporadic
disease with no evidence of having inherited the disorder, whilst 20% seem to be
attributed to a definable genetic component (Cannon-Albright et al., 1998).
Evidence for a genetic factor playing a role in colorectal cancer includes
increased risk of colorectal malignancy in persons with a family history and
familial aggregation of colorectal cancer consistent with autosomal dominant
inheritance. In 5-6% of all colorectal cancer cases a germline genetic mutation,
conferring high lifetime risk of colorectal cancer in carriers, has been found
(Lynch et al., 2003). Additional gene mutations, some with lower lifetime risks,
are continuing to be characterized (Narayan et al., 2003).
Colon cancer can be effectively prevented through timely removal of
adenomatous polyps by endoscopy (recto-sigmoidoscopy or colonoscopy). Once
a carcinoma has developed, surgery is the primary treatment for most patients,
sometimes in combination with a 5-fluorouracil-based adjuvant chemotherapy.
Inherited Genetic Susceptibility to Colorectal Cancer:
Approximately 15-20% of all colorectal adenocarcinomas are familial in origin.
The best-defined inherited syndromes are Hereditary Non-Polyposis Colorectal
Cancer (HNPCC) (and its rare variants Muir-Torre and Turcot syndromes)
(Lynch, 2000) and Familial Adenomatous Polyposis (FAP) (Beech et al., 2001),
which are estimated to account for 2-5% and less than 1% of all colorectal
cancers in Western countries, respectively. Other, albeit very rare, inherited
cancer predisposition syndromes include Juvenile Polyposis, Gardner’s
syndrome and Peutz-Jeghers syndrome. Although many familiar aggregations of
colon cancer remain etiologically undefined, HNPCC appears to be the most
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frequently inherited cancer syndrome in humans. The main focus points of the
chapters to come, are HNPCC and FAP.
Hereditary Non Polyposis Colorectal Cancer (HNPCC):
The clinical definition of HNPCC describes a syndrome with an excess of colon
cancer and a defined spectrum of extracolonic manifestations, diagnosed at an
early age and inherited via an autosomal dominant mechanism. Individuals with a
HNPCC gene mutation have a 70-80% lifetime risk of developing colorectal
cancer (Lynch et al., 2003). The renown international diagnostic criteria for
HNPCC, known as the Amsterdam Criteria I (primarily concerned with colorectal
cancers only) and Amsterdam Criteria II (concerning cancers of the colon and
rectum, endometrium, small bowel, ureter and renal pelvis) rely on these clinical
characteristics (Vasen et al., 1991).
Hereditary Non Polyposis Colorectal Cancer, an autosomal dominant disorder,
represents 1-5% of all colorectal cancers, has a frequency of between 1:2000
and 1:200 and is hence one of the most commonly observed cancer syndromes
in humans (Lynch et al.,1998; Aaltonen et al., 1998). It is characterised by a
number of criteria:
1. the involvement of several family members. In accordance with the
Amsterdam criteria (Vasen et al.,1991 and 1999), at least 3 family members in 2
generations should be affected (by colon or endometrial cancer, see below), with
one being a first degree relative of the other two.
2. diagnosis made at or below 50 years of age in at least one of the affected
family members. Typically, HNPCC tumours occur at an average age of 45 years
compared to 65 for sporadic colon cancer.
3. a higher frequency of tumours in other organs, primarily the endometrium,
followed by the ovaries, stomach, small bowel, ureter, and renal pelvis.
General Introduction
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4. an 80% and 60% lifetime risk for developing colorectal and endometrial
cancer, respectively, compared to 6% and 1-2% in the general population.
5. tumours that are more commonly located in the right (proximal) portion of
the colon
6. an increased incidence of synchronous (more than 1 primary colon cancer
occurring at the same time) and metachronous (more than one primary colon
cancer occurring at different times) cancers.
7. tumours that demonstrate an increased rate of transformation of the
benign polyp, but a better prognosis.
8. germline mutations in  mismatch repair (MMR) genes
In addition, skin tumours (sebaceous adenomas, sebaceous carcinomas and
karatoacanthomas) are apparent in a few families affected by Muir-Torre
syndrome (Coldron and Reid, 2001) and brain tumours (glioblastomas or
medulloblastomas) in families with Turcot syndrome (Hampel and Peltomaki,
2000).
Due to the increasing number of small families in Western countries with high
migration rates, the criteria for HNPCC diagnosis have been relaxed. Today,
families with only 2 colon or endometrial cancers occurring before the age of 50
are also screened for HNPCC.
HNPCC results from germline mutations in one of the four major HNPCC-
associated mismatch repair (MMR) genes: hMSH2 (human mutS homolog 2) on
chromosome 2p16 (Aaltonen et al.,1993; Peltomaki et al., 1993), hMLH1 (human
mutL homolog 1) on chromosome 3p21 (Lindblom et al., 1993), hMSH6 (human
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mut S homolog 6) on chromosome 2p16 (Palombo et al., 1995) and hPMS2
(human postmeiotic segregation 2) on chromosome 7q11 (Nicolaides et al.,
1994). An excess of 400 different predisposing MMR gene mutations are known
to date with germline mutations of hMSH2 (frameshift = 60%, or nonsense
mutations = 23%) and hMLH1 (frameshift = 40% and missense alterations =
31%) accounting for more than 95% of the mutations found in HNPCC families;
they are distributed throughout the 16 and 19 exons of these two genes,
respectively (International Collaborative Group on HNPCC Web site:
http://www.n-fdht.nl). Less than 5% of hPMS2 mutations attribute to the HNPCC
syndrome. Recently, the newly established MMR gene hMSH3 has been shown
to play a small role in HNPCC, although additional data regarding prevalence,
pathogenicity and clinical correlations, is required to reinforce its part as an
HNPCC predisposition gene (Hienonen et al., 2003).
Microsatellite instability (MSI) is a phenomenon detected in the colorectal tumour
DNA of individuals with mismatch repair gene mutations. Tumours developing
through this pathway have alterations in the length of short, repeated
mononucleotide or dinucleotide sequences of DNA ie. microsatellites, caused by
the insertion or deletion of repeated units. MSI has been found in most cases
(>90%) of HNPCC that fulfil the Amsterdam Criteria and 15% of sporadic
colorectal cancers. This phenomenon reflects the underlying defect in the DNA
mismatch repair gene system (Dietmaier et al., 1997).
Germline mutations in hMLH1 or hMSH2 generally lead to a classical HNPCC
phenotype with families fulfilling the Amsterdam Criteria and tumours displaying a
high degree of microsatellite instability (Peltomaki et al., 1993; Boland et al.,
1998). Mutations in MSH6 and PMS2 however, are less frequently observed in
the classical HNPCC families and present themselves in a more atypical HNPCC
phenotype (Table 1). Severe MSI has been occasionally observed in conjunction
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with hPMS2 mutations, but hMSH6 mutations are more often associated with a
low degree MSI phenotype (Nicolaides et al., 1994; Miyaki et al., 1997).
Gene Phenotypic features of HNPCC
hMLH1 Primarily typical HNPCC. ca30% of mutations are the missense type.
Varying phenotype
hMSH2 Primarily typical HNPCC. Extracolonic manifestations occurring more
frequently than in MLH1 mutation carriers
hMSH6 Typical or atypical HNPCC. Late CRC onset, frequently affected
endometrium, distal location of CRC, MSI-Low tumours
hPMS2 Typical or atypical HNPCC.
hMSH3 Primarily atypical HNPCC. Distally located and MSI-Low tumours
Table 1: clinical features associated with germline mutations in the MMR genes
associated with a predisposition to HNPCC
HNPCC Screening:
Given that colorectal cancer incidence in Switzerland is approximately 90 new
cases per100’000 inhabitants each year, and that 1-5% of these are attributed to
HNPCC, it is estimated that between 60 and 300 individuals in this country
develop HNPCC colon cancer each year. Using the screening program outlined
below, it is our aim to identify these individuals and to characterise the germline
mutations in their MMR genes.
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Microsatellite analysis is a valuable assessment of instability in repetitive
regions of DNA and highlights those individuals that should be screened further
for germline mutations in MMR genes. Matched tumour and normal DNA are
extracted from the histologic sections and blood, respectively, and are analysed
for differences in the lengths of a subset of microsatellite motifs (figure 3). Any
differences indicate an unstable sequence in the tumour tissue and the case is
referred for further screening.
Familial clustering of colorectal cancer
Microsatellite analysis with 10  x 10m histologic sections from
paraffin embedded tumours and 20 ml of blood collected in Heparin,
and Immunohistochemistry for MMR proteins with 5  x 5m
sections
If microsatellite instability (MSI) is found and one of the MMR
proteins is not expressed, 20 ml of blood are collected in EDTA
Protein Truncation Test (PTT) and DNA sequencing for the detection
of germline-mutations
General Introduction
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Figure 3. Microsatellite analysis. The comparison between DNA extracted from
the normal tissue and from the tumour tissue is made for the microsatellite
markers BAT25, BAT26, D5S346 and D2s123. Additional peaks in the tumour
DNA are indicative of microsatellite instability (MSI)
Microsatellite
Marker D5S346
Microsatellite
Marker BAT25
Microsatellite
Marker D2S123
Microsatellite
Marker BAT26
Genomic
DNA
Tumour
DNA
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Immunohistochemistry is a simple and effective method for determining the
loss of MMR proteins from the tumour as a result of two events: the inherited
germline mutation on one allele of the MMR gene and a second somatic event
(ie. in the colonocytes) on the wild-type allele (mutation of loss of heterozygosity).
Normal mucosa and tumour tissue are analysed in the same histologic section
for the expression of hMSH2, hMSH6, hMLH1 and hPMS2 proteins. The loss of
expression of one of these proteins suggests which MMR gene should be
screened for the germline mutation.
The protein truncation test (PTT) is employed specifically for establishing
truncating mutations and large insertions or deletions in MMR genes. In these
cases, shorter gene products are detected on a denaturing gel.
With indications from both IHC and PTT, the search for mutated MMR genes is
narrowed down.  Subsequently, direct genomic DNA sequencing is employed to
screen the genes for point mutations exon by exon. To date, there are more than
400 HNPCC mutations described in the databanks
(http://www.nfdh.nl/database/mdbchoice.htm), with ~60% being in hMLH1 and
~35% in hMSH2.  In three years of screening, we have identified more than 100
Swiss HNPCC families carrying mutations in the hMSH2 or hMLH1 loci.
Relatives of the index patient are easily screened for the presence of the ‘familiar
mutation’, the only requirement being 10 ml of blood in EDTA. Non-carriers can
be excluded from the screening program, since cancer incidence in these
individuals is comparable to that found in the general population. The mutation
carriers are invited for regular (2-yearly) consultations, including endoscopic
surveillance, which has proved itself to be extremely effective in colon cancer
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prevention. In addition, these individuals are encouraged to enrol in genetic
counselling programs, in order to gain the support they may require for dealing
with the psychological burden of living with HNPCC.
The HNPCC screening information detailed here was initially written with
clinicians and patients in mind and was published in the Schweizer Krebs Bulletin
(No. 4. Dec 2001).
Familial Adenomatous Polyposis (FAP):
FAP is an autosomal dominant syndrome, accounting for ca.1% of all colorectal
cancers, those results from germline mutations in the adenomatous polyposis
coli (APC) gene. It is estimated to occur at a frequency of 1 in 8300 to 1 in
14,025 and affects both sexes equally (Bisgaard et al., 1994). Characteristically,
teenaged patients develop multiple (>100) adenomatous polyps diffusely
throughout the colon and rectum. Approximately 50% of FAP patients develop
adenomas by 15 years of age and 95% by the age of 35 (Bulow et al., 1995).
The average age at diagnosis ranges from 34.5 to 43 years. Colorectal cancer is
inevitable in FAP patients if colectomy is not performed (Lynch et al., 2003).
FAP patients frequently develop a variety of benign extracolonic manifestations
in addition to polyposis coli. These may include extracolonic adenomas
(adenomas of the small intestine and stomach, fundic gland retention polyps of
he stomach), cutaneous lesions (lipomas, fibromas, sebaceous, and epidermoid
cysts), desmoid tumours, osteomas, dental abnormalities and pigmented ocular
fundic lesions (congenital hypertrophy of the retinal pigment epithelium).
Furthermore, extracolonic malignancies that can develop in FAP patients include
hepatoblastoma, upper gastrointestinal tract malignancies, thyroid gland, biliary
tree, pancreas and brain (Knudsen et al., 2000; Giardiello et al., 2001).
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Almost all cases of FAP are attributed to germline mutations of the APC gene
located on chromosome 5q21 (Bodmer et al., 1987; Groden et al., 1991). The
APC gene is a tumour suppressor or "gatekeeper" gene with 15 exons encoding
a protein considered essential in cell adhesion, signal transduction and
transcriptional activation, with C-myc and -catenin having been established as
downstream targets (Fearnhead et al., 2001). An excess of 300 different APC
mutations have been described to date, the majority being insertions, deletions
and nonsense mutations that subsequently lead to frameshifts or premature stop
codons, resulting in the truncation of the APC gene product
(http://www.umd.necker.fr:2008). Such a truncated protein lacks all
axin/conductin binding motifs and a variable number of the 20 amino acid repeats
that are associated with the down regulation of intracellular -catenin levels. In
FAP, germline mutations are found throughout the 5’ region of the APC gene.
However, somatic mutations are found grouped between codons 1286 and 1513
in the so-called “Mutation Cluster Region” (MCR). The most commonly occurring
APC mutation, detected in 10% of FAP patients, is a deletion of AAAAG in codon
1309 (Miyoshi et al., 1992).
Studies involving genotype-phenotype correlations have revealed that APC gene
mutations between codons 169-1393 result in classical FAP (Fearnhead et al.,
2001), whilst 3' and 5' mutation predispose to attenuated FAP (Su et al., 2001),
and mutation I1307K increases colorectal cancer risk in Ashkenazi Jews (Zauber
et al., 2003). Other observations include profuse colorectal polyposis between
codons 1250 and 1464, predilection for extraintestinal manifestations at codons
1465, 1546 and 2621, and occurrence of retinal lesions with mutations located
within codons 463 to 1444. However, it is well established that intra- and
interfamilial phenotypic variability can occur even in patients with identical gene
alterations (Laurent-Puig et al., 1998).
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Attenuated Familial Adenomatous Polyposis A(FAP):
Attenuated familial adenomatous polyposis (AFAP) is a clinical variant of FAP
and is characterised by less than 100 polyps and presents mutations in the
extreme 5’ or 3’ region of the APC gene or in the alternatively spliced region of
exon 9 (Fearnhead et al., 2001). Tumour development in at least some AFAP
patients appears to require somatic second and third hits of the wild-type and
attenuated APC alleles (Spirio et al., 1998; Su et al., 2000). Extracolonic
manifestations commonly observed in AFAP include fundic gastric polyps and
duodenal polyps, whereas less frequently detected are congenital
hyperpigmentation of the retina (CHRPE) and desmoid tumours. The onset of
colorectal cancer is 15 years later than in classical FAP, the average age being
55 years compared to 39 years, respectively. The disease manifestation of AFAP
patients can phenotypically overlap with that of the HNPCC syndrome (Knudsen
et al., 2003). However, MYH associated polyposis, arising from deficient base
excision repair (BER), was initially reported in a single Caucasian family. Al
Tassan et al. connected multiple adenomas and carcinomas to a previously
undescribed autosomal recessive condition involving germline mutations of the
base excision repair gene MYH (Al-Tassan et al., 2002).
Mismatch Repair (MMR):
Mismatch repair operates to maintain genome stability by correcting mismatches
and small insertion or deletion loops (IDLs) introduced through errors made by
DNA polymerases during DNA replication. In addition, MMR counteracts
recombination between homologous but diverged DNA sequences. Throughout
the evolution of eukaryotes, the initial steps of MMR have been conserved.
However, it appears that the mechanisms of the strand-discrimination signal and
the downstream steps in mammalian MMR are mostly exclusive (Peltomaki and
Vasen, 1997).
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In eukaryotes, the heterodimeric MutS homologue MSH2/MSH6 (MutS)
functions in the repair of mismatches and short IDLs, whilst the MSH2/MSH3
(MutS) heterodimer repairs the longer IDLs. In addition, the MutL homologues,
MLH1/PMS2, form a heterodimeric complex (MutL) and aid the repair
mechanism by recruiting a number of different proteins eg. helicases,
exonucleases for excising abnormally based pairs (Jiricny and Nyström-Lahti,
2000).
Predisposition to colon cancer in HNPCC results from a germline-mutation (ie.
inherited in all cells of the body) in one of several DNA mismatch repair (MMR)
genes described so far (Peltomaki and Vasen, 1997). Gene mutations in either
hMSH2 (on chromosome 2) or hMLH1 (on chromosome 3) have been found in
the majority of HNPCC families, whilst only a few atypical kindred carry mutations
in the gene encoding hMSH6 (on chromosome 2).
Figure 4 . Putative model of human MMR. (i) The mismatched <T< introduced
into the newly synthesised strand by the replication complex, is recognised by
the hMSH2/hMSH6 heterodimer. (ii) ATP drives the bi-directional threading of
DNA which makes a loop and (iii) recruits other essential members of the
MMR complex, such as the hMLH1/hPMS2 heterodimer and PCNA. (iv)
Exonucleolytic degradation of the T-containing strand is initiated by an as yet
unidentified helicase(s) and exonuclease(s). (v) DNA synthesis is re-initiated
by the replication complex and a <C> is normally paired with <G>.
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Base Excision Repair (BER):
Germline mutations in the BER MYH gene may contribute to individuals with a
multiple colorectal adenoma phenotype (Sieber et al., 2003).
Reactive oxygen species (ROS), for example hydrogen peroxide, superoxide and
hydroxyl radicals, are the mutagenic by-products of normal aerobic cellular
metabolism. Elevated levels of ROS can result in DNA damage and have been
related to several degenerate diseases: cancer, immune system decline,
cataracts, cardiovascular disease, ageing and brain dysfunction (Ames et al.,
1991). One of the most stable products of oxidative DNA damage and also the
most deleterious due to its mispairing capacity with adenine, is 7,8-dihydro-8-
oxo-guanine (8-oxoG). 8-oxoG has been connected with spontaneous G:CT:A
transversion mutations in BER defective bacteria and yeast (Michaels et al.,
1992; Thomas et al., 1997).
In the prevention of 8-oxoG induced mutagenesis, proteins from 3 genes of the
BER pathway, hMTH1, hOGG1 and hMYH, interact together both within the
nucleus and the mitochondria. hMTH1, with its nucleoside triphosphatase
activity, is responsible for the hydrolysis of 8-oxo-dGTP, hence preventing the
inclusion of the oxidised nucleotide during DNA replication. hOGG1 establishes
and eliminates ring-opened purine lesions and mutagenic 8-oxoG adducts, whilst
hMYH, an adenine specific DNA gycosylase, removes adenines mismatched with
8-oxoG or guanines during DNA replication errors (Lindhal et al., 1993).
This thesis concentrates on two colorectal cancer causing diseases with clear
identities, HNPCC and FAP, and aims to:
i) Study the mechanisms leading to hereditary colorectal cancer (Chapter I parts
   i-iv)
ii) Identify causing mutations (Chapter II)
iii) Assess the phenotypical consequences of established germline gene
   mutations (Chapters III, IV and V).
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Thesis Chapters:
Chapter I part i details further correlations made between MYH germline
mutations and APC-negative individuals in what was an attempt to establish
genotype-phenotype correlations in a Swiss study cohort in order to aid in the
optimisation of clinical screening and future prevention strategies. This chapter
has been prepared for publication as a scientific paper and is currently under
review by the participating authors.
Chapter I part ii, a collaboration with Petr Cejka already published in the EMBO
Journal Vol. 22, No. 9, pg2245-2254, 2003, highlights the phenotypic
consequences correlated to reduced levels of MMR proteins, as demonstrated by
a new cell line, epithelial in origin, in which the expression of hMLH1 could be
strictly regulated by doxycycline (Dox).
Chapter I part iii, a collaboration with Luigi Lhagi that has been prepared as a
scientific paper for publication, investigated the prevalence of frameshift
mutations in secondary mutator genes and in other target genes in a series of
MSI-high CRCs with hMLH1 and hMSH2 deficiency, from both hereditary and
sporadic cases in different pathological stages.
Chapter I part iv, a collaboration with Giancarlo Marra which will lead to the
eventual publication of a scientific paper, reports further on the value of
microsatellite instability testing and immunohistochemical analysis in the
identification of MMR gene mutations.
Chapter I part v, a collaboration, with Giancarlo Marra as part of an ongoing
study, branches onto new ground with the investigation into hMSH6 mutations in
HCT116+chr 3 clones, after treatment with the DNA methylating agent N-methyl-
N’-nitro-N-nitrosoguanidine (MNNG).
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Chapter II reports on one of the largest FAP kindreds ever published. Although
all affected family members harbour the same germline mutation of the APC
gene, they display marked phenotypic variability. Through linkage analysis the
1p33-36 region was excluded as a modifier locus, and MYH as a modifier gene,
for extracolonic disease in this FAP kindred. This paper has already been
published in the European Journal of Human Genetics Vol.12 pg 365-371, 2004.
Chapter III of this thesis, a draft of a scientific paper prepared for publication,
documents results cleaved from a study of 222 Swiss patients, where phenotypic
and molecular differences between patients belonging to different HNPCC
referral criteria groups were investigated. In addition, through the assessment of
the diagnostic accuracy of different screening procedures, the most reliable
algorithm for the identification of mismatch repair gene mutation carriers, has
been defined.
Chapter IV, also a scientific paper draft, goes on to define the phenotypic
differences between the MMR gene mutation positive and the mutation negative
individuals in an attempt to highlight characteristics which may aid in the
detection of HNPCC individuals and MMR gene mutation carriers.
The planned addition of data collected by Pierre Hutter, Institut Central des
Hospitaux Valaisans, Sion, Switzerland, will enable us to publish chapters III and
IV as Swiss national studies.
Chapter V has been submitted as a scientific paper to the Gastroenterology
journal. It reports on a study that assessed the occurrence of genetic anticipation
in HNPCC ie. the earlier age at diagnosis of colorectal cancer in successive
generations. It appears to be a phenomenon that occurs in HNPCC kindreds with
identified mismatch repair gene mutations. These results may have important
implications for genetic counseling and clinical management of HNPCC families.
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Chapter I part i
Prevalence of MYH germline mutations in Swiss APC mutation-
negative polyposis patients
This chapter has been prepared for publication as a scientific paper and is
currently under review by the participating authors.
Abstract
In 10-30% of patients with classical familial adenomatous polyposis (FAP) and up
to 90% of those with attenuated (<100 colorectal adenomas; AFAP) polyposis no
pathogenic germline mutation in the adenomatous polyposis coli (APC) gene can
be identified (APC mutation-negative). Recently, biallelic mutations in the base
excision repair gene MYH have been shown to predispose to a multiple adenoma
and carcinoma phenotype. This study aimed to i) assess the MYH mutation
carrier frequency among Swiss APC mutation-negative patients and ii) identify
phenotypic differences between MYH mutation carriers and APC/MYH mutation-
negative polyposis patients. Sixty-five unrelated APC mutation-negative Swiss
patients with either classical (n=18) or attenuated (n=47) polyposis were
screened for germline MYH mutations by dHPLC and direct genomic DNA
sequencing. Eleven tumours from 4 biallelic mutation carriers were further
investigated for microsatellite instability, loss of heterozygosity (LOH) at the APC
locus and for somatic mutations in the mutation cluster region (MCR) of APC as
well as in exon 1 of KRAS. Phenotype comparisons were statistically assessed
using the Chi square, Fisher’s exact and Student’s t-test. Overall, 13 (20%)
individuals were found to harbour MYH germline mutations (7 bi- and 6
monoallelic mutation carriers). Among patients with a family history compatible
with autosomal recessive inheritance (n=33), 2 (22%) out of 9 classical polyposis
and 5 (21%) out of 24 attenuated polyposis patients carried biallelic MYH
alterations, 3 of which represent novel gene variants (R168H, R171Q and
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R231H). Despite the absence of somatic mutations in APC’s MCR, LOH at the
APC locus and the G12C mutation in KRAS were detected in adenocarcinomas
from 2 biallelic MYH mutation carriers. Colorectal cancer was significantly
(p<0.01) more frequent in biallelic mutation carriers (71%) compared to
monoallelic and MYH mutation-negative polyposis patients (15 and 18%,
respectively). In this nation-wide survey, 1 in 5 Swiss APC mutation-negative
polyposis patients with a family history compatible with autosomal recessive
inheritance was found to harbour biallelic MYH germline mutations. MYH
mutation screening should be offered if the following criteria are fulfilled: i)
absence of pathogenic APC mutation, ii) presence of classical or attenuated
polyposis and iii) family history compatible with an autosomal recessive mode of
inheritance.
Introduction
Familial adenomatous polyposis (FAP) is an autosomal dominantly inherited
colorectal cancer (CRC) predisposition caused by germline mutations in the
adenomatous polyposis coli (APC) gene and characterised by the development
of hundreds to thousands of adenomatous polyps throughout the intestinal tract1.
Attenuated FAP (AFAP) represents a clinical variant of classical FAP, associated
with multiple (<100) colorectal adenomas and caused by mutations in the most 5’
or 3’ regions of APC or in the alternatively spliced region of exon 92-4. With
routine screening techniques failing to detect pathogenic APC germline
mutations in 10 to 30% of classical FAP patients and in up to 90% of AFAP
patients5, investigations about the role of other polyposis predisposition genes
are topical.
Recently, Al Tassan et al. demonstrated that biallelic germline mutations in the
human homologue of the base excision repair gene MutY (MYH) cause a
phenotype of multiple colorectal adenomas and carcinomas, thus describing for
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the first time an autosomal recessively inherited CRC predisposition6,7. The DNA
glycosylase MYH removes adenines from mispairs with 8-oxoguanine that occur
during replication of oxidized DNA. Failure to correct these mispairs
consequently leads to G:CT:A transversion mutations, a typical “footprint” of
oxidative DNA damage19. The observation of an excess of transversion
mutations in tumours eventually led to the discovery of MYH-associated
polyposis (MAP). A number of studies have already attempted initiated and
conducted in attempts to establish the extent to which germline mutations in the
MYH gene may contribute to individuals with an AFAP phenotype6,7,8,9. As a
result, biallelic MYH germline mutations have been attributed to approximately 1-
3% of all unselected CRC patients6,7. This nation-wide study aimed to i) assess
the frequency of MYH mutation carriers in 65 unrelated Swiss patients presenting
with either classical or attenuated polyposis and in whom no pathogenic APC
germline mutation could be identified and ii) to identify phenotypic differences
between biallelic, monoallelic mutation carriers and APC/MYH mutation-negative
patients.
Patients and Methods
This nation-wide study investigated 65 unrelated Swiss index patients referred
between 1994 and 2002 to either the Research Group Human Genetics, Division
of Medical Genetics, Basel, or the Unit of Genetics, Institut Central des Hôpitaux
Valaisans, Sion, Switzerland, because of classical (>100 polyps, n=18) or
multiple adenomas/attenuated (5-99 polyps) FAP (n=47). In all patients, no
germline APC mutation could be established by means of the protein truncation
test and/or direct DNA sequencing (patients thereafter referred to as APC
mutation-negative). In addition, 100 healthy Swiss individuals were enrolled in
order to establish the carrier frequency of previously reported MYH variants as
well as novel mutations of unknown pathogenic significance in unaffected
individuals,. Informed consent for the study was obtained from all individuals
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investigated. Patients were considered as anonymous cases and the results of
the various genetic analyses were independently assessed by at least two
reviewers.
DNA Extraction
Genomic DNA was isolated from EDTA blood using methods previously
described by Miller, 199810. Tumor DNA was isolated from formalin fixed, paraffin
embedded tissue using the QIAMP DNeasy Tissue kit and according to the
suggested protocol of the manufacturer (Qiagen, Basel, Switzerland). After
verification of the tumor cell content (>50%) of HE stained tumor specimen, ten 5
to 8m thick tumor sections were cut from each paraffin block. Lysis of the tissue
was carried out overnight with Qiagen buffer, Proteinase K at an incubation
temperature of 55°C. The samples were then washed twice with Qiagen wash
buffer and the DNA finally eluted in 30 l elution buffer provided.
MYH mutation analysis
Exon specific primer pairs were used to amplify the 16 exons of MYH, including
the respective exon-intron boundaries (GenBank accession number NM012222;
primer sequences and PCR conditions available from the authors upon request).
Twenty-five l of PCR reaction mixture contained 50 ng of genomic DNA, 10
pmol of each primer and a PCR mastermix at 1.5 mM MgCl2 according to the
manufacturer’s instructions (Invitrogen, Switzerland). All PCR reactions were
done on a Hybaid OmnE thermocycler (Catalys AG, Wallisellen, Switzerland).
As a prescreening mean to detect DNA sequence changes denaturing high
performance liquid chromatography (dHPLC) was performed using the 3500HT
WAVE nucleic acid fragment analysis system (Transgenomic, Crewe, UK).
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Melting temperatures for dHPLC were predicted by the Wavemaker software
version 4.1.42 (Transgenomic) (dHPLC melting temperatures available from the
authors upon request). Where different elution profiles were observed, in
comparison to control samples run in parallel, direct DNA sequencing was
performed in order to establish the nature of the sequence alteration.
For DNA sequencing, PCR products were purified using the QIAquick PCR
Purification kit (Qiagen, Basel, Switzerland). The sequencing reaction was
performed using the Big Dye Teminator Cycle Sequencing kit (Applied
Biosystems, Rotkreuz, Switzerland), according to the manufactures' guidelines.
After purification using the DyeEx 2.0 Spin Kit (Qiagen, Basel, Switzerland)
sequencing products were analysed on an ABI PRISM 310 Genetic Analyser
(Applied Biosystems). Germline mutations identified in MYH were confirmed in
both forward and reverse directions, and from at least 2 independent PCR
products. Exons 2, 5, 7, 8, 12 and 13 were routinely sequenced regardless of the
dHPLC elution profile. Germline mutations Y165C and G382D were further
confirmed by restriction enzyme digest, using IlaI and BglII, respectively.
Screening for Somatic KRAS and APC Mutations in Colorectal Tumors
Tumor tissue encompassing 2 colorectal adenocarcinomas and 9 adenomas was
available from 4 patients harboring biallelic MYH mutations (no. 1775, 1828,
2013 and 2073). These tumours were investigated for mutations commonly found
in exon 1 of the KRAS gene (primers and methods from Lipton, L., 2003)11 and
the mutation cluster region (MCR, codons 653-1513)12 of APC. KRAS PCR
products were subsequently sequenced, as described before. The 12 PCR
fragments covering the MCR were first screened by dHPLC analysis. Whenever
different elution profiles were observed, in comparison to control samples run in
parallel, direct DNA sequencing was performed.
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Loss of heterozygosity analysis at the APC gene locus
Loss of heterozygosity (LOH; allelic loss) analysis at the microsatellite loci MCB,
D5S346 and D5S299 was performed according to the standard protocol (Applied
Biosystems) with the use of fluorescently labeled oligonucleotides and analysed
on an ABI PRISM 310 Genetic Analyser. Informative samples were defined as
having allelic loss if the amount of one allele in the tumor was at least 50% lower
than that of the other allele, after correction for the relative peak areas of the
alleles found in leukocyte-derived DNA of the same patient8.
Assessment of microsatellite instability (MSI)
Microsatellite instability was assessed using the monomorphic mononucleotide
repeat BAT26. PCRs were carried out in a total volume of 25 l containing 50 to
100 ng of leukocyte-derived and tumour DNA, respectively. PCR products were
diluted 1:4 and 0.5 l was added to 10 l deionized formamide, denatured at
95°C for 5 min, chilled on ice and loaded on a ABI PRISM 310 genetic analyser.
MSI was defined as the occurrence of novel alleles that differed by 3 nucleotides
from the constitutional DNA (Loukola et al., 2001)26.
Statistical Analysis
Statistical comparison of patients’ features, encompassing phenotypic
characteristics (gender, age at diagnosis, polyp number, extracolonic
manifestations, family history), and mutational status, was performed using the
Chi-square and Fisher’s exact test for categorical variables, or Student’s t-test for
continuous variables, with all of the probabilities reported as two-tailed ps,
considering a p value of <0.05 to be statistically significant.
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Results
Sixty-five unrelated APC mutation-negative Swiss polyposis patients were taken
from the Basel (n=44) and Sion (n=21) medical genetic centres and investigated
for the presence of MYH germline alterations. Twenty-eight percent of the
individuals were referred because of suspected classical FAP (n=18), whilst the
majority exhibited an attenuated or multiple adenoma phenotype (n=47).
MYH mutation analysis
The complete coding sequence of the MYH gene was investigated in all 65 index
patients. Thirteen (20%) individuals, 4 (22%) out of 18 FAP and 9 (18%) out of 47
AFAP patients, were identified either as biallelic (n=7) or monoallelic (n=6) MYH
mutation carriers. If only individuals with a family history compatible with
autosomal recessive inheritance were considered (n=33), 22% (2/9) of patients
with classical polyposis and 21% (5/24) of AFAP patients harboured biallelic
MYH germline mutations (Table 1).
Besides the homozygous mutations Y165C and G382D, each of which
accounted for 29% of mutant alleles in the biallelic patients, a novel mutation
R168H (Figure 1a) was present on both alleles in one AFAP patient. Additional
novel mutations were detected in 2 AFAP patients compound heterozygote for
Y165C/R171Q and Y165C/R231H (Figures 1b and 1c). In addition, one FAP
patient was found to be a compound heterozygote with a 252delG/137insIW
mutation previously reported by Sieber et al8. The healthy parents of this
individual were available for investigation and were found to be heterozygous
carriers of the 137insIW or the 252delG alteration, respectively. Although the
pathogenicity of R168H, R171Q and R231H remains to be established by
functional studies, such gene alterations were not observed in 200 chromosomes
from healthy Swiss individuals. Furthermore, the 3 amino acid positions are
known to be evolutionary highly conserved across species (E.coli, S. pombe,
mouse, rat, and human).
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Figure 1: Sequencing chromatograms displaying the three novel MYH germline
variants: 1a) patient 2107 (T7 Forward Sequence), R168H (homozygous), 1b)
patient 2073, (T7 Forward Sequence), R171Q (heterozygous) and 1c) patient
2185 (SP^ Reverse Sequence), R231H (heterozygous).
Figure 1a)
Figure 1b)
Figure 1c)
 T   T     C   T   C  A  T    G   G     C    C   G
 G   G   C   C  G  G  C G/A G  C  T  G  C  A  G  G
T  C    T  T  A  T  C G/A  T  C  G   G   G  T  C  C
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Table 1: Phenotypic features and germline mutations identified in MYH
mutation carriers. CRC, colorectal cancer; FAP, familial adenomatous polyposis;
AFAP, attenuated FAP.
MYH
Patient
ID
Sex Age Polyp
No.
Clinical
classification
CRC Extracolonic
disease
1st
Mutation
2nd
Mutation
Biallelic MYH mutation carriers
1775/01 M 38 >100 FAP Yes Yes 252del G 137ins IW
1828/01 F 42 <100 AFAP Yes No Y165C Y165C
2013/01 M 50 <100 AFAP Yes No G382D G382D
2073/01 F 60 >50 AFAP No No Y165C R171Q
2107/01 M 35 30 AFAP Yes No R168H R168H
2184/01 M 48 >100 FAP No No G382D G382D
2185/01 M 48 74 AFAP Yes No Y165C R231H
Monoallelic MYH mutation carriers
1384/01 F 20 multiple AFAP Yes No G382D wild-type
1665/01 F 54 >100 FAP No No I209V wild-type
DFAP
17
F 34 20 AFAP No Yes G382D wild-type
DFAP
82
M 58 100 FAP No No G382D wild-type
DFAP
99
F 63 43 AFAP No No G382D wild-type
SA 453 M 41 5 AFAP No No G382D wild-type
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Six patients were identified as monoallelic MYH mutation carriers with the G382D
mutation present in 5 (83%) of them (Table 1). In the remaining 52 (80%)
patients, no pathogenic MYH mutations could be identified. The previously
described polymorphisms in exon 2 (G64A; V22M) and exon 12 (G972C; Q324H)
were detected with allele frequencies of 4% and 14%, respectively, similar to that
of a Swiss control sample population (200 chromosomes) assessed in parallel
(2% V22M and 12% Q324H).
Genotype-phenotype comparisons
The phenotypic features of the 7 biallelic MYH mutation carriers (5 males, 2
females) are depicted in Table 2, where two of them display classical FAP. In 5
(71%) patients colorectal carcinomas had been diagnosed at a median age of 38
years, with 3 of them located proximal to the splenic flexure. The family history in
all biallelic mutation carriers corresponded to an autosomal recessive mode of
inheritance. Remarkably, in 3 out of 11 siblings of patient 2073/01
(Y165C/R171Q) a CRC had been diagnosed at a median age of 51 years (range
49 to 54). Except for patient 1775, in whom duodenal adenomas had been
detected, no apparent extracolonic disease manifestations were present in the
other biallelic mutation carriers.
Among the 6 monoallelic MYH mutation carriers, AFAP patient 1384/01 had
developed a CRC of the sigmoid colon at the age of 20 years (Tables 1 and 2).
Three patients (no. 1384/01, DFAP17 and DFAP 82) had siblings with either
CRC or polyps reported. A facial lipoma was present in patient DFAP 17.
Twenty (38%) out of 52 MYH mutation-negative patients had family histories on
CRC and/or polyposis compatible with an autosomal recessive mode of
inheritance and could therefore be included in the genotype-phenotype analysis
(Table 2). Comparing the phenotypic properties of biallelic, monoallelic MYH
mutation carriers and APC/MYH mutation-negative polyposis patients, colorectal
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cancer was found to occur significantly more frequent in biallelic mutation carriers
than in the other subgroups (71% vs 18% and 15%, respectively; Fisher’s exact
test p<0.01). No further statistically significant phenotypic differences with
respect to polyp number, age at diagnosis or extracolonic disease were
observed.
Table 2: Phenotypic characteristics of biallelic, monoallelic MYH  mutation
carriers and APC/MYH mutation-negative patients with a family history
compatible with autosomal recessive inheritance.
Biallelic  MYH
mutation
carriers
Monoallelic MYH
mutation
carriers
MYH mutation-
negative
patients
n=7 n=6 n=20
Sex
Male 5 (71%) 2 (33%) 12 (60%)
Female 2 (29%) 4 (67%) 8 (40%)
Clinical classification
FAP (>100 polyps) 2(29%) 2 (33%) 5 (25%)
AFAP (<100 polyps) 5 (71%) 4 (67%) 15 (75%)
Age at diagnosis
(years)
Median
IQR
Range
48
10.5
35-60
47.5
24.0
20-63
46
16.0
22-77
Colorectal cancer
Present 5 (71%) 1 (17%) 3 (15%)
Absent 2 (29%) 5 (83%) 17 (85%)
Extracolonic disease
Present 0 1 (17%) 2 (10%)
Absent 7 (100%) 5 (83%) 18 (90%)
MYH Polymorphisms:
Q324H 0 1 (17%) 5 (25%)
V22M 1 (14%) 0 2 (10%)
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Molecular analysis of tumours from biallelic mutation carriers
We further investigated the presence of somatic mutations typical of MYH (base
excision repair) deficiency ie. G to T transversions, in the mutation cluster region
(MCR) of the APC gene, spanning codons 653-1513, a renown mutational
hotspot. In total, 11 tumours, 9 colorectal adenomas and 2 adenocarcinomas,
from 4 biallelic MYH mutation carriers (no. 1775, 1828, 2013 and 2073) could be
investigated. No somatic APC mutations could be identified within the MCR
region. Consistent LOH (at the MBC and the D5S346 loci) was only observed in
colorectal adenocarcinomas of patients 1828 and 2013, respectively.
Additionally, these cancers as well as a tubular adenoma of patient 2013 were
found to harbour the KRAS target gene mutation 34G>T (G12C). All tumours
investigated were microsatellite stable as judged by the BAT26 amplification
profile.
Discussion
In this nation-wide survey on Swiss APC mutation-negative polyposis patients,
about 20% were found to harbour either biallelic (n=7) or monoallelic (n=6)
germline mutations in the base excision repair gene MYH. Considering only
patients with a family history compatible with autosomal recessive inheritance,
biallelic and monoallelic mutation carriers accounted for 22% of patients with
classical as well as 21% of those with attenuated polyposis, respectively. No
MYH alterations were identified in patients exhibiting a family history suggestive
of an autosomal dominant inheritance pattern.
In addition to the most frequent pathogenic missense mutations, Y165C and
G382D6-8,13, three novel alterations in the MYH gene, R168H, R171Q and
R231H, were detected. Two hundred control chromosomes, assessed in parallel,
did not harbour these missense changes, which proved to be target amino acids
highly conserved across 5 species. Furthermore, whilst R168 and R171
constitute part of a 6 helix barrel domain which contains the Helix-Hairpin-Helix
motif, R231 lies within the alpha-8 helix making up the cluster domain14. Together
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they form part of a DNA binding complex where 9 lysines and 5 arginines form an
electrostatically positive DNA interaction surface. Functional studies are needed
to ascertain the pathogenicity of these mutations. Moreover, since the parents of
the individuals harbouring these gene alterations were not available for
screening, we cannot exclude the possibility that the mutations in the compound
heterozygotes may lie on the same allele.
In our study population, the overall allele frequency of the missense variants
Y165C and G382D amounted to 0.03 (3 from 130) and 0.07 (9 from 130),
respectively. In contrast, these alterations were not present in Swiss control
samples (0/100), similar to reports on Finnish blood donors (0/424) and healthy
British controls (2/100) 6,13. This further substantiates the view that the frequency
of the Y165C and G382D mutations in the general population is too low to justify
large-scale mutation screening19.
Biallelic and monoallelic mutation carriers were evenly classified by the classical
FAP (11% and 11%, respectively) and the AFAP (11% and 8%, respectively)
phenotypes. These values are comparable to previously reported data by Sieber
et al.8. Five (71%) out of 7 biallelic MYH mutation carriers were found to have
less than 100 polyps at the time of diagnosis, four of which also presented with
colorectal cancer. Thus, in contrast to initial studies reporting classical disease
(>100 adenomas) in all biallelic mutation carriers7, the MYH associated-polyposis
phenotype in our patients is predominantly an attenuated one, which is in
accordance with recent investigations by Enholm et al. who investigated a
population-based series of Finnish CRC patients13.
Loss of heterozygosity (LOH) at the APC locus was only present in colorectal
carcinomas, available from two biallelic mutation carriers. Mutation screening of
the mutation cluster region (MCR) of the APC gene did not reveal any pathogenic
somatic mutation, in particular G>T changes, in the colorectal tumor specimens.
This could in part be due to technical problems and/or background contamination
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with normal tissue. Alternatively, the somatic mutations may lie outside of the
region screened. Similar to a recent report by Lipton et al.11, who detected KRAS
oncogene mutations in 60% of carcinomas and 30% of colorectal adenomas, we
identified the KRAS hotspot mutation K12C in both adenocarcinomas as well as
in 1 out of 9 colorectal adenomas. All tumours investigated were microsatellite
stable confirming the negative association reported by Lipton et al.11.
Based on clinicopathological features, it is virtually impossible to separate
biallelic from monoallelic MYH mutation carriers and MYH mutation-negative
polyposis patients who have a family history compatible with autosomal-
recessive inheritance. In all groups, median age at diagnosis did not differ
significantly and family history as well as occurrence of extracolonic disease
were similar. Colorectal adenocarcinomas were significantly (p<0.01) more
frequent among biallelic as compared to monallelic MYH mutation carriers and
MYH mutation-negative polyposis patients, but due to the small number of CRC
patients in the latter group (n=4) no meaningful statistical evaluations could be
performed.
In conclusion, biallelic MYH germline alterations were identified in about 20% of
Swiss APC mutation-negative patients with a family history compatible with
autosomal recessive inheritance and they occurred at similar frequencies in
those with a classical as well as those with an attenuated polyposis phenotype.
Colorectal cancer was significantly more frequent in biallelic as compared to
monoallelic mutation carriers or those without MYH alterations. Based on our
experience and earlier reports, we suggest that MYH mutation screening should
be offered to individuals who fulfill all of the following criteria: a) presence of
classical or attenuated polyposis, b) absence of an APC germline mutation and
c) pedigree compatible with autosomal recessive mode of inheritance. It remains
to be determined within the framework of international collaborative studies if
monoallelic MYH mutation carriers, compared to the general population, may
actually be at an increased risk for developing colorectal cancer.
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Chapter I part ii
Methylation-induced G2/M arrest requires a full
complement of the mismatch repair protein hMLH1
A collaboration with Petr Cejka, University of Zürich, already published in the
EMBO Journal Vol 22. No. 9, p 2245, 2003
Introduction
In approximately 50% of all hereditary nonpolyposis colon cancers (HNPCC) the
mismatch repair (MMR) gene hMLH1 is mutated, whilst in approximately 25% of
sporadic tumors of the right colon hMLH1 is transcriptionally silenced. Through
the study of HNPCC tumor cells it has been demonstrated that repeated
sequence elements (microsatellites) in the genomic DNA are commonly
mutated1. Microsatellite instability (MSI) is now a distinctive feature of defective
mismatch repair, having been demonstrated in all organisms tested to date, and
has been proven to be present in all tumor cell lines having lost both alleles of
hMSH2 and hMLH12,3. It is hence assumed that for a MMR defect to be
apparent, both wild type alleles of the respective MMR gene in cells of HNPCC
tumors have been lost or inactivated by mutation.
The cells’ tendency to acquire mutations increases, especially in genes with
microsatellite repeats, once both MMR gene alleles have been inactivated4. In
cells where the mutated genes are involved in the control of cell proliferation, for
example in the colonic epithelium, then uncontrolled dividing of the cells would
give rise to adenomatous polyp formation. The acquisition of additional mutations
upon subsequent cell divisions within this benign growth would lead to the rapid
transformation of the adenoma into a carcinoma5.
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However, the theory behind cellular transformation and tumour progression still
has to address one question; does the transformation process commence only
following the inactivation of both MMR gene alleles. or does it already begin
when only one allele is affected or when the expression of the MMR gene is only
reduced, such as in cells where the hMLH1 promoter is partially methylated.
In order to be able to study the phenotypic consequences correlated to reduced
levels of MMR proteins, the Zurich group developed a new cell line, epithelial in
origin, in which the expression of hMLH1 could be strictly regulated by
doxycycline (Dox) in conjunction with the TetOff system. Cells grown in the
presence of 0.1, 0.2, 0.4, 0.8 and 1.5 ng/ml Dox contained steadily decreasing
amounts of hMLH1 and hPMS2, as compared with cells grown in the absence of
the drug. My part in this study was to assess the MSI status of the BAT26
chromosomal locus of the 284 293T L cells expressing varying amounts of
hMLH1.
MSI analysis
293T L cells grown with 50, 0.2 and 0 ng/ml Dox were subcloned, and grown
independently for 35 generations. The chromosomal DNA was extracted using
the TRI Reagent (Molecular Research Center, Lucerne, Switzerland). MSI was
assessed for 284 clones at the mononucleotide repeat locus BAT26. PCRs were
carried out in a total volume of 25 ml containing ~100 ng of genomic DNA, as
described by Loukola et al. (2001). The PCR products were diluted 1:4 and 0.5
ml was added to 10 ml deionized formamide (including 0.5 ml GS size standard
400 ROX), denatured at 95°C for 5 min, chilled on ice and loaded on a 96-
capillary ABI PRISM 3700 DNA Analyzer (PE Applied Biosystems). MSI was
defined as the occurrence of novel alleles that differed by 3 nucleotides from the
control3.
Chapter I part ii
39
Results
For the analysis of MSI, the BAT26 microsatellite marker, which contains a
repeat of 26 deoxyadenosines, and which is considered to be a reliable indicator
of MSI, was employed. Since the 293T L cells are hypotriploid, and because the
cell line was MMR deficient for many generations prior to this investigation, the
BAT26 locus was found to be highly heterogeneous. The product of PCR
amplification had on average 8 peaks (Tables 1-3) and hence the HNPCC criteria
of MSI were applied3 whereby only PCR products that differed by 3 or more
peaks at this locus were considered to be a sign of MSI. Following these criteria,
the BAT26 instability in the cells propagated for 35 generations in 0 or 0.2 ng/ml
Dox was approximately 1%, whereas cells grown with 50 ng/ml Dox displayed
MSI that was approximately 5 fold higher (Table 4). Closer inspection of the data
however, revealed that cells propagated in 0 or 0.2 ng/ml Dox displayed no
alleles (0/211) that differed by more than 4bp from the median. In contrast, 2
such alleles (2 out of 73: 2.7%) were found in the cells grown with 50 ng/ml Dox
(Table 1, numbers in brackets). This suggests that MSI at the BAT26 locus in the
293T L cells is substantially greater than in cells expressing hMLH1, and thus
that expression of even low amounts of hMutL are sufficient to correct MMR
defect in these cells.
Table 1: Instability of the BAT26 chromosomal locus in 293T L cells expressing
varying amounts of hMLH1
Dox (ng/ml) MSI+ve / total % MSI +ve
0 2 (0) / 131 1.5
0.2 1 (0) / 80 1.3
50 4 (2) / 73 5.5 (2.7)
MSI+ve clones were defined as those displaying more than 3 extra peaks in the
sequence of the PCR product. Numbers in brackets refer to clones with more
than 4 extra peaks.
Chapter I part ii
40
Discussion
It was observed in this study that hMLH1 expression in 293T L cells corrected
the MMR effect in vitro and in vivo. The 293T L+ cells also proved to be >100
fold more sensitive to killing by MNNG than the isogenic cells lacking hMLH1.
MMR proficient cells treated with MNNG were arrested in the G2/M phase of the
cell cycle which was a reaction found to be solely and entirely dependent on the
function of hMLH1.
It was also apparent that the consistency of hMLH1/hPMS2 heterodimer levels,
essential for MMR proficiency and DNA damage repair, were significantly
different6. Previously proposed was the theory that the constant loading of
hMutS sliding clamps at MeG/T mispairs was responsible for the transmission of
the DNA damage signal to the checkpoint machinery7, and that this process
becomes less efficient in cells expressing only low amounts of the mismatch
binding factor hMutS. However, in this study, the levels of hMutS in 293T L+
and 293T L- cells were equal, and in similar quantities to those found in MMR
proficient cells. Therefore, the results cleaved here, add to the above hypothesis
and suggest that the signal transduction process also needs the hMLH1/hPMS2
heterodimer, which is involved in downstream damage recognition. Interestingly,
MMR proficiency was restored even at low hMLH1 concentrations, while
checkpoint activation required a full complement of hMLH1.
Furthermore, this investigation illustrated that cells with lower than wild-type
amounts of MMR proteins are not phenotypically normal, despite being MMR
proficient. The observed abnormal DNA damage signalling may affect cellular
transformation and tumour progression, especially in epithelial cells that are
proliferating quickly and that may be exposed to stress or carcinogens. Upon
epithelial cell damage, the cell should undergo apoptosis and prevent the
production of mutant progeny. However, cells with defective DNA damage
signalling, such as those with suboptimal levels of MMR proteins, fail to activate
cell cycle checkpoints and apoptosis and hence cells acquire mutations that
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enable them to uncontrollably proliferate and progress eventually into an
adenoma. In the MMR proficient cells, activation of the MNNG-induced G2/M
checkpoint was accompanied by phosphorylation of p53, but the cell death
pathway was p53 independent, as the latter polpeptide is functionally inactivated
in these cells by SV40 large T antigen.
This study has shown that the activation of exogenous hMLH1 transcription
reverses the MMR defect carried by the 293T cells and reactivates their
responsiveness to methylating agents, only when MMR protein levels are
sufficiently high enough to initiate the DNA damage induced checkpoint. The fully
isogenic system used in this study should be employed further for the research
into other DNA metabolism pathways that involve MMR mechanisms.
Furthermore, 293T L cells would be valuable for the screening of substances
that preferentially kill MMR deficient cells, hence proving crucial in the treatment
of tumours displaying aberrant MMR.
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Table 1: Samples 1-136, 0-DOX. MSI present in %
Sample No. Peak size 1 Peak size 2 Total allele no. MSI ( > 11 alleles)
1 112.38 115.35 8 stable
2 112.38 115.4 8 stable
3 112.4 7 stable
4 112.43 115.45 8 stable
5 112.44 116.4 9 stable
6 112.36 116.33 9 stable
7 112.27 116.35 9 stable
8 112.37 115.36 8 stable
9 LOW
10 111.33 115.43 10 stable
11 112.4 115.3 7 stable
12 111.27 115.37 8 stable
13 113.43 6 stable
14 112.37 115.41 9 stable
15 112.45 116.4 9 stable
16 112.39 115.33 9 stable
17 111.41 115.38 10 stable
18 112.29 115.27 10 stable
19 112.37 115.31 9 stable
20 114.32 8 stable
21 112.43 8 stable
22 112.41 115.5 8 stable
23 112.37 116.33 9 stable
24 112.38 116.37 9 stable
25 112.42 8 stable
26 112.46 7 stable
27 112.3 116.42 9 stable
28 112.43 8 stable
29 112.38 115.33 8 stable
30 112.36 115.38 9 stable
31 111.4 114.32 9 stable
32 112.35 115.27 8 stable
33 112.29 116.29 9 stable
34 112.3 115.24 10 stable
35 113.37 116.36 8 stable
36 111.4 115.37 9 stable
37 112.42 8 stable
38 112.4 7 stable
39 112.46 8 stable
40 112.41 116.41 9 stable
41 112.44 115.37 8 stable
42 112.35 116.29 9 stable
43 112.33 116.34 9 stable
44 LOW
45 112.3 116.27 9 stable
46 112.32 116.31 9 stable
47 112.52 115.32 9 stable
48 112.41 115.4 11 unstable
49 112.44 116.43 9 stable
50 111.45 115.4 8 stable
51 112.41 115.41 8 stable
52 112.37 115.34 7 stable
53 112.39 115.33 7 stable
54 112.37 116.3 9 stable
55 112.41 114.37 8 stable
56 111.34 115.3 9 stable
57 112.35 116.26 9 stable
58 112.34 116.32 9 stable
59 112.5 8 stable
60 111.43 115.39 9 stable
61 112.29 115.4 8 stable
62 112.38 115.41 8 stable
63 112.41 115.45 8 stable
64 112.41 115.45 9 stable
65 112.32 116.37 9 stable
66 112.36 116.3 9 stable
67 112.37 115.39 10 stable
68 112.39 116.35 9 stable
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69 112.55 9 stable
70 112.36 116.33 8 stable
71 112.48 115.34 8 stable
72 111.51 114.35 9 stable
73 112.31 8 stable
74 112.42 115.4 9 stable
75 112.37 115.35 8 stable
76 112.39 116.34 9 stable
77 112.38 116.34 9 stable
78 112.32 9 stable
79 112.31 115.35 9 stable
80 112.39 116.28 9 stable
81 112.37 115.31 8 stable
82 112.31 9 stable
83 112.41 9 stable
84 112.26 115.31 8 stable
85 112.28 9 stable
86 111.49 115.38 9 stable
87 111.42 9 stable
88 112.41 116.41 9 stable
89 112.35 116.36 9 stable
90 112.35 116.35 9 stable
91 111.39 115.4 9 stable
92 112.35 116.38 9 stable
93 112.35 8 stable
94 112.32 115.28 9 stable
95 112.36 115.34 9 stable
96 112.39 8 stable
97 111.33 115.36 9 stable
98 112.35 115.35 8 stable
99 112.33 116.31 10 stable
100 112.38 115.41 8 stable
101 112.39 116.34 9 stable
102 112.43 115.36 8 stable
103 112.47 8 stable
104 110.45 115.36 11 unstable
105 112.37 8 stable
106 110.39 112.35 9 stable
107 112.35 116.29 10 stable
108 112.35 115.28 8 stable
109 112.44 8 stable
110 112.48 7 stable
111 112.39 115.37 9 stable
112 111.42 115.38 9 stable
113 112.44 116.36 9 stable
114 112.42 115.32 8 stable
115 112.35 115.33 8 stable
116 112.36 115.38 8 stable
117 LOW
118 112.33 116.34 9 stable
119 112.32 115.25 8 stable
120 112.35 115.33 8 stable
121 112.43 115.38 8 stable
122 LOW
123 112.27 115.36 9 stable
124 112.51 114.44 8 stable
125 112.37 115.35 9 stable
126 112.43 115.38 9 stable
127 112.43 115.38 9 stable
128 112.32 115.32 9 stable
129 112.48 115.39 9 stable
KO
130 112.33 8 stable
131 112.38 8 stable
132 111.36 7 stable
133 112.41 8 stable
134 112.41 116.35 9 stable
135 LOW
136 112.35 115.44 8 stable
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Table 2: Samples 1-84, 50-DOX. MSI present in %
Sample No. Peak size 1 Peak size 2 Total allele no. MSI ( > 11 alleles)
1 111.43 8 stable
2 112.4 8 stable
3 112.43 114.34 8 stable
4 112.33 9 stable
5 LOW
6 LOW
7 112.43 115.42 8 stable
8 112.39 115.32 9 stable
9 111.55 8 stable
10 112.45 8 stable
11 112.41 115.4 9 stable
12
13 112.44 115.45 9 stable
14 112.49 115.43 9 stable
15 112.3 8 stable
16 110.48 115.38 11 unstable
17 112.47 115.48 9 stable
18 112.45 115.42 9 stable
19 112.41 115.46 9 stable
20 111.47 115.5 8 stable
21 115.41 8 stable
22 112.4 9 stable
23 112.35 115.4 9 stable
24 112.42 8 stable
25 111.42 115.38 10 stable
26
27 112.44 5 stable
28 112.41 115.41 9 stable
29 111.39 115.39 9 stable
30 112.44 115.44 9 stable
31 112.42 114.41 8 stable
32 112.4 9 stable
33 111.45 9 stable
34 112.45 8 stable
35 112.44 9 stable
36 112.37 8 stable
37 112.45 8 stable
38 112.41 9 stable
39 112.41 115.41 8 stable
40 111.39 115.4 8 stable
41 112.39 115.38 9 stable
42 112.37 115.31 9 stable
43 111.38 115.39 9 stable
44 112.38 115.36 9 stable
45 109.47 115.4 13 unstable
46 111.34 113.32 8 stable
47 112.42 115.39 9 stable
48 112.37 9 stable
49 112.38 9 stable
50 112.31 116.3 9 stable
51 112.35 115.33 10 stable
52 112.36 115.34 10 stable
53 112.37 114.35 9 stable
54 LOW
55 112.28 9 stable
56 112.34 115.36 9 stable
57 112.45 8 stable
58
59 112.31 115.35 9 stable
60 111.38 115.38 10 stable
61 112.35 9 stable
62 112.52 115.5 9 stable
63 112.39 8 stable
64 112.32 115.32 9 stable
65 LOW
66 112.31 115.29 9 stable
67 112.42 115.42 9 stable
68 LOW
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Table 3: Samples 1-86, 0.2-DOX. MSI present in %
69 LOW
70 111.37 115.4 8 stable
71 112.33 115.32 9 stable
72 LOW
73 112.34 115.27 9 stable
74 112.29 115.28 10 stable
75 112.29 115.28 10 stable
76 112.36 115.31 10 stable
77 LOW
78 112.31 115.32 8 stable
79 112.36 8 stable
80 110.35 114.29 11 unstable
81 112.34 8 stable
82 112.37 115.37 9 stable
83 112.33 6 stable
84 112.32 13 unstable
Sample No. Peak size 1 Peak size 2 Total allele no. MSI ( > 11 alleles)
1 112.54 115.37 9 stable
2 112.29 115.27 8 stable
3 112.4 115.4 8 stable
4 112.42 115.34 7 stable
5 112.55 115.38 9 stable
6 112.38 116.37 9 stable
7 112.46 115.46 7 stable
8 112.36 115.4 9 stable
9 112.4 115.38 9 stable
10 112.42 116.29 9 stable
11 112.41 8 stable
12 LOW
13 112.36 116.36 9 stable
14 112.35 116.32 9 stable
15 112.4 115.37 8 stable
16 112.43 115.45 9 stable
17 112.39 115.33 9 stable
18 112.38 116.4 9 stable
19 112.32 115.17 8 stable
20 112.47 115.4 9 stable
21 112.42 115.4 9 stable
22 112.47 115.47 8 stable
23 112.37 116.36 9 stable
24 112.35 116.35 9 stable
25 112.37 116.33 9 stable
26 LOW
27 110.43 114.34 9 stable
28 111.45 115.37 10 stable
29 112.33 116.31 9 stable
30 112.37 116.33 9 stable
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31 112.4 115.4 8 stable
32 LOW
33 112.4 116.34 10 stable
34 112.41 115.34 9 stable
35 112.36 115.35 8 stable
36 112.43 7 stable
37 112.35 116.35 9 stable
38 112.34 116.32 9 stable
39 112.34 6 stable
40 112.39 115.29 9 stable
41 112.39 115.34 8 stable
42 112.32 116.37 9 stable
43 112.38 115.27 8 stable
44 112.36 115.34 8 stable
45 111.31 115.28 9 stable
46 111.38 114.35 9 stable
47 112.38 115.41 8 stable
48 112.32 115.29 9 stable
49 111.27 115.27 9 stable
50 112.33 115.26 9 stable
51 112.38 9 stable
52 112.33 116.28 10 stable
53 112.45 115.41 9 stable
54 112.33 116.34 9 stable
55 112.29 115.27 9 stable
56 112.31 115.29 9 stable
57 112.34 116.35 9 stable
58 LOW
59 112.32 9 stable
60 112.32 115.33 9 stable
61 112.34 116.35 9 stable
62 112.3 116.33 10 stable
63 112.33 115.26 10 stable
64 112.29 116.29 10 stable
65 112.32 115.25 9 stable
66 112.27 115.26 10 stable
67 112.35 116.32 10 stable
68 112.34 115.27 9 stable
69 LOW
70 112.36 115.34 9 stable
71 112.28 114.32 8 stable
72 112.34 115.29 9 stable
73 112.32 115.32 8 stable
74 LOW
75 112.37 115.37 8 stable
76 112.29 115.3 9 stable
77 110.34 112.28 11 unstable
78 111.4 114.34 9 stable
79 112.3 116.27 10 stable
80 112.29 116.26 10 stable
81 112.28 115.3 9 stable
82 112.31 7 stable
83 112.29 115.3 10 stable
84 112.33 116.44 9 stable
85 112.32 116.34 10 stable
86 111.39 115.33 10 stable
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Chapter I part iii
Mismatch repair haploinsufficiency and accumulation of target
gene mutations in colorectal cancer with microsatellite
instability
A collaboration with Luigi Lhagi, Istituto Clinico Humanitas, Rozzano, that has
been prepared as a scientific paper for publication
Introduction
It is now well known that cancers with defects in the mismatch repair system
display characteristic changes at repetitive DNA sequences1, termed as
microsatellite instability2. MSI has been observed in both hereditary cancer
syndromes (Hereditary Non Polyposis Colorectal Cancer, HNPCC) and those
arising sporadically3. On acquiring a germline mutation in one of the mismatch
repair genes hMLH1, hMSH2 or hMSH6, the gene becomes predisposed to
inactivation4. In sporadic MSI cancers, the inactivation of hMLH1 is often a result
of epigenetic silencing through promoter hypermethylation5.
MMR proficiency is reliant on multiple protein interactions which form functional
DNA repair complexes. Hence, the inactivation of one gene causes unbalanced
protein equilibrium and results in deficient repair complexes. In a fully functional
MMR system, the hMSH2-hMSH6 (MutS-) preferentially recognises mispaired
bases and single repeat frameshifts due to insertion/deletion loops, whilst the
larger loops are delt with by the hMSH2-hMSH3 heterodimers (MutS-). The
hMLH1-hPMS2 (MutL) complex functions to excise replication errors6. Therefore,
despite sharing the common  characteristic of MSI, carcinomas harbouring a
MMR defect differ with regards to the specific mutation type7,8 depending on the
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MutS-/ or MutL activity and also in relation to the presence of hMSH3 and
hMSH69. It has further been shown that MSI cancers accumulate inactivating
frameshift mutations in secondary mutators as well as in other cancer related
genes eg. target genes TGFRII, BAX, CASP-5, TCF4 and MBD4. The joint
existence of primary and secondary mutations can reduce further the efficiency
of repair at mutated sequences, and hence increase the risk of accumulating
replication errors10. It therefore follows that the accumulation of several MMR
gene mutations may result in haploinsufficiency of the MMR, which would
subsequently be reflected in the degree of the mutator phenotype and hence, if
the mutational spectrum of MSI cancer cells reflect the type and the extent of
MMR deficiency, the prevalence of frameshift mutations in target genes may be
related to the deficiency of the primary mutator as well as to the presence of
genetic alterations in secondary mutators. Although research with cell lines
support this hypothesis, additional data from MSI tumour series are required to
define this theory further.
Mutations in the hMSH3 and hMSH6 genes may affect the haplotype of the
repair complexes MutS and MutS, respectively, and hence the variability of
frameshift mutations, and the degree to which secondary mutator frameshift
mutations affect these, aswell as the effect on the pathological invasive
behaviour of the MSI CRC caused by such genetic damage, may differ between
MSI CRCs. It was therefore the aim of this study to investigate the prevalence of
frameshift mutations in secondary mutator genes and in other target genes in a
series of MSI-high CRCs with hMLH1 and hMSH2 deficiency, from both
hereditary and sporadic cases in different pathological stages.
We established 18 CRCs to be microsatellite unstable, through BAT26 analysis,
and arranged to have them included in the Milan mismatch repair
haploinsufficiency research project. My part in this study was to confirm MSI
status and extract DNA from the 18 CRC samples proving to be unstable. I also
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conducted the DNA sequence analysis for 2 individuals suspected of harbouring
an hMSH2 gene mutation, as determined through immunohistochemistry testing.
Methods
DNA Extraction
Tumor DNA was isolated from formalin fixed, paraffin embedded tissue using the
QIAMP DNeasy Tissue kit and according to the suggested protocol of the
manufacturer (Qiagen, Switzerland). After verification of the tumor cell content
(>70%) of HE stained tumor specimen, 10x 5-8m thick tumor sections were cut
from each paraffin block. Lysis of the tissue was completed overnight with
Qiagen buffer, Proteinase K and an incubation temperature of 55°C. The
samples were then washed twice with Qiagen wash buffer and the DNA finally
eluted in 100 l elution buffer provided.
Microsatellite Instability Analysis
Microsatellite instability was confirmed for a total of 18 tumors at the
mononucleotide repeat locus BAT26. PCRs were carried out in a total volume of
25 ml containing ~50 ng of tumor DNA. The PCR products were diluted 1:4 and
0.5 ml was added to 10 ml deionized formamide (including 0.5 ml GS size
standard 400 ROX), denatured at 95°C for 5 min, chilled on ice and loaded on a
96-capillary ABI PRISM 3700 DNA Analyzer (PE Applied Biosystems). MSI was
defined as the occurrence of novel alleles that differed by ±3 nucleotides from the
median, 8 peaks (Loukola et al., 2001).
Direct DNA Sequencing of hMSH2
Exon specific primer pairs (sequences as reported by Kolodner) were used to
amplify the 16 exons of hMSH2, including the respective exon-intron boundaries,
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from genomic DNA. Fifty microlitres of PCR reaction mixture contained 100ng of
genomic DNA, 0.5M each primer, 2.5M each dNTP, 5mM MgCl2, 10x reaction
buffer, and 0.2U Taq polymerase (Qiagen, Switzerland). The reaction parameters
were; 94°C-3 mins for 1 cycle, 94°C-30 secs, 53°C-30 secs and 72°C-45 secs for
35 cycles, and 72°C-3 mins for 1 cycle, for a Hybaid OmnE Thermocycler
(Catalys AG, Wallisellen, CH). The sequencing reaction was completed using the
Thermosequenase Sequencing Kit (Amersham Pharmacia, Switzerland). PCR
amplicons were diluted 1:3 and enzymatically purified with shrimp alkaline
phosphatase and exonuclease I (Amersham Pharmacia, Switzerland). The
purified PCR products were run through a cycle sequencing reaction with primers
labeled with an infrared dye; T7-IRD800 and SP6-IRD-800 for forward and
reverse sequencing, respectively. Cycle sequencing parameters were 95°C-
3min. for 1 cycle, 95°C-30 sec. 55°C-30 sec. and 72°C-1min. for 30 cycles. The
resulting products were loaded onto a 6% denaturing polyacrylamide gel and
analysed on a LiCor 4000L automated DNA Sequencer (LiCor, Lincoln, NE).
Results
We involved 18 MSI CRC samples from the cohort of patients enrolled in the
HNPCC screening program, of the Human Genetics Department, Basel. These
together with 43 identified from the patients undergoing surgery for colorectal
cancer at the Istituto Clinico Humanitas from 1997 to 2002, comprised a total of
61 MSI CRC specimens. All cancers shared BAT26 instability; hMLH1 and
hMSH2 protein loss (either by in vitro test or by immunoistochemistry) was
determined in every instance, and mutational status was assessed in 25 cases.
Seven hMLH1 and 6 hMSH2 germline mutations were detectable (Table 1 for my
contribution). Amsterdam criteria for HNPCC were fulfilled in 29 cases. Among
the investigated cancers, 38 were of A or B Dukes’ stage, and 19 were of C or D
stages, and in 4 cases it was not possible to properly ascertain the pathological
stage.
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Considering the 7 studied targets, the medians of frameshift mutations were
similar in hMLH1 and in hMSH2 deficient cancers (4 and 5, respectively), and
inheritance did not correlate with the severity of the mutator phenotype.
However, the hMSH2 deficient and the hMLH1 deficient cancers with
frameshifted hMSH3 and/or hMSH6 harboured a median of 4 frameshifts in the
other investigated genes, while the hMLH1 deficient cancers with wild-type
secondary mutators  had a median of only 2 frameshifts (p<0.0023). Non-
metastic and metastatic MSI CRC also showed similar frameshift medians (5 and
4, respectively), but the prevalence of cancers with alterations of both MutSα and
MutSβ haplotypes was higher in non-metastatic (23 out of 29, 79%) than in
metastatic (15 out of 28, 53%) cases (p=0.04).
hMSH2 Gene Sequence Analysis Results
Family
ID
Gene Exon Codon DNA
Change
Mutation
Consequence
MSI/
RER
Sex Age at
Diagnosis
Primary
Cancer
BItalia 1 MSH2 10 526 1576del
A
Frameshift MSI-
High
F 36 Rectum
BItalia 9 MSH2 16 882 2646del
A
Frameshift MSI-
High
M 76 Sigmoid
Table 1: The 2 Basel samples I sequenced, for the specific identification of hMSH2 mutations
Discussion
In microsatellite unstable colorectal tumours (MSI CRCs), instability at target
genes varies. The individual mutational frequency and also the distribution of
frameshift mutations differs among colorectal cancers with a mismatch repair
deficiency11,12. Laghi et al. discovered that in the tumours they investigated in this
study, carcinomas with MutS haplotype deficiencies displayed a higher number
of frameshift mutations than the MutL deficient cancers. Such a finding fits the
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progressive model of mutator mutations initially suggested by Malkhosyan et al13,
which notes the importance of secondary monoallelic mutator mutations in the
context of a cumulative haploinsufficiency model14. Laghi also observed that a
higher number of frameshifts occurred in those tumours with MutS haplotype
deficiencies as compared to those with MutL deficiency only, and in addition, any
MutS haplotype deficiency can lead to an increased number of frameshifts of the
investigated targets in MutL deficient tumours. Previous studies report that an
inherited modality of MMR defects can affect the extent of the microsatellite
mutator phenotype2. However, Laghi observed in this study that an increased
number of frameshifts in tumours with an hMLH1 loss correlates with MutS
deficiencies, as opposed to correlating with the inheritance of a CRC
predisposition15,16.
In this study, the hMSH2 deficient tumours, with and without secondary mutator
alterations, had a median of four target gene frameshifts at the investigated
targets. This suggests that the MutS deficient tumours share a similar unrepaired
instability of short repeats once their mutator phenotype is established. They
suggest further investigation into the role of hMSH3 and hMSH6 mutations in
hMSH2 deficient cancers in order to assess the relevance of secondary mutator
mutations in hMLH1 deficient cell lines11,12.
With the exception of the early TGFRII mutations17,18 the genotype-phenotype
correlations of CRCs during carcinogenesis of the microsatellite pathway are not
well documented. In addition, it is still a question whether some target gene
mutations (eg TGFRII, BAX) can influence MSI tumour progression19,20,21.
Recent reports suggest that the frequency of somatic mutations of TGFRII,
BAX, hMSH3, hMSH6, TCF4 and IGFRII is not different in the metastatic
tumours as compared to the primary ones22. In the tumours Laghi investigated,
target gene frameshifts were as equally common in non metastatic MSI CRCs as
they were in metastatic ones. Hence, the accumulation of frameshifts at the
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targets observed does not appear to be related to the stage of tumour
progression. Laghi suggests that it is rather a multistep mutator damage pathway
that affects MMR proficiency and hence unrepaired target gene mutations
accumulate during MSI carcinogenesis. In addition, since defects in both MutS
haplotypes was observed to be significantly associated with non metastatic
disease in Laghi’s study, importantly, a high degree of instability can potentially
be a positive prognostic factor.
In conclusion, this study has been able to expand the notion that MMR
haploinsufficiency in CRCs of the microsatellite mutator phenotype vary to an
extent, by illustrating that frameshift mutations inactivating the alleles of target
genes are more prevalent in tumours with MutS deficiencies than in tumours with
MutL deficiencies only.
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Chapter I part iv
The investigation into the loss of MMR genes in a consecutive
series of 1048 colorectal tumors from patients with familial
colorectal carcinomas
A collaboration with Giancarlo Marra, University of Zürich, which will lead to the
eventual publication of a scientific paper.
Introduction
In 60-70% of HNPCC kindreds the disease is caused by germline mutations in
one of the DNA mismatch repair (MMR) genes, hMSH2, hMLH1,hMSH6, hPMS1
or hPMS21. Two of these genes, hMLH1 and hMSH2,account for almost 90
percent of all identified mutations known to date. hMSH6 accounts for almost 10
percent, but its role in the typical as opposed atypical hereditary nonpolyposis
colorectal cancers remains to be fully established2,3. Additionally, rarer germline
mutations have been reported in hPMS24,5.
Gene No. of mutations
identified to date
No. of missense
mutations (% of
total)
No. of
polymorphisms
hMLH1
hMSH2
164
121
47 (29)
19 (16)
20
24
hMSH6 31 12 (39) 43
hPMS2 1 0 0
hPMS1 5 1 (20) 5
Table 1: Total of mutations and polymorphisms established to date in patients suspected of
harboring HNPCC. Data source: the International Collaborative Group on HNPCC,
http://www.nfdht.nl
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When inactivated they lead to genetic instability and thus, by increasing the
genome-wide mutation rate, indirectly promote tumour growth6. The evolutionarily
highly conserved MMR genes function as “guardians of the genome.” They
detect and initiate the repair of both base:base mispairs and insertion/deletion
mispairs which occur during replication and in addition prevent the recombination
of divergent sequences (for review see Jirincy, 1999)7. Inactivation of the MMR
system through mutation of one of its components consequently leads to
genomic instability, as illustrated by microsatellite instability (MSI). MSI can be
observed in 75 to almost 100% of tumours stemming from HNPCC patients8,9.
Approximately 11-38% of sporadic CRCs also display genomic instability in
conjunction with a somatic mismatch repair defect, mainly due to promoter
hypermethylation of hMLH110.
The immunohistochemical technique has been proven to be the most sensitive
and specific method for the identification of hMLH1 and hMSH2 gene alterations
in our studies (data not published 2003) and hence, along with the conclusions of
previous reports11,12 this method can be said to be a rapid and efficient means of
detecting colorectal carcinomas associated with the HNPCC syndrome.
The Zurich group investigated, via IHC screening, 1048 consecutive colorectal
cancers in a prospective study of patients suspected of having an HNPCC
syndrome. They found that 13.2% of these individuals lacked the expression of
one of the mismatch repair proteins. They felt it necessary to confirm the IHC
data with MSI analysis. They sent the tumour DNA from 187 patients to our
department for me to conduct BAT26 MSI testing.
In addition, the IHC screening identified 15 patients with tumours depicting a loss
of the hPMS2 protein in the presence of hMLH1. The hPMS2 gene encodes a
homolg of the bacterial MutL and the yeast PMS1 MMR proteins. It functions in a
heterodimer with MLH1, which may bind to a complex of hMSH2 and
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mismatched DNA12. Subsequently, the mismatched bases are excised and
replaced with the appropriate nucleotides12. The identification of germline
mutations in hPMS2 in patients affected with HNPCC has highlighted its role in
cancer predisposition4,5,13. To assess the true nature of this hPMS2 IHC negative
staining, three routes of investigation were proposed i) hPMS2 LOH analysis, ii)
hPMS2 methlation status analysis and iii) hPMS2 direct DNA sequencing. I
conducted the hPMS2 LOH analysis.
Methods
MSI analysis
MSI was assessed for a total of 187 tumors from patients with suspected
HNPCC, at the mononucleotide repeat locus BAT26. DNA was extracted by the
Zürich research group and sent to Basel. DNA concentrations varied from 12
ng/l (microdissected tumor) to 99 ng/l. PCRs were carried out in a total volume
of 25 ml containing ~100 ng of tumour DNA, 50ng of DNA for the microdissected
sample. The PCR products were diluted 1:4 and 0.5 ml was added to 10 ml
deionized formamide (including 0.5 ml GS size standard 400 ROX), denatured at
95°C for 5 min, chilled on ice and loaded on a 96-capillary ABI PRISM 3700 DNA
Analyzer (PE Applied Biosystems). MSI was defined as the occurrence of novel
alleles that differed by ±3 nucleotides from the median, 8 peaks14.
PMS2 LOH Analysis
Loss of heterozygosity (allelic loss) analysis at the microsatellite loci D7S517,
D7S518 and D7S666 (for hPMS2) was performed according to the standard
protocol with the use of 6-FAM, HEX and TET-labeled oligonucleotides. Twenty-
five microlitres of PCR reaction mixture contained approximately 50ng of
genomic DNA, 0.5M each primer, 2.5M each dNTP, 5mM MgCl2, 10x reaction
buffer, and 0.2U Taq polymerase (Invitrogen, Switzerland). The reaction
parameters were; 94°C-2 mins for 1 cycle, 94°C-1 min, 55°C-1 min and 72°C-1
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min for 30 cycles, and 72°C-6 mins for 1 cycle, for a Hybaid OmnE Thermocycler
(Catalys AG, Wallisellen, CH). Samples were analysed on an ABI Prism 310
Genetic Analyser (Applied Biosystems) and classified as having allelic loss if the
dose of one allele in the tumor was at least 50% lower than that of the other
allele.
Results
For the analysis of MSI, the BAT26 microsatellite marker, which contains a
repeat of 26 deoxyadenosines, and which is considered to be a reliable indicator
of MSI, was employed. The product of PCR amplification had on average 8
peaks and hence the HNPCC criteria of MSI were applied14 whereby only PCR
products that differed by 3 or more peaks at this locus were considered to be a
sign of MSI. Following these criteria, the BAT26 instability in the tumors samples
investigated was equal to 75% (141 from 187 unstable, Table 2). These unstable
tumors proved to be 100% consistent with those lacking the expression of either
hMLH1 or hMSH2 (data not shown).
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Table 2: The MSI Status of the 187 tumors investigated as determined by
microsatellite analysis with BAT26.
Sample No. Hospital Tumour
No.
Year DNA Conc.
ng/ul
BAT26 MSI
Status
1 Aarau 22529 2000 100 unstable
2 Aarau 23416 2000 60.5 stable
3 Aarau 22104 2000 57 stable
4 Aarau 20758 2000 91.5 unstable
5 Aarau 6579 J 2000 100 unstable
6 Aarau 6579 K1 2000 61 unstable
7 Aarau 9465 2000 86 stable
8 Aarau 10570 2000 88 unstable
9 Aarau 15659 2000 48 unstable
10 Aarau 25013 2000 100 unstable
11 Aarau 6110 2001 42 unstable
12 Aarau 7869 2001 100 stable
13 Aarau 15581 2001 63 unstable
14 Aarau 1398 2004 100 unstable
15 Aarau B00.16655 2000 100 unstable
16 Aarau B01.5194 2001 100 unstable
17 Aarau B01.6831 2001 100 unstable
18 Aarau B01.7467 2001 100 unstable
19 Aarau B01.14685 2001 100 unstable
20 Aarau 5160 2002 95 unstable
21 Aarau 10335 2001 100 unstable
22 Aarau B01.7467 2001 100 unstable
23 Luzern B 1081 2000 100 unstable
24 Luzern B 55121 2000 35 unstable
25 Luzern B 53430 2000 100 unstable
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26 Luzern B65453 2000 93 unstable
27 Luzern B63887 2000 100 unstable
28 Luzern B58560 2000 38 unstable
29 Luzern B56727 2000 96.5 unstable
30 Luzern B56601 2000 100 stable
31 Luzern B63850 2000 100 unstable
32 Luzern B69999 2000 100 unstable
33 Luzern B67543 2000 46 unstable
34 Luzern B50005 2001 93.5 unstable
35 Luzern B53460 2001 100 unstable
36 Luzern B9549 2001 40.5 unstable
37 Luzern B63.585 2001 100 unstable
38 Luzern B60661 2001 60 unstable
39 Luzern B67255 2001 46 unstable
40 Luzern B70511 2001 100 unstable
41 Luzern B20244 2001 71.5 stable
42 Luzern B52458 2002 100 unstable
43 Luzern B50263 2002 64.5 unstable
44 Luzern B52201 2002 100 unstable
45 Luzern 50716 2002 100 stable
46 Luzern 55998 2000 100 unstable
47 Luzern 307 2001 100 unstable
48 Luzern 23.348 2001 100 unstable
49 Luzern 55843 2002 100 unstable
50 Luzern 54631 2002 96 unstable
51 Luzern B6852 2001 46 stable
52 Luzern B60404 2002 100 unstable
53 Luzern B61104 2002 100 unstable
54 Luzern B64041 2002 100 unstable
55 Luzern B65509 2002 100 unstable
56 Luzern B66221 14X 2002 100 unstable
57 Luzern B66221 5X 2002 100 unstable
58 Luzern B66221 6X 2002 100 unstable
59 Luzern B66062 2002 100 stable
60 Luzern B64501 2000 63 unstable
61 Luzern B69770 2000 100 unstable
62 Luzern B53072 2001 100 unstable
63 Luzern B61263 2001 83 unstable
64 Luzern B59255 2001 100 unstable
65 Luzern B66543 2001 100 unstable
66 Luzern B66686 2001 100 stable
67 Luzern B66732 2001 100 unstable
68 Luzern B69101 2001 100 unstable
69 Luzern B52557 2002 51 stable
70 Luzern B54832 2002 100 unstable
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71 Luzern B53989 100 unstable
72 Luzern B60244 100 stable
73 Luzern B61162 73 unstable
74 Luzern B65950 100 unstable
75 Luzern B17676 100 stable
76 Luzern B50612 79 stable
77 Luzern B51692 100 stable
78 Luzern B52086 64 stable
79 Luzern B50.316 15 stable
80 Luzern B61282 100 unstable
81 Luzern B51385 100 unstable
82 Luzern B2248 100 stable
83 Luzern B51527 100 stable
84 Luzern B52187 100 unstable
85 Luzern B50.316 BIS 100 stable
86 Luzern B52557 BIS 92 stable
87 Luzern B52013 100 unstable
88 Luzern B51.470 100 unstable
89 Luzern B52285 100 unstable
90 Luzern B67035 100 stable
91 Luzern B50633 100 unstable
92 Luzern B54013 100 stable
93 Luzern B59519 100 unstable
94 St Gallen B00/218 D 99 unstable
95 St Gallen B00/2019 F 100 unstable
96 St Gallen B00/2503 H 100 unstable
97 St Gallen B00/12306 C 48 unstable
98 St Gallen B00/17296 D 75 unstable
99 St Gallen B00/17520 F 52 unstable
100 St Gallen B00/18573 I 67 unstable
101 St Gallen B00/19353 D 82 unstable
102 St Gallen B00/7366 H 60 unstable
103 St Gallen B00/21492 D 100 unstable
104 St Gallen B00/22391 45 unstable
105 St Gallen B00/18102 BIS 100 unstable
106 St Gallen B00/27498 BIS 100 unstable
107 St Gallen B00/31381 BIS 100 stable
108 St Gallen B00/17879 56 unstable
109 St Gallen B00/27300 G 100 stable
110 St Gallen B00/31381 D 62 stable
111 St Gallen B00/34746 E 100 unstable
112 St Gallen B00/32757 F 100 unstable
113 St Gallen B00/32707 F 100 unstable
114 St Gallen B00/35096 I 100 unstable
115 St Gallen B00/37919 J 42 unstable
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116 Triemli 9521 45 unstable
117 Triemli 10024 100 stable
118 Triemli 7713 100 stable
119 Triemli 8771 97 stable
120 Triemli 12167/00 100 stable
121 Triemli 13458T/00 100 unstable
122 Triemli 662/02 100 unstable
123 Triemli 14016/02 59 unstable
124 Triemli 00/11628 100 unstable
125 Triemli 13297/00 100 unstable
126 Triemli 7784/00 100 stable
127 Triemli 2421/00 100 unstable
128 Triemli 6534/00 100 unstable
129 Triemli 6459/00 99 unstable
130 Triemli 655/00 75 unstable
131 Triemli B01.20140 90 unstable
132 Triemli 3950/02 100 stable
133 Triemli 12886/02 100 unstable
134 Triemli 14503/02 100 unstable
135 Triemli 00/20719T 100 stable
136 Triemli 00/19372T 100 unstable
137 Triemli 00/17325 100 unstable
138 Triemli 00/16165 100 unstable
139 Triemli 5941/00 43 unstable
140 Triemli 00/20079T 100 unstable
141 Triemli 14895/00 100 unstable
142 Triemli 22857 T4/00 100 unstable
143 Triemli 22643/00 100 unstable
144 Triemli B01.19698 100 unstable
145 Triemli B01.12251 76 stable
146 Triemli B01.1648 100 unstable
147 Triemli B01.11768 100 unstable
148 Triemli B01.13452 100 unstable
149 Triemli B01.13674 100 unstable
150 Triemli 14230 T/00 100 unstable
151 Triemli 20719T BIS 100 stable
152 Triemli 12287 I/01 100 unstable
153 Triemli 12406 T2/01 100 stable
154 Triemli 11656 T3/01 100 unstable
155 Triemli 11779 T1/01 100 unstable
156 Triemli 14124 T1/01 100 unstable
157 Triemli 15600 T2/01 100 unstable
158 Triemli 17291 T3/01 100 unstable
159 Triemli 19604 T1/01 100 unstable
160 Triemli 4734 T3/01 100 unstable
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161 Triemli 22752 T1/01 100 unstable
162 Triemli 22666 T4/01 100 unstable
163 Triemli 23697/01 91.5 stable
164 Triemli 700/01 100 unstable
165 Triemli 9658 T1/01 100 unstable
166 Triemli 11318 T1/01 100 unstable
167 Triemli 13617 T1/01 90.5 unstable
168 Triemli 21532 T1/01 100 stable
169 Triemli 22577 T2/01 100 stable
170 Triemli B01.21269 100 unstable
171 Triemli B00.11752 100 stable
172 Triemli B00.7429 100 unstable
173 Triemli B00.20498T 100 unstable
174 Triemli B00.13894T 30 stable
175 Triemli B00.4556 87 stable
176 Triemli B00.12167 BIS 100 stable
177 Triemli B02.22058 T3 37 unstable
178 Triemli B02.22058 M 82 unstable
179 Triemli B02.25698 146 unstable
180 Triemli B02.25898 38 unstable
181 Triemli B02.24854 126 unstable
182 Triemli B03.1953 87 unstable
183 Triemli B03.2243 35 unstable
184 UNIspital B01.20938 90 stable
185 UNIspital B01.20938 BIS 89 unstable
186 UNIspital B01.27499 63 stable
187 UNIspital B01.27499 12
(microdissected)
stable
The 187 tumour samples investigated for BAT26 MSI. Microsatellite unstable
tumours were defined as those displaying more than 3 extra peaks in the
sequence of the PCR product. The hospital which made the referral for analysis
is listed.
Further analysis involved the investigation of 15 tumour samples, depicting loss
of the hPMS2 protein in the presence of hMLH1 as demonstrated via IHC testing,
for PMS2 LOH. Three microsatellite markers were employed, D7S517, D7S518
and D7S666. Non of the samples showed LOH for any of the hPMS2 markers.
However, MSI was detected through the use of these markers in 13/15 (87%) of
the tumours (Table 3). The microsatellite marker D7S517 identified 11/15 (73%)
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of the unstable tumours, whilst marker D7S666 highlighted instability in 8/15
(53%) and marker D7S518 only 2/15 (13%). Overall, marker D7S517 was the
most informative giving a result for each tumour sample analysed. Markers
D7S666 and D7S518 produced results after repeated runs for 9/15 (60%) and
5/15 (33%) of the samples, respectively.
Sample No. Hospital Tumour
No.
D7S517 D7S518 D7S666
1 Aarau 5194 MSI Non
informative
MSI
2 Aarau 16655 MSI MSI MSI
3 Triemli 11318 MSI 0.85 MSI
4 Triemli 20498 1.02 Non
informative
MSI
5 Luzern 53072 0.64 0.74 MSI
6 Luzern 66543 MSI Non
informative
Non
informative
7 Luzern 66732 MSI Non
informative
Non
informative
8 Luzern 52557 1.22 Non
informative
Non
informative
9 Luzern 54832 MSI MSI 1.40
10 Luzern 59519 MSI Non
informative
MSI
11 Luzern 64501 MSI Non
informative
Non
informative
12 Luzern 61263 1.03 Non
informative
Non
informative
13 Luzern 53989 MSI 1.05 Non
informative
14 Luzern 61162 MSI Non
informative
MSI
15 Luzern 65950 MSI Non
informative
MSI
Table 3: The 15 tumour samples investigated for LOH at the D7S517, D7S518
and D7S666 hPMS2 loci. Non depicted LOH although 87% showed MSI.
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Discussion
The concordance between BAT26 instability testing and IHC negative staining is
100% accurate and proves not only the sensitivity and specificity of both methods
in identifying tumors of an HNPCC nature, but also highlights their efficiency as
prescreening methods for the identification of mismatch repair (MMR) gene
mutations.
BAT26, has before been proven to be the most sensitive and the most specific
microsatellite marker for the identification of aberrant mononucleotide repeats15
and certainly proves its value here. However, despite its high sensitivity and
specificity in this study, and other recent reports that use BAT26 as the sole
studied microsatellite marker, caution needs to be applied as MSI-High tumors
have been described that do not display instability at the BAT26 locus16. Caution
should also be taken when employing immunohistochemistry as the sole
screening method for the identification of MMR gene alterations. Optimal
screening, and hence the best rate of mutation detection, is possibly only
achieved through a combined approach, incorporating immunohistochemical
analysis as well as a DNA and an mRNA-based method. This is a suggestion
based on two facts i) different screening methods have their own failures: IHC
and PTT fail to detect missense mutations whilst direct DNA sequencing fails to
identify large, exon spanning deletions/insertions aswell as hypermethylation of
the hMLH1 promoter ii) MMR genes have a diverse mutational spectra and lack
regions of “hot spots”.
The microsatellite marker D7S517 proved to be the most effective and reliable
LOH/MSI marker, giving a result for each tumor sample analysed and depicting
hPMS2 microsatellite instability in 73% of the investigated tumor samples.
However, further investigations, ie. DNA methylation and sequence analyses,
into the cause of the hPMS2 protein loss have yet to be conducted and the
results cleaved. Before these projects are completed, the full extent to the
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success of IHC in the screening of colorectal cancer patients cannot be
concluded and phenotypic/geneotypic correlations concerning the hPMS2 IHC
negative staining cases cannot be made.
When the Zürich group have completed all lab based investigations and their
collection of clinical data on the consecutive series of the 1048 patients enrolled
in this study, the results cleaved from the analyses correlating phenotypical and
genotypic characteristics will be ultimately important in aiding the future
identification of MMR gene mutations in HNPCC patients.
Chapter I part iv
70
References
1. Lynch, H. T., de la Chapelle, A.: Hereditary colorectal cancer. N Engl J
Med 348 919-32 Review,  2003
2. Wijnen, J., de Leeuw, W., Vasen,  H., van der Klift, H., Moller, P.,
Stormorken,  A., Meijers-Heijboer, H., Lindhout, D., Menko, F., Vossen, S.,
Moslein, G., Tops, C., Brocker-Vriends,  A., Wu, Y., Hofstra, R., Sijmons,
R., Cornelisse, C., Morreau, H., Fodde, R.: Familial endometrial cancer in
female carriers of MSH6 germline mutations. Nat Genet 23 142-4, 1999
3. Park, Y. J., Shin, K. H., Park, J.G.: Risk of gastric cancer in hereditary
nonpolyposis colorectal cancer in Korea. Clin Cancer Res 6 2994-8, 2000
4. Nicolaides, N. C., Papadopoulos, N., Liu, B., Wei, Y. F., Carter,  K. C.,
Ruben, S. M., Rosen, C. A., Haseltine, W. A., Fleischmann, R. D., Fraser,
C. M., et al.: Mutations of two PMS homologues in hereditary
nonpolyposis colon cancer. Nature 371 75-80, 1994
5. Nicolaides, N. C., Carter,  K. C., Shell, B. K., Papadopoulos, N.,
Vogelstein,  B., Kinzler, K. W.: Genomic organization of the human PMS2
gene family. Genomics 30 195-206, 1995
6. Kinzler, K. W. and Vogelstein, B: Cancer-susceptibility genes.
Gatekeepers and caretakers. Nature 386 761-3, 1997
7. Jiricny, J. and Nyström-Lahti, M: Mismatch repair defects in cancer. Curr
Opin Genet Dev. 10 157-61, 2000
8. Peltomaki,  P. T.: Genetic basis of hereditary nonpolyposis colorectal
carcinoma (HNPCC). Ann Med 26 215-9, 1994
9. Dietmaier, W., Wallinger, S. Bocker, T., Kullmann, F., Fishel, R., Ruschoff,
J.: Diagnostic microsatellite instability: definition and correlation with
mismatch repair protein expression. Cancer Res 57 4749-56, 1997
10. Wheeler, J. M., Bodmer, W. F., Mortensen, N. J.: DNA mismatch repair
genes and colorectal cancer. Gut 47 148-53, 2000
11. Chaves, P., Cruz, C., Lage,  P., Claro, I., Cravo,  M., Leitao,  C. N.,
Soares, J.: Immunohistochemical detection of mismatch repair gene
Chapter I part iv
71
proteins as a useful tool for the identification of colorectal carcinoma with
the mutator phenotype. J Pathol  191 355-60, 2000
12. Modrich, P.: Mismatch repair, genetic stability, and cancer. Science 266
1959-60 Review, 1994
13. Hamilton, S. R., Liu, B., Parsons, R. E., Papadopoulos, N., Jen, J., Powell,
S. M., Krush, A. J., Berk, T., Cohen,  Z., Tetu, B., et al.: The molecular
basis of Turcot's syndrome. N Engl J Med  332 839-47, 1995
14. Loukola,  A., Eklin, K., Laiho, P., Salovaara,  R., Kristo, P., Jarvinen,  H.,
Mecklin, J. P., Launonen, V., Aaltonen,  L. A.: Microsatellite marker
analysis in screening for hereditary nonpolyposis colorectal cancer
(HNPCC). Cancer Res 61 4545-9, 2001
15. Dietmaier, W., Wallinger, S., Bocker, T.,  Kullmann, F., Fishel, R.,
Ruschoff, J.:  Diagnostic microsatellite instability: definition and correlation
with mismatch repair protein expression. Cancer Res 57 4749-56, 1997
16. Hoang, J. M., Cottu,  P. H., Thuille, B., Salmon, R. J., Thomas,  G.,
Hamelin, R.: BAT-26, an indicator of the replication error phenotype in
colorectal cancers and cell lines. Cancer Res 57 300-3, 1997
Chapter I part v
72
Chapter I part v
Frequency of MSH6 mutations in HCT116 clones on treatment
with the DNA methylating agent N-methyl-N’-nitro-N-
nitrosoguanidine (MNNG)
A collaboration, with Giancarlo Marra, University of Zürich, as part of an ongoing
study.
Introduction
Only a limited number of germline mutations in hMSH6 and hMSH3 have been
reported in HNPCC patients suggesting that inherited mutations in these
mismatch repair genes do not play a crucial role in the predisposition to
hereditary colon cancers1-5. The proteins of these two genes independently form
complexes with hMSH26-8. The hMSH2-hMSH6 complex recognises single-base
mispairs and small (ie. single-base) insertion/deletion loops9,10, whilst the
hMSH2-hMSH3 complex focuses on small and large deletion loops but does not
appear to have the ability to identify single-base substitution mispairs6,7,9,11,12.
Germline mutations of hMSH6 found to be associated with HNPCC have been
reported in limited numbers13-17. Since hMSH6 gene alterations result in the high
accumulation of base substitution mutations there are two possible explanations
for the rarity of hMSH6 mutations in HNPCC families11,18. In the first instance, all
investigated HNPCC families were microsatellite unstable (MSI) at dinucleotide
repeat loci, a phenotype not caused by the loss of MSH6 function, hence
disqualifying potential hMSH6 mutant families from further study4,11,15. Secondly,
the great majority of target tumor suppressor genes inactivated in HNPCC are
done so by frameshift mutations in mononucleotide repeats11,19,20. Since the loss
of functional MSH6 proteins does not cause the rate of frameshift mutations to
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increase11 these target genes may not be hypermutable when hMSH6 is
mutated.
Since the very first reports on hMSH6 mutations were made13,14, an atypical
clinical phenotype of families with hMSH6 germline mutations has begun to
formulate. An excess of endometrial cancers17, and late onset17,21 have
characterised the individual, whilst a low degree of microsatellite instablity16
and/or preferential involvement of mononucleotide repeats have proposed to
characterise the tumors from patients carrying hMSH6 mutations15,22. However,
typical Amsterdam-I HNPCC families have also been documented as hMSH6
mutation positive17, with the prevalence of endometrial cancers reportedly low21,
22. In addition, hMSH6 mutations are occasionally related to the early onset of
cancer15 and a high degree of tumor microsatellite instability13,17. In families not
harboring hMSH2 or hMLH1 germline mutations, the frequency of hMSH6
germline mutations vary from 0% among Amsterdam I families with MSI-high
tumours4 to 22% among families with suspected HNPCC and MSI-low tumours16.
In families with hMSH2 and hMLH1 germline mutations excluded, hMSH6
germline mutations have been reported to occur in 5-10%17,21.
The Zürich research group I was working with in collaboration on this project,
observed that on treatment with the DNA methylating agent N-methyl-N’-nitro-N-
nitrosoguanidine (MNNG), HCT116+chr.3 clones did not express MSH6 proteins.
It appears to be a response exclusive to the HCT116+chr.3 cell line since they
treated other cell lines similarly but did not achieve the same response. It was my
responsibility to conduct the hMSH6 mutation analysis on the DNA from these
clones in order to establish any hMSH6 germline mutations. I established an
optimised protocol for the rapid and sensitive mutation analysis of hMSH6 via
high performance liquid chromatography (DHPLC) and subsequent direct DNA
sequencing.
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Methods
MSH6 PCR Amplification
Exon specific primer pairs (sequences as reported by Kolodner et al. 1999)21
were used to amplify the 10 exons of MSH6, including the respective exon-intron
boundaries. Twenty-five microlitres of PCR reaction mixture contained 50ng of
genomic DNA, 0.5M each primer, 2.5M each dNTP, 5mM MgCl2, 10x reaction
buffer, and 0.2U Taq polymerase (Invitrogen, Switzerland). The reaction
parameters were set in three different programs;  96°C-4 mins for 1 cycle,
96°C-20 sec, 70°C-20 sec (-1°C/cycle) and 68°C-20 sec for 15 cycles; 96°C-20
sec, 55°C-20 sec and 68°C-20 sec for 25 cycles, and 68°C-7 mins for 1 cycle, 
95°C-10 mins for 1 cycle, 95°C-40 sec, 65°C-20 sec (-1°C/cycle) and 72°C-20
sec for 10 cycles; 94°C-20 sec, 55°C-20 sec and 72°C-20 sec for 25 cycles, and
72°C-7 mins for 1 cycle,  same as program 2 although the time for incubation at
72°C was increased to 40 sec, all for a Hybaid OmnE Thermocycler (Catalys AG,
Wallisellen, CH).
Denaturing High Performance Liquid Chromatography (dHPLC)
dHPLC was performed using the 3500HT WAVE nucleic acid fragment analysis
system (Transgenomic, Crewe, UK). Melting temperatures for dHPLC were
predicted by the Wavemaker software version 4.1.42 (Transgenomic) (dHPLC
melting temperatures available from author upon request). Where different
elution profiles were observed, in comparison to control samples run in parallel,
direct DNA sequencing was performed in order to establish the nature of the
sequence alteration.
MSH6 Mutational Analysis
PCR products were purified using the QIAquick PCR Purification kit (Qiagen,
Basel, Switzerland). The sequencing reaction was performed using the Big Dye
Teminator Cycle Sequencing kit (Applied Biosystems, Rotkreuz, Switzerland),
according to the manufactures' guidelines. Subsequently, sequencing products
were purified using the DyeEx 2.0 Spin Kit (Qiagen, Basel, Switzerland) and
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analysed on an ABI PRISM 310 Genetic Analyser (Applied Biosystems).
Germline mutations established in MSH6 were confirmed in both forward and
reverse directions, from at least 2 independent PCR products.
Results
In table 1 are listed the sequencing results from the hMSH6 mutation analysis
screening. All clones harboured the same hMSH6 gene alteration in exon 5, an
inserted C at position 2631. Clones 202G, 202T and 202U displayed a frameshift
mutation which resulted from the deleted G at position 2804-2805. In clone 202 a
splice donor site mutation was established. This was the only clone to display a
G>A substitution. This latter mutation is the only mutation to be known and
documneted as a result of MNNG treatment.
Exon BVEC
D9
BVEC
E2
BVEC
F7
202
A
202
C
202
E
202
G
202
Q
202
T
202
U
202
X
HCT116
+3
1 OK OK OK OK OK OK OK OK OK OK OK OK
2 OK OK OK OK OK OK OK SD(+1)
G>A
OK OK OK OK
3 OK OK OK OK OK OK OK OK OK OK OK OK
4A OK OK OK OK OK OK OK OK OK OK OK OK
4B OK OK OK OK OK OK OK OK OK OK OK OK
4C OK OK OK OK OK OK OK OK OK OK OK OK
4D OK OK OK OK OK OK OK OK OK OK OK OK
4E OK OK OK OK OK OK OK OK OK OK OK OK
4F OK OK OK OK OK OK 2804-
5delG
OK 2804-
5delG
2804-
5delG
OK OK
5 326
insC
326
insC
326
insC
326
insC
326
insC
326
insC
326
insC
326
insC
326
insC
326
insC
326
insC
326
insC
6 OK OK OK OK OK OK OK OK OK OK OK OK
7 OK OK OK OK OK OK OK OK OK OK OK OK
8 OK OK OK OK OK OK OK OK OK OK OK OK
9 OK OK OK OK OK OK OK OK OK OK OK OK
10 OK OK OK OK OK OK OK OK OK OK OK OK
Table 1: The results of the hMSH6 mutation analysis involving the direct DNA
sequencing of HCT116+chr.3 clones. hMSH6 germline mutations are highlighted
in green.
Discussion
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MNNG causes methylation in the O6 position of guanine and the resulting O6-
methylguanine (O6-MeG) pairs with thymine instead of cytosine, leading to GC to
AT transition mutations23,24,25. O6-MeG paired with thymine is subject to repair by
the mismatch repair system26,27. O6-MeG-generating agents are powerful
mutagens and carcinogens but a lack of mismatch repair confers resistance to
cytotoxicity and hence raises the level of mutagenic response in cells28,29,30. This
suggests that genotoxic and cytotoxic effects of O6-MeG are mediated by
mismatch repair. Such an erroneous mismatch repair response may be related to
the repeated misincorporation of thymine opposite O6-MeG or by the signalling
for apoptotic functions due to faulty mismatch repair mechanisms.
The repair of O6-methylguanine-thymine base pairs by mismatch repair is
correlated to the binding of the MSH2-MSH6 protein complex31,32. Although
functional studies have been conducted on the individual mismatch repair
proteins, little has been reported on the regulation of mismatch repair as a whole.
It has previously been shown that MSH2 is cell cycle dependent, since MSH2 is
higher in abundance in proliferating rather than resting cells33. Whether MSH2
and/or other mismatch repair proteins are controlled by exogenous stimuli,
especially mutagenic treatments, has yet to be established.
One group34 reported an observed increase in MutS and GT binding activity in
the nucleus on treatment with O6-methylguanine generating mutagens, indicating
a novel type of genotoxic stress response. They suggest that the regulation of
mismatch repair upon DNA damage occurs primarily at the level of post-
translational modification (including nuclear transportation) as opposed to at the
level of gene activation. The early translocation of mismatch repair proteins into
the nucleus is intended to increase mismatch repair capacity in the nucleus. This
would be highly important with regard to the O6-MeG/C lesions forming on
replication of the mutagenic GT mismatches.
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Mismatch repair defects are associated with various hereditary cancers35,32,36 and
have also been shown to increase immensely the resistance of cells to O6-MeG
generating agents23,24,30,37,38. Mismatch repair defects hence have a strong
involvement with the mutagenic and carcinogenic response of cells to alkalyting
agents.
The Zürich group are in the process of planning further projects in relation to this
study. Future studies may involve the transfection of MSH3 into this cell line,
which is currently hMSH3 mutated, to establish any correlation between MSH3
being present and functional, and the presence of MSH6.
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Chapter II
Exclusion of a modifier gene locus on chromosome 1p33-36 in a
large Swiss familial adenomatous polyposis kindred
This paper has already been published in the European Journal of Cancer.
Abstract
Familial adenomatous polyposis (FAP), an autosomal dominantly inherited
colorectal cancer predisposition syndrome, displays considerable inter- and intra-
familial phenotypic heterogeneity, which represents a major problem in genetic
counselling of APC mutation carriers. The Min mouse model indicated a putative
disease modifier locus on chromosome 4, which is syntenic to human
chromosome 1p35-36. This finding was subsequently supported by parametric
and non-parametric linkage analyses in FAP families, however, without
identifying functional variants in candidate genes. Recently, germline mutations
in the base-excision repair gene MYH, which maps to the 1p33-34 region, have
been described in patients with multiple adenomas, pointing to a possible role as
disease modifier in FAP. Here, we present critical re-assessment of one of the
largest FAP kindreds published, which was previously used in linkage mapping of
1p35-36. In this family all affected members harbour the same germline mutation
(5945delA) at codon 1982 of the APC gene but display marked phenotypic
variability, in particular regarding the occurrence of extracolonic disease which
segregates in several branches of the family tree.
Using up-dated clinical information, additional mutation carriers and polymorphic
markers, fine-mapping of the critical region as well as mutation analysis of the
MYH gene were performed. These investigations allowed us to (i) significantly
exclude the 1p33-36 region as a modifier locus and (ii) MYH as a modifier gene
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for extracolonic disease in this FAP kindred. The results indicate that linkage
analysis of further putative candidate regions is necessary to identify a disease
modifier locus in FAP.
Introduction
Familial adenomatous polyposis (FAP) is an autosomal dominantly inherited
predisposition to colorectal cancer caused by germline mutations in the APC
(adenomatous polyposis coli) gene. Patients develop hundreds to thousands of
adenomas throughout the large intestine some of which, unless prophylactic
colectomy is performed, eventually progress to colorectal cancer before the age
of 40 1. Phenotypically, it is a heterogenous disease in which patients may also
present with a number of extracolonic disease manifestations such as congenital
hypertrophy of the retinal pigment epithelium (CHRPE), osteomas, and soft
tissue tumors (epidermoid cysts, lipomas, fibromas, desmoid tumors), as well as
upper gastrointestinal (GI) polyposis 2,3. Desmoid tumours and duodenal cancer
represent the major cause of mortality in FAP patients who have undergone
colectomy 4. The inability to predict disease severity in the individual FAP patient
(APC mutation carrier) represents a major difficulty in genetic counselling and in
defining optimal clinical screening and prevention strategies. Part of the inter-
and intra-familial phenotypical differences can be explained by the position of the
germline APC mutations. However, despite established genotype-phenotype
correlations, many phenotypic differences can not be completely explained by
the site and type of the germline APC mutation 5, and other genetic factors
(modifier genes) are expected to play important roles in disease development.
In support of this, two loci that modify polyp multiplicity in the FAP phenotype
have been identified in the Min (multiple intestinal neoplasia) mouse model of
FAP. The Mom1 locus (Modifier of Min 1) has been assigned to the mouse
chromosome 4 6, which has synteny to human chromosome 1p35-36, and where
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the secretory phospholipase A2 (Pla2g2a) gene has been identified as a strong
candidate for suppression of the Min phenotype 7,8. The second locus, Mom2
(Modifier of Min 2), has recently been mapped to mouse chromosome 18 which
has synteny to the human chromosome 18q21 and 18q23 9,10. Both loci, Mom1
and Mom2, were found to reduce the number of polyps in Min mice and their
synteny regions on the human chromosomes 1 and 18 are known to be
frequently deleted/lost in a variety of human cancers, including colon tumors 11-
14.
So far, by means of mutation analysis, no functional variants of Pla2G2A have
been detected in humans 15-17, and the possibility that another locus close to
Pla2G2A actually represents Mom1 lead our group and others to further
investigations of the 1p35-36 region by means of parametric- and non-parametric
linkage analysis. However, these studies neither significantly excluded nor
confirmed a human FAP modifier locus in 1p35-36 18,19. Furthermore, germline
mutations in the base-excision gene MYH, which maps to the 1p33-34 region,
have recently been described in patients with multiple adenomas, in some of
which extracolonic disease (desmoids) are also present 20,21. This may
implicate MYH as a possible FAP modifier, as MYH mutations/variants in
combination with germline APC mutations could be expected to enhance the
FAP disease phenotype.
To assess the role of the 1p32-36 region as a candidate modifier locus, we re-
investigated a large Swiss FAP kindred (No. 1460) part of which was previously
used in linkage analysis of this region, and where a lod score of 2.08 was found
for an autosomal recessive model 19. In the 7 years since this analysis has been
performed, 13 additional members of family 1460 were identified and up-dated
clinical information on the known mutation carriers gathered, which enabled us to
perform an extended linkage analysis of the 1p32-36 region as well as a mutation
analysis of the new candidate modifier gene in this region, the MYH gene.
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Methods
Patient data
The large Swiss FAP kindred comprises over 200 family members, whereof all
affected members (n=63) share the same APC germline mutation in exon 15n,
5945delA, leading to a frameshift starting from codon 1982 and a premature stop
codon at position 2044. In 50 members (Figure 1; Table 1) belonging to the
pedigree branches with extracolonic manifestations, histopathological data and
reports from colonoscopies, gastro-duodenal endoscopies, computer
tomographies, surgery, autopsies, as well as information from regular dental
examinations, were collected and re-evaluated for the present study. Only
patients with verified data from clinical and histopathological reports were used
for linkage analysis. Written informed consent was obtained from all individuals.
Figure 1 Extract from FAP kindred no.1460 displaying branches with
extracolonic disease manifestations. Symbol description: (a) upper right
quadrant: presence of desmoids and fibromas, (b) lower right quadrant: upper
gastrointestinal polyps, (c) lower left quadrant: osteomas, (d) upper left quadrant:
other extracolonic manifestations.
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Genotyping of polymorphic markers
Genotyping was performed using fluorescently-labelled primers from the ABI
Prism Linkage mapping Set-MD10 (PE Applied Biosystems; 22-24) and by
means of custom primers of the markers from the 1p32-36 region. These
markers were selected according to their map location and their heterozygosity
status, using the following internet websites: http://www.ucsc.genome.org 25,
ftp://bioinformatics.weizmann.ac.il/pub/databases/genethon/Gmap/Nature1995/d
ata/ 24. Primers were FAM and HEX fluorescently-labelled, and PCR reactions
done according to the manufactures' protocol, using True Allele PCR Premix
(Applied Biosystems), and a Gradient Mastercycler (Eppendorf). PCR products
were pooled according to their size, subsequently combined with ROX400-HD
size standard (Applied Biosystems) and electrophoresed on an ABI PRISM®
3700 DNA Analyzer (Applied Biosystems). Genotype determinations were
automated using GeneScan and Genotyper softwares (Applied Biosystems).
Genotyping was only performed in APC mutation carriers and their married-in
members.
Linkage analysis
Microsatellite data was checked for genotyping errors using the PEDCHECK
program 26. Two-point parametric LOD score linkage analysis was performed
using the MLINK program from the LINKAGE package 27. Lod scores were
calculated for both autosomal dominant (disease allele frequency 0.0781) and
autosomal recessive (disease allele frequency 0.1000) models. Marker allele
frequencies were set to be equal. Disease allele frequencies for the dominant
model were calculated using the Hardy-Weinberg equilibrium formula
(p2+2pq+q2=1), assuming a 10% frequency of extracolonic disease
manifestations in FAP patients. Penetrance of 1.00 and 0.95 was used for the
recessive model, and of 0.90 and 0.85 for the dominant model. Furthermore, age
dependent penetrance for extracolonic manifestation was estimated from our
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pedigree and followingly 6 different liability classes were used in the dominant
model: 0.157 (20 years), 0.368 (30 years), 0.684 (40 years), 0.895 (50
years), 0.947 (60 years), 0.999 (70 years). Penetrance of phenocopies was set
to be 0.001. Only APC mutation carriers (and their married-in members) were
included in the analysis, as only in these members extracolonic manifestations
are expected to result from both APC and modifier gene mutations. Polyposis
patients with colonic disease only were classified as having an “unaffected“
affection status, married-in members as having an “unknown“ phenotype.
Patients presenting with extracolonic disease manifestation(s) were evaluated
applying two different sets of criteria: (a) stringent criteria: only patients
displaying at least adenomatous polyps in the upper GI tract and/or desmoids
were classified as `affected` with the others being classified as `unknown`; (b)
loose criteria: all patients with confirmed extracolonic manifestation(s) were
scored as `affected` (Table 1). One patient with bronchial carcinoma was
classified as `unknown` in all analyses.
MYH Mutational Analysis
Exon specific primer pairs were used to amplify the 16 exons of MYH, including
the respective exon-intron boundaries20. Twenty-five microlitres of PCR reaction
mixture contained 100ng of genomic DNA, 0.5mol/l each primer, 2.5mol/l each
dNTP, 1.5mmol/l MgCl2, 10x reaction buffer, and 0.2U Taq polymerase
(Invitrogen). The reaction parameters were; 95°C-5 mins for 1 cycle, 95°C-1 min,
60°C-1 min and 72°C-1 min for 35 cycles, and 72°C-10 mins for 1 cycle, for a
Hybaid OmnE Thermocycler (Promega).
Subsequently, dHPLC was performed using the 3500HT WAVE nucleic acid
fragment analysis system (Transgenomic). Melting temperatures for dHPLC were
predicted by the Wavemaker software version 4.1.42 (Transgenomic). Where
different elution profiles were observed, in comparison to control samples run in
parallel, direct DNA sequencing was performed in order to establish the nature of
the sequence alteration.
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PCR products were purified using the QIAquick PCR Purification kit (Qiagen).
The sequencing reaction was performed using the Big Dye Teminator Cycle
Sequencing kit (Applied Biosystems), according to the manufactures' guidelines.
Sequencing products were purified using the DyeEx 2.0 Spin Kit (Qiagen) and
analysed on an ABI PRISM 310 Genetic Analyser (Applied Biosystems).
Germline mutations established in MYH were confirmed in both forward and
reverse directions, from at least 2 independent PCR products.
Results
Clinical data
In previous studies 19,28 we reported a large FAP kindred (no. 1460), originating
from the Poschiavo region in Switzerland, whose affected members present with
a highly variable phenotype, on the level of both, colonic as well as extracolonic
disease manifestations. Fifty family members of this kindred, belonging to sub-
branches displaying extracolonic disease were clinically re-evaluated for this
study (Table 1). In general, the polyposis phenotype among APC mutation
carriers was found to be relatively mild, as could be expected by the site of the
germline mutation, with 26 (65%) patients displaying attenuated polyposis (less
than 100 polyps). However, the polyposis phenotype was very variable, ranging
from severe forms with more than 1000 polyps (2 patients) to the very mild form,
where no polyps (3 patients at age 22, 29, and 47, respectively) or less then 10
polyps (3 patients at age 32, 33, 47, respectively) were present.
In 26 patients, extracolonic tumours developed, the majority of these being
desmoids (15/26; 57.7%) and upper gastrointestinal polyps (16/26; 61.5%).
Adenomatous origin of the polyps was confirmed in 9 patients, other polyps were
diagnosed as fundus gland polyps, which developed to a great extent in 3
patients (one of them without colon polyps at age 47). Apart from these frequent
disease manifestations, others were also reported (see Table 1).
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Table 1: Phenotypic characteristics in 50 APC mutation carriers from FAP family no.1460.
LA = linkage analysis; AS = affection status used in linkage analysis;
         * = patients included in MYH mutation screening
ID Colorectal polyps
Stomach 
polyps
Duodenum 
polyps
Desmoids or 
Fibromas
Included in 
LA AS
1460-1 <100 yes 1
1460-4 <100 yes yes 2
1460-6 >100 yes yes 2
1460-7 <100 yes yes yes 2
1460-8 unknown yes yes 2
1460-9 >100 yes 1
1460-10 <100 yes yes yes 2
1460-11 <100 yes 1
1460-16 >100 yes Osteoma yes 0/2
1460-19* >100 yes yes 2
1460-21 unknown Osteoma yes 0/2
1460-24 <100 yes salivary gland adeno-carcinoma prostate tumour yes 2
1460-26 >100 yes yes yes yes 2
1460-28 <100 yes 1
1460-33 <100 yes 1
1460-42 >100 yes 1
1460-44 <100 yes 1
1460-46* <100 yes yes 2
1460-47 >100 Bronchial-Ca yes 0
1460-48* >100 yes 1
1460-55 >100 yes 1
1460-86 <100 yes 1
1460-88 <100 yes 1
1460-89 <100 yes 1
1460-91 <100 yes yes yes 2
1460-93 >100 yes 1
1460-12 <100 yes 1
1460-106 <100 yes 1
1469-1 <100 yes yes yes Osteomas, Lipoma yes 2
1469-4 <100 yes Osteoma no 0/2
1489-B* >100 yes yes 2
1489-E unknown yes 1
1501-1* < 100 yes yes Osteomas yes 2
1501-2 >100 yes yes yes 2
1501-4 <100 yes yes 2
1501-5 unknown yes 1
1747-1 <100 yes 1
1779-1* >100 yes Osteoma yes 0/2
1489-C unknown yes 1
1489-D unknown yes 1
1489-F unknown yes 1
1460-112 <100 yes no 0/2
1779-2 >100 yes yes 0/2
1460-116 <100 yes yes no 2
1460-105 <100 yes 1
1460-122 unknown yes leukemia no 2
1460-5 unknown yes 1
1489-no <100 yes yes no 2
1489-no unknown yes yes 2
1624-4 <100 yes yes yes no 2
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Linkage analysis
Simulation linkage analysis, previously performed in family no.1460 using the
same diagnostic criteria and parameters as employed for linkage analysis (see
methods), revealed a maximum expected lod score of 3.8 to 5.3 for autosomal
dominant models, and 1.9 to 2.7 for autosomal recessive models.
Twenty-eight polymorphic markers spanning 58.7 cM and 50.2 Mb 25 of the
1p32-36 region (Figure 2), respectively, were used for two-point linkage analysis
under an autosomal dominant model with age-dependent penetrance. No
evidence for the existence of a dominant modifier locus for extracolonic FAP
disease was found. Lod scores throughout the region 1p33-36 were below –2
(except for three markers, D1S3669, D1S255 and D1S2733, with lod scores of -
1.6, -1.9 and –0.6, respectively), thus excluding this region as a possible modifier
locus (Table 2). This region is known to include both the Pla2G2A and MYH
genes. In the region 1p32.1-32.3, although most of the markers gave negative
lod scores, only a portion of markers showed lod scores below –2, thus
significantly excluding some loci. In one marker a slightly increased lod score
(D1S417, maximum lod score of 0.7 at =0) was found, which is not exclusive,
and possibly results from low informativity of this particular marker in our family.
To exclude the possibility that our negative results were due to choosing the
wrong mode of inheritance, the analysis was also performed using an autosomal
recessive model at penetrance 0.95 and 1.00, as well as an autosomal dominant
model at reduced penetrance of 0.90 and 0.85, respectively (data not shown). All
analyses, under both stringent and loose diagnostic criteria, resulted in negative
lod scores below –2, except for the above mentioned markers D1S3669 and
D1S417, and marker D1S231 (lod scores below –1.5, 0.1, and 0.8, respectively)
hence excluding the 1p32-36 region as a modifier locus of extracolonic disease
in our FAP kindred.
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Figure 2  Physical map of the 1p32-36 region.  Marker order and physical
distance (Mb) were determined according to the UCSC genome bioinformatics
site 25.
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Lod score at recombination fraction ()
Marker Region 0 0.005 0.01 0.02 0.03 0.04 0.05 0.06 0.07 0.1 0.2 0.3 0.4
D1S2667 1p36.22 -4.94 -2.67
-
2.34
-
1.99
-
1.77
-
1.60
-
1.46
-
1.35
-
1.25
-
1.01
-
0.53
-
0.25
-
0.08
D1S436 1p36.13 -3.95 -1.72
-
1.41
-
1.11
-
0.93
-
0.81
-
0.72
-
0.65
-
0.59
-
0.47
-
0.28
-
0.18
-
0.09
D1S2697 1p36.13 -3.45 -2.03
-
1.70
-
1.33
-
1.11
-
0.94
-
0.81
-
0.70
-
0.61
-
0.40
-
0.10
-
0.03
-
0.01
D1S3669 1p36.13 -1.63 -1.55
-
1.49
-
1.38
-
1.28
-
1.19
-
1.11
-
1.04
-
0.97
-
0.79
-
0.40
-
0.17
-
0.04
D1S2647 1p36.13 -2.37 -2.18
-
2.03
-
1.80
-
1.62
-
1.47
-
1.35
-
1.24
-
1.15
-
0.93
-
0.49
-
0.26
-
0.11
D1S199 1p36.13 -5.86 -4.18
-
3.79
-
3.32
-
3.01
-
2.75
-
2.54
-
2.36
-
2.20
-
1.81
-
0.97
-
0.46
-
0.15
D1S2864 1p36.12 -4.71 -4.07
-
3.70
-
3.19
-
2.82
-
2.53
-
2.28
-
2.06
-
1.88
-
1.42
-
0.56
-
0.18
-
0.03
D1S234 1p36.11 -6.23 -5.10
-
4.62
-
4.01
-
3.59
-
3.25
-
2.98
-
2.74
-
2.53
-
2.03
-
1.01
-
0.46
-
0.14
D1S2885 1p36.11 -4.59 -3.63
-
3.15
-
2.56
-
2.16
-
1.86
-
1.62
-
1.42
-
1.25
-
0.86
-
0.24
-
0.06
-
0.03
D1S2787 1p35.3 -2.38 -2.26
-
2.15
-
1.97
-
1.81
-
1.68
-
1.56
-
1.45
-
1.36
-
1.11
-
0.56
-
0.25
-
0.07
D1S2830 1p35.1 -2.87 -2.19
-
1.88
-
1.50
-
1.24
-
1.04
-
0.88
-
0.74
-
0.62
-
0.34 0.11 0.18 0.07
D1S255 1p34.3 -1.98 -1.48
-
1.23
-
0.92
-
0.71
-
0.56
-
0.43
-
0.33
-
0.24
-
0.04 0.23 0.24 0.12
D1S2743 1p34.2 -2.77 -1.86
-
1.56
-
1.22
-
1.00
-
0.83
-
0.69
-
0.58
-
0.48
-
0.26 0.10 0.17 0.10
D1S2645 1p34.2 -2.50 -2.14
-
1.91
-
1.57
-
1.33
-
1.14
-
0.98
-
0.84
-
0.72
-
0.44 0.02 0.13 0.08
D1S2733 1p34.1 -0.66 -0.63
-
0.60
-
0.55
-
0.50
-
0.45
-
0.41
-
0.37
-
0.33
-
0.23
-
0.04 0.00
-
0.01
D1S2797 1p33 -2.66 -1.76
-
1.46
-
1.12
-
0.91
-
0.75
-
0.62
-
0.51
-
0.42
-
0.22 0.07 0.08 0.01
D1S2874 1p33 -2.74 -2.41
-
2.17
-
1.82
-
1.57
-
1.37
-
1.20
-
1.06
-
0.94
-
0.65
-
0.12 0.07 0.07
D1S2748 1p33 -3.99 -3.06
-
2.72
-
2.32
-
2.04
-
1.82
-
1.63
-
1.48
-
1.34
-
1.00
-
0.37
-
0.10 0.00
D1S197 1p33 -0.78 -0.75
-
0.71
-
0.65
-
0.59
-
0.54
-
0.49
-
0.45
-
0.41
-
0.31
-
0.11
-
0.04
-
0.04
D1S231 1p32.3 -0.08 -0.07
-
0.06
-
0.05
-
0.04
-
0.03
-
0.03
-
0.02
-
0.02
-
0.01
-
0.01
-
0.01
-
0.01
D1S417 1p32.3 0.77 0.76 0.74 0.72 0.70 0.67 0.65 0.63 0.61 0.54 0.36 0.22 0.10
D1S475 1p32.3 -1.94 -1.60
-
1.39
-
1.10
-
0.91
-
0.76
-
0.63
-
0.53
-
0.44
-
0.25 0.03 0.06 0.02
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D1S200 1p32.3 -1.73 -1.25
-
0.99
-
0.68
-
0.47
-
0.31
-
0.17
-
0.06 0.03 0.24 0.51 0.46 0.24
D1S2867 1p32.2 -2.21 -1.78
-
1.52
-
1.15
-
0.90
-
0.71
-
0.55
-
0.42
-
0.31
-
0.07 0.25 0.22 0.06
D1S2665 1p32.2 -2.24 -1.92
-
1.71
-
1.43
-
1.22
-
1.06
-
0.93
-
0.82
-
0.72
-
0.48
-
0.09
-
0.01
-
0.06
D1S2890 1p32.2 -2.14 -2.01
-
1.89
-
1.69
-
1.51
-
1.36
-
1.22
-
1.09
-
0.98
-
0.69
-
0.13 0.07 0.06
D1S2873 1p32.1 -0.95 -0.74
-
0.59
-
0.37
-
0.22
-
0.10
-
0.01 0.07 0.13 0.26 0.38 0.28 0.11
D1S230 1p31.3 -2.57 -2.37
-
2.22
-
1.98
-
1.80
-
1.65
-
1.51
-
1.39
-
1.28
-
1.00
-
0.41
-
0.13
-
0.01
Table 2  Lod scores for autosomal dominant model with age dependent
penetrance using markers from the 1p32-36.
MYH mutation analysis
Six patients from different pedigree branches and with different extracolonic
manifestations were selected for MYH gene mutation analysis (Table 1): three
patients, 1460-46, 1489-B and 1460-19, with desmoids coming from different
pedigree branches (with <100, >100 and >1000 polyps, respectively); patient
1460-48 with more than 1000 colonic polyps; patient 1779-1 with osteomas,
fundus gland polyps and >100 colonic polyps; patient 1501-1 with multiple
desmoids, osteomas, stomach and duodenum adenomas, and only one colonic
polyp. No DNA variants could be detected in all but one of them. Patient 1501-1
was found to harbour a heterozygous G64A alteration (exon 2), resulting in a
substitution of valine to methionine at codon 22 (V22M) of the MYH gene.
Subsequent segregation analysis of the V22M variant identified only one more
patient (1460-16) and his non-affected father as carriers. The variant represents
an already described polymorphism, which was previously reported at a
population frequency of 9-10% 20,21.
Chapter II
94
Discussion
In the present study the 1p33-36 region can be excluded as a modifier gene
locus for extracolonic disease in our large Swiss FAP kindred no.1460. The
analysis was performed on updated family information, and investigating both
more affected family members and more microsatellite markers.  Since our initial
investigation restricted to the 1p35-36 region in 1996, 13 additional patients
either developed extracolonic tumours or were newly referred to our department.
Out of these, 4 were classified as having an `affected` or  `unknown` diagnosis,
depending on the stringency of the affection criteria used. Four patients
previously classified as `affected` were for the present analysis scored as
`unknown`, because original data provided by the patient’s record could not be
confirmed from histopathological records. Furthermore, unlike the previous
analysis, only APC mutation carriers and their spouses were used for linkage
analysis. These differences may explain why the lod score for the autosomal
recessive model dropped from a previously observed 2.08 (D1S211) to below -2
(instead of marker D1S211, markers D1S2645 and D1S2733 were used), and for
the autosomal dominant model a decrease from 1.77 (D1S197) to below –0.7
(Table 2).
Although our linkage results for an autosomal recessive mode of inheritance
resulted in significant exclusion of the 1p32-36 region, we put our emphasis on
autosomal dominant models which seem to be more appropriate in our FAP
kindred for several reasons. Firstly, the ratio of APC mutation carriers with
compared to those without extracolonic disease varied between 0.42 and 0.52,
depending on the affection criteria applied. Secondly, in some of the sub-
branches of family no.1460, extracolonic manifestations are clearly transmitted
through generations (Figure 1). When comparing 12 parent-child pairs with
extracolonic disease present, transmission of extracolonic disease through the
generations could be observed in 100% of informative pairs, suggesting an
autosomal dominant mode of inheritance. Using the stringent phenotype criteria,
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ie. only including patients with at least upper GI adenomatous polyps or
desmoids, transmission was seen in 8 out of 9 pairs (88%).
Phenotype analysis revealed the same clinical heterogeneity as previously
reported 28. Furthermore, when comparing the group of patients with <100 and
those with >100 colorectal polyps, no statistically significant relationship could be
found between polyp number and the occurrence of extracolonic disease in
general (2=0.44, p=0.50). The same was true if only desmoids (2=1.20, p=0.27)
or only upper GI polyps were taken into account (2=0.10, p=0.75). This indicates
that the severity of colonic polyposis does not correlate with the presence of
extracolonic disease manifestations, hence, polyp number and extracolonic
disease may represent two genetically related but distinct entities.
Our linkage analysis data are in agreement with the results from the mutation
screening in PLA2G2A16 and MYH, where, except for the heterozygous V22M
variant present in two patients belonging to different branches of family tree, no
other DNA alterations could be identified in the coding region of the MYH gene.
Although residues 6 to 32 of the MYH protein contain a conserved replication
protein A (RPA)-binding motif 29, valine22 does not belong to the conserved
amino acids. In view of these findings, the V22M variant is unlikely to contribute
to extracolonic disease in this family.
In conclusion, our data on this large Swiss FAP kindred significantly exclude the
1p33-36 region as a modifier locus and MYH as a modifier gene for extracolonic
disease. Since simulation linkage analysis revealed a maximum expected lod
score of 3.8 to 5.3 for autosomal dominant and 1.9 to 2.7 for autosomal recessive
models, future work will concentrate on performing a genome-wide linkage
analysis in this FAP kindred which should help in the identification of a modifier
locus in FAP.
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Chapter III
The phenotypic characterisation of hereditary nonpolyposis
colorectal cancer patients in relation to mismatch repair gene
mutation status
A draft of a scientific paper prepared for publication.
Abstract
Hereditary nonpolyposis colorectal cancer (HNPCC), an autosomal dominantly
inherited syndrome, accounts for approximately 1-5% of all colorectal cancers
and is hence one of the most commonly inherited cancer predispositions.
HNPCC has a frequency of between 1:2000 and 1:200 but has a lower than
expected detection rate, probably accountable for by the failure of the mutation
detection techniques employed, to identify all occurring mismatch repair (MMR)
gene mutations. This study aims to further characterise the phenotype of HNPCC
patients by comparing MMR gene mutation carriers to gene alteration negative
individuals in an attempt to ultimately aid the identification of HNPCC individuals
and MMR gene mutation carriers. One hundred and twenty individuals suspected
of HNPCC were assigned to either the Amsterdam Criteria I/II (AC), the restricted
(ie. minus ACI/II) Bethesda Guidelines (rBG) or the Neither Criteria (NC) group.
Forty-six individuals were assigned a MMR gene mutation positive status, a
further 84 individuals were established as mutation negative, as determined via
microsatellite marker analysis, immunohistochemistry, direct DNA sequencing
and multiplex PCR of short fluorescent fragments for the detection of large
genomic deletions. Statistical evaluation of genotype-phenotype correlations
involved the Chi-square, Fischer exact or Student’s t-test, with all probabilities
reported as two-tailed Ps, considering a P of <0.05 to be statistically significant.
Ninety-four percent (n=43) of the mutation positive patients were classified by
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either the Amsterdam Criteria (AC) or the restricted Bethesda Guidelines (rBG) in
comparison to only 76%, of the mutation negative individuals (p<0.0005).
Mutation positive patients were on average 3 years younger than mutation
negative individuals at the time of their CRC diagnosis. Whilst the sex ratio
divided the overall study population evenly, the investigated females were
significantly more frequently found to be mutation negative than mutation positive
(73%vs27%, p<0.0005). Sixty-three percent of the mutation positive patients had
CRCs located in the proximal region of the colon compared to 21% in the
mutation negative individuals (p<0.0001). In addition, a higher prevalence of
extra colonic manifestations was observed and more syn-/metachronous CRCs
were found, in mutation positive compared to mutation negative patients (p<0.03
and p<0.05, respectively). Using the HNPCC referral criteria as a basis, and
subsequently phenotypic differences such as those established in this study,
namely age at CRC diagnosis, CRC location, the occurrence of syn-
/metachronous cancers, and the presence of extracolonic manifestations, a
possible distinction between mutation positive and mutation negative individuals
could be made by clinicians and be used as a means to prioritise patients for
genetic surveillance, mutation screening and genetic counselling.
Introduction
One of the most crucial stages in the diagnosis of a hereditary cancer syndrome
is the compilation of an indepth family pedigree that highlights cancer
development1-3. Hereditary nonpolyposis colorectal cancer (HNPCC) is the most
frequently occurring form of hereditary colorectal cancer4 and affects multiple
generations with carcinomas at an early age.
Syndromes that possess distinguishing phenotypes are more simple to diagnose
than hereditary disorders that lack clear phenotypic characteristics. Where
HNPCC is concerned, there are 5 cardinal features that help in the identification
of affected families. Primarily, there is the earlier than average age of cancer
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onset compared to the general population ie. the average of onset of hereditary
nonpolyposis colorectal cancer is 45 years5 compared to 63 years in the general
population. Secondly, there is a specific spectrum of primary cancers segregating
within the pedigree, such as colonic and endometrial cancers5,6. There is also an
excess of synchronous colorectal cancer (multiple colorectal cancers at or within
six months after surgical resection for colorectal cancer) and metachronous
colorectal cancer (colorectal cancer occurring more than six months after
surgery)5. Furthermore, there is an excess of extracolonic manifestations eg.
carcinoma of the ovary (second only to colorectal cancer in frequency), ovary,
stomach (especially in Asian countries such as Japan and Korea)7, small bowel,
pancreas, hepatobiliary tract, brain and upper uroepithelial tract6,8. Thirdly is the
survival rate that differs from the norm for the particular cancer9-12.Forthly is
distinguishing pathological features13 and finally, there is the identification of a
germline mutation in affected members of the family4. As far as the colorectal
tumours are concerned, those stemming from patients with HNPCC are more
commonly proximally located (approximately 70% are proximal to the splenic
flexure), more likely to have diploid DNA, possess microsatellite instability,
harbour mutations in the mismatch repair genes, and behave less aggressively
than other carcinomas5. They also appear more often to be poorly differentiated,
with an excess of mucoid and signet-cell features and possess infiltrating
lymphocytes within the tumour14-17. Patients with HNPCC may also present
sebaceous adenomas, sebaceous carcinomas, and multiple
keratocanthomas5,18.
Since microsatellite instability (MSI) is established in almost all hereditary
nonpolyposis colorectal carcinomas19 it is perhaps unnecessary to investigate for
mismatch repair (MMR) gene germline mutations (ie, hMSH2 and hMLH1) in
patients whose tumours do not display MSI. However, the exception to this rule
may be in families with hMSH6 mutations, in which MSI may or may not be
present20,21.
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Germline mutations in MMR genes have previously been established in between
40 and 80 percent of the families fulfilling the Amsterdam Criteria I and between
5 and 50 percent of families fulfilling the Amsterdam Criteria II22,23. However,
some investigated families, despite a family history indicative of HNPCC, are
established as mismatch repair gene mutation negative and appear not to
harbour a MMR gene alteration. This phenomenon may correlate to as yet
undiscovered gene mutations being responsible for the presence of the
syndrome or that the aggregation of cancers may be attributed to environmental
factors or be due to chance14.
Estimates made to date describing the frequency of HNPCC occurrence, are
more than likely low. The majority of mutational studies have not included the
investigation for hMSH6 mutations, which undoubtedly account for a proportion
of HNPCC cases or predispose to an atypical and more benign form of this
syndrome20. In addition, some of the more conventional techniques for mutation
detection cannot highlight mutations that are only obvious when the two alleles
are studied separately24 eg, mainly mutations in control regions or introns that
affect transcription or splicing25. Furthermore, large deletions in the hMSH2 gene
are more common than previously thought and can be detected through
Southern hybridisation26 or multiplex PCR of short fluorescent fragments27.
Due to the low detection of HNPCC individuals and MMR gene alterations, it
would be useful to further characterise the phenotype of MMR gene mutation
carriers in order to help in the identification of affected individuals and hence,
quickly organise the necessary treatment, surveillance and genetic counselling
required.
Patients and Methods
This study investigated 130 unrelated Swiss patients who were referred to the
Medical Genetics department by the consulting physician due to an observed
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familial clustering of colorectal cancer (CRC) or young age at diagnosis of CRC.
Informed consent was obtained from all individuals studied and following
assessment of a detailed personal and familial history, patients were assigned to
one of the following referral criteria groups: the Amsterdam Criteria I (ACI) which
are defined as follows; 1) three or more relatives with histologically verified CRC
one of whom is a first-degree relative of the other two; 2) CRC involving at least
two generations; 3) one or more CRC cases diagnosed before the age of 50
years; and 4) familial adenomatous polyposis must be excluded (14). The
Amsterdam Criteria II (ACII) differs from the ACI only in that they encompass a
defined spectrum of additional HNPCC associated cancers (cancer of the
endometrium, small bowel, ureter or renal pelvis) (12).
The Bethesda Guidelines (BG) are fulfilled if any of the following criteria are met:
1) individuals with cancer in families that fulfill the Amsterdam Criteria; 2)
individuals with at least 2 HNPCC related cancers, including synchronous and
metachronous CRC (endometrial, ovarian, gastric, hepatobiliary or small-bowel
cancer or transitional cell carcinoma of the renal pelvis or ureter); 3) individuals
with CRC and a first degree relative with CRC and/or HNPCC related
extracolonic cancer and/or a colorectal adenoma; one of the cancers diagnosed
at age <45 years, and the adenoma diagnosed at <40 years; 4) individuals with
CRC or endometrial cancer diagnosed at <45 years; 5) individuals with right-
sided CRC with an undifferentiated pattern on histopathology diagnosed at age
<45 years; 6) individuals with signet-ring CRC diagnosed at <45 years; 7)
individuals with adenomas diagnosed at age <40 years (15). In order to clearly
distinguish the referral groups and avoid double classification of patients, only
patients that did not fulfill the ACI or ACII but otherwise complied with the BG
were included in the so-called restricted Bethesda Group (rBG). Patients fulfilling
neither the AC nor the rBG constituted the Neither Criteria (NC) group.
All patients were investigated as anonymous cases and the results of the various
analyses were assessed by at least two reviewers independently.
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DNA Extraction
Genomic DNA was isolated from EDTA blood using the methods previously
described by Miller (16). In short, 10ml blood were mixed with 30ml EL buffer
(55mM NH4Cl, 10mM KHCO3, 1mM EDTA, pH7.4) and left on ice for 15 minutes.
The lysate was centrifuged at 2000rpm for 10 minutes and washed twice with EL
buffer. The resulting pellet of intact lymphocytes was resuspended in NL buffer
(10mM Tris.HCl, pH8.2, 400mM NaCl, 2mM Na2EDTA, 1% SDS and 200g/ml
protein K) and subsequently incubated at 37°C overnight. The following day, 1ml
of 6M NaCl was added, the mix was vigorously shaken and then centrifuged in
order to remove cellular proteins. The supernatant containing DNA was
transferred to a fresh tube and the DNA precipitated with ethanol. The final DNA
pellet was washed with 70% ethanol, dried briefly and resuspended in 1ml of TE
buffer (10mM Tris.HCl, pH 7.5, 0.7m EDTA).
Tumor DNA was isolated from formalin fixed, paraffin embedded tissue using the
QIAMP DNeasy Tissue kit and according to the suggested protocol of the
manufacturer (Qiagen, Switzerland). After verification of the tumor cell content
(>70%) of HE stained tumor specimen, 10x 5-8m thick tumor sections were cut
from each paraffin block. Lysis of the tissue was completed overnight with
Qiagen buffer, Proteinase K and an incubation temperature of 55°C. The
samples were then washed twice with Qiagen wash buffer and the DNA finally
eluted in 200 l elution buffer provided.
MSI Analysis
For MSI analysis, matched normal (ie. leukocyte-extracted) and tumor DNA were
investigated using a panel of 14 microsatellite markers in two stages. Initial
screening consisted of microsatellite markers BAT 25, BAT 26, D10S197,
D18S58, D2S123, D5S346 and MFD15. In cases where none or only one of the
markers was unstable anadditional set of markers were employed to detect low
degree instability: BAT 40, D18S69, D19S210, D22S257, D3S1265, D4S243,
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and MYCL1. PCR amplifications were performed with approximately 100ng of
genomic DNA and 200ng of tumor DNA, in a total volume of 50l, using a Hybaid
Omn-E Thermocycler (Catalys AG, Wallisellen, CH); 94°C-3mins for 1 cycle,
94°C-20 secs, 56°C-30 secs, and 72°C-45secs for 35 cycles, and 72°C-5mins for
1 cycle. Subsequently, PCR products were loaded onto an ABI PRISM 310
Genetic Analyser using the POP4 polymer (PE Applied Biosystems, USA), a
HEX, TET, FAM and TAMRA matrix, and the GENESCAN software for analysis.
Although experiments were repeated several times, PCR amplification was not
possible in 9 tumor specimens. These patients were therefore omitted from
further study. In addition, another 2 patients, with an MS-Stable status, were
eliminated from the study since their tumor content was below 70% and thus too
low for reliable assessment of MSI status. MSI was allocated with respect to the
number of microsatellite markers displaying allelic expansions or contractions.
Assessment was based on the recommendations of the NCI workshop on
microsatellite instability (17): >30% of the investigated loci unstable were
classified as being MSI-High (MSI-H), >0% and <30% unstable loci MSI-Low
(MSI-L) and no unstable microsatellite loci defined MSI-Stable (MSS). Loss of
heterozygosity (LOH) was defined as a >50% reduction in relative intensity of
one allele compared to the other.
IHC
Four micrometer serial sections from paraffin blocks were mounted on silanized
slides, deparaffinized and rehydrated. Antigen retrieval was obtained by heating
the sections in a pressure cooker at 120°C for 2 min in 10mM citrated-buffered
solution (pH 6.0). DAKO peroxidase blocking reagent and goat serum were
sequencially used to suppress nonspecific staining due to endogenous
peroxidase activity and nonspecific binding of antibodies, respectively.
Incubations with primary monoclonal antibodies were performed as follows: anti-
hMSH2: 24 hours at 4C with Ab NA26 (Oncogene Research), 1µg/ml; anti-
hMSH6: 2 hours at RT with Ab G70220 (Transduction Laboratories), 4µg/ml; anti-
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hMLH1: 1 hour at RT with Ab 13271A (PharMingen), 1.2 µg/ml; anti-hPMS2: 24
hours at 4C with Ab 65861A (PharMingen), 3 µg/ml. After washing, anti-mouse
secondary antibodies conjugated to peroxidase labelled polymer (DAKO
EnVision+kit) were applied for 30 min at RT, and the peroxidase activity was
developed by incubation with 3,3‚diaminobenzidine  (DAB) chromogen solution
(DAKO). Sections were then counterstained slightly with hematoxylin.
Sequence Analysis
Exon specific primer pairs (sequences as reported by Kolodner (19,20) were
used to amplify the 16 exons of hMSH2 and the 19 exons of hMLH1, including
the respective exon-intron boundaries, from genomic DNA. Fifty microlitres of
PCR reaction mixture contained 100ng of genomic DNA, 0.5M each primer,
2.5M each dNTP, 5mM MgCl2, 10x reaction buffer, and 0.2U Taq polymerase
(Qiagen, Switzerland). The reaction parameters were; 94°C-3 mins for 1 cycle,
94°C-30 secs, 53°C-30 secs and 72°C-45 secs for 35 cycles, and 72°C-3 mins
for 1 cycle, for a Hybaid OmnE Thermocycler (Catalys AG, Wallisellen, CH). The
sequencing reaction was completed using the Thermosequenase Sequencing Kit
(Amersham Pharmacia, Switzerland). PCR amplicons were diluted 1:3 and
enzymatically purified with shrimp alkaline phosphatase and exonuclease I
(Amersham Pharmacia, Switzerland). The purified PCR products were run
through a cycle sequencing reaction with primers labeled with an infrared dye;
T7-IRD800 and SP6-IRD-800 for forward and reverse sequencing, respectively.
Cycle sequencing parameters were 95°C-3min. for 1 cycle, 95°C-30 sec. 55°C-
30 sec. and 72°C-1min. for 30 cycles. The resulting products were loaded onto a
6% denaturing polyacrylamide gel and analysed on a LiCor 4000L automated
DNA Sequencer (LiCor, Lincoln, NE).
Multiplex PCR of short fluorescent fragments
Short exon fragments corresponding to the 19 hMLH1 exons and the 16 hMSH2
exons were amplified via PCR from approximately 50 ng of genomic DNA, using
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6-FAM labeled primers (Charbonnier, F., 2000). Exons 1-10 and exons 10-19 of
hMLH1 and exons 2, 3, 5, 8-10, 12, 14 and 15 and exons 1, 4, 6, 7, 8, 11, 13 and
16 of hMSH2 were PCR amplified in four separate tubes. PCR was performed in
a final volume of 50l containing between 0.2 and 1M of each pair of primers
and 1 unit of Taq DNA polymerase (Invitrogen, Switzerland). After a 3 min
denaturation at 950C, the PCR consisted of (a) nine cycles of 10 secs at 940C, 10
secs at 600C (with a decrease of 10C/cycle), and 10 secs at 720C; (b) 12 cycles
of 10 secs at 940C, 10 secs at 480C, and 10 secs at 720C; and (c) a final 7 min
extension at 720C. Subsequently, PCR products were loaded onto an ABI PRISM
310 Genetic Analyser using the POP4 polymer (PE Applied Biosystems, USA), a
HEX, TET, FAM and TAMRA matrix, and the GENESCAN software for analysis.
Statistical Analysis
Statistical comparison of patients’ features, encompassing referral criteria,
phenotypic characteristics (sex, age at diagnosis of CRC, tumor location,
extracolonic cancers and degree of differentiation), MSI and mutational status,
was performed using the Chi-square and Fisher exact test for categorical
variables, or Student’s t-test for continuous variables, with all of the probabilities
reported as two-tailed Ps, considering a P of <0.05 to be statistically significant.
To assess the value of the referral criteria and the screening methods employed
calculations for sensitivity, specificity, false positive and negative rates as well as
diagnostic accuracy were performed according to Jaeschke, Guyati and Sackett
(21).
Results
This study aimed to further characterise the phenotype of HNPCC patients by
comparing MMR gene mutation carriers to gene alteration negative individuals in
an attempt to aid the identification of HNPCC individuals and MMR gene
mutation carriers. In total, 130 Swiss HNPCC individuals were investigated. All
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were screened for mutations via microsatellite (MSI) analysis,
immunohistochemistry (IHC) and for those subsequently displaying a MMR
protein loss, direct DNA sequencing was performed. Forty-six (35%) individuals
has a confirmed MMR gene mutation (Table 1), the remaining 84 (65%)
individuals were classified as MMR mutation negative.
Of the mutation positive patients, 54% (n=25) were found to harbour a mutation
in the MMR gene hMLH1, whilst 41% (n=19) had mutations in hMSH2
established. The most common overall gene alteration was a frameshift mutation
(1bp – 3 exons long deleted), making up 41% (n=22) of the total observed. Other
mutations found were base substitutions, 27% (n=12) and splice site mutations,
23% (n=10). Of the hMLH1 mutations, frameshifts were the most common,
accounting for 48% (n=12) of the total, followed by base substitutions (28%, n=7)
and splice site mutations (24%, n=6). From the hMSH2 mutations, frameshifts
were observed in 53% (n=10), base substitutions in 26% (n=5) and splice site
mutations in 21% (n=4).
GENE/
EXON
DNA CHANGE AMINO ACID
CHANGE
REFERRAL
CRITERIA
FAMILY
NUMBER
hMLH
1
2 1995 G>A G67R AC 1652
2 184 C>T Q61X rBG 1900
3 292 G>C G98R AC 2047
4 341 C>G T117R AC 434
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4 1050 C>T T350M AC 1936
5 IVS4-2 A>G splice acceptor site AC 1500
7-9 Exons 7-9 del frameshift AC 1806
10 811-815delTCCTT frameshift AC 1805
10 IVS9-4/791-
5delTTAGATCGT
frameshift AC 1834
13 1490 insC frameshift AC 1754
13 1490 insC frameshift rBG 1902
13 1490 insC frameshift NC 1906
13 1410-1413 Del
AAAG
frameshift BG 1917
15 1731 G>A splice donor site AC 1801
15 1690-
1693delCTCA
frameshift rBG 1808
16 1896 Del G frameshift AC 1033
16 1946-1848 Del
AAG
frameshift AC 2151
16 1946-1848 Del
AAG
frameshift AC 1848
16 1846-1848delAAG frameshift rBG 1760
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16 1852 A>T K618X BG 1956
16 1896+1 G>T splice donor site AC 2048
17 1976 G>C A658P AC 1921
18 IVS18+1 G>T splice donor site AC 1813
19 IVS18-2A>T splice acceptor site AC 1121
19 IVS18+1 G>T splice donor site AC 1831
hMSH
2
2 261-262delTT frameshift rBG 1820
3 388-389 Del TC frameshift AC 1097
5 942+3 A>T splice donor site BG 2170
5 942+3 A>T splice donor site BG 1893
7 1148 C>T R383X AC 1587
7 1165 C>T STOP AC 2025
7-8 Exons 7-8 del frameshift AC 1817
7-8 Exons 7-8 del frameshift AC 1835
10 1576 Del A frameshift AC 1846
10 1576 delA frameshift NC BItalia1
11 1740 G>T E580X AC 1642
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11 IVS11+2 T>C splice donor site AC 1807
12 1787-1789 AAT
Del
frameshift AC 1383
12 1853delC frameshift rBG 1886
12 1760-1 G>A splice acceptor site AC 1989
14 2261delC frameshift AC 1827
15 2503 A>G N835D AC 1991
16 2740 G>T E914X AC 1841
16 2646 del A frameshift NC BItalia9
Table 1: Mismatch repair gene mutation carriers and the confirmed mutations to
date.
No statistically significant phenotypic differences were observed between
mutation positive patients harbouring hMLH1 mutations and those patients
carrying hMSH2 mutations. This enabled all subsequent phenotypic comparisons
between mutation positive and mutation negative individuals to be done directly,
regardless of the MMR gene affected.
Ninety-four percent (n=43) of the mutation positive patients were classified by
either the Amsterdam Criteria (AC) or the restricted Bethesda Guidelines (rBG)
(32 AC and 11 rBG, Table 2). In comparison a smaller proportion, 76% (n=54), of
the mutation negative individuals fulfilled the referral criteria (27 AC and 44 rBG).
Interestingly, whilst 70% of the mutation positive patients satisfied the AC, only
32% of the mutation negative individuals were classified by these criteria. More
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mutation negative patients fulfilled the rBG as compared to the mutation positive
patients, 44% vs 24%, respectively (p<0.0005) (Figure 1).
Total Mutation
Positive
Individuals
Mutation Negative
Individuals
REFERRAL
CRITERIA:
Amsterdam
Criteria (I/II)
59 32 27
rBethesda
Guidelines
48 11 37
Neither
Criteria
23 3 20
AGE AT
DIAGNOSIS:
Average
(yrs)
SD (yrs)
Range (yrs)
45.5
11.94
27-76
48.1
13.48
22-90
SEX: Male 52 25 27
Female 21 41 57
TUMOUR
LOCATION :
Proximal 46 28 18
Distal 84 18 66
ADDITIONAL
CANCERS:
Syn-/ meta-
chronous
CRC
11 8 3
Extracolonic
Cancer
16 9 7
TOTAL: 130 46 84
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Table 2: Overall phenotypic characteristics of all patients investigated and
divided according to mutational status.
Figure 1: The 46 mutation positive and the 84 mutation negative individuals
divided according to the referral criteria they fulfil.
In the 30-39 and the 40-49 age groups, mutation positive patients dominated,
whilst in all of the other age categories, it is the mutation negative individuals that
make up the greater proportion (Figure 2). The oldest mutation positive patient at
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76 years, is 14 years younger than the oldest mutation negative patient at 90
years.
Figure 2: The age categories that the mutation positive and mutation negative
patients fall into.
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The average age at diagnosis of a colorectal cancer in mutation positive patients
it 45 years (SD  11.94, range 27-76). This is on average 3 years younger than
the mutation negative individuals who have an average age at diagnosis of 48
years (SD  13.48, range 22-90).
The overall sex ratio of the 130 investigated patients was 40%:60%
(males:females). Whilst the mutation positive patients were evenly split by
males:females, 54% to 46%, the mutation negative group was not so evenly
divided, 32% to 78%. Females were significantly more frequently found to be
mutation negative than mutation positive (73% vs 27%, respectively, p<0.0005,
Table 2).
Another statistically significant finding was related to the location of the CRC.
Sixty-three percent of the mutation positive patients had CRCs located in the
proximal region of the colon compared to only 21% proximally located
carcinomas in the mutation negative individuals (p<0.0001, Figure 3).
Furthermore, almost half (45%) of the CRCs stemming from mutation negative
patients were found located in the sigma (p<0.0001).
Extracolonic manifestations (ECMs) were observed in 20% of the mutation
positive patients compared to only 8% of the mutation negative individuals
(p<0.03). Of the ECMs observed, endometrium carcinomas were the overall most
commonly occurring, with 38% of those patients having an ECM, possessing it in
the endometrium. Furthermore, endometrium carcinomas were most frequently
observed in the mutation positive patients with 67% of the ECM affected mutation
positive patients having an endometrium carcinoma. Other ECMs observed in
mutation positive patients were carcinomas of the skin (11%), ovaries (11%) and
the adrenal glands (11%). Mutation negative individuals had ECMs of the
stomach (30%), ovaries (14%), liver (14%), oesophagus (14%), breast (14%) and
of the renal cells (14%) (Table 2).
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In addition, mutation positive patients had a higher prevalence of synchronous
and metachronous CRCs compared to mutation negative individuals, 17% vs
4%, respectively (p<0.05, Table 2).
Figure 3: Location of colorectal cancers according to mutation positive and
mutation negative status.
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Discussion
HNPCC predisposition is correlated with germline mutations in five genes
functional in mismatch repair (MMR); MSH2, MLH1, MSH6, PMS1 and PMS2. To
date, more than 300 different mutations in these genes (the majority in MSH2
and MLH1) have been identified and are known to account for HNPCC in
approximately 500 kindreds from various countries (28 and http://www.nfdht.nl).
Although a great number of predisposing mutations have been found, the
connections between genotype and phenotype are insufficiently understood. No
statistically significant phenotypic differences were observed in this study
between mutation positive patients harbouring hMLH1 mutations and those
patients carrying hMSH2 mutations. However, previous studies have tentatively
made some associations, for example, Vasen et al.29 determined an increase risk
of extracolonic manifestations in carriers of MSH2, compared to MLH1, mutations
and Kruse et al.30 found that MSH2 mutations were significantly more frequently
found than MLH1 mutations in connection with the Muir-Torre variants of
HNPCC. Furthermore, Jager et al.31 found that one common mutation in MLH1,
exon 4, dictated a milder phenotype, especially with less frequently observed
extracolonic cancers. The severity vs mildness of the disease may in part be due
to the ability32 vs inability31 of the defective proteins to produce a dominant
negative effect on the overall action of the mismatch repair system. The majority
of information available concerning the HNPCC phenotypes comes from
retrospective studies on families already identified as HNPCC due to a observed
family history of HNPCC associated cancers. These data suggest that the
phenotype in HNPCC varies from individual to individual33.
The age at diagnosis of colorectal cancer in mutation positive patients was 45
years, with a peak in the 4th decade. Mutation negative patients were on average
3 years older than mutation positive patients at the time of their diagnosis, and
although also having a peak incidence occurring in the 4th decade, the mutation
negative patients were more frequently observed in the 5th to the 7th, and only in
the 8th and 9th, decades. The peak incidence occurring in the 4th decade differed
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significantly (p<0.001) from the Swiss population (Swiss Cancer Registries’
Association database, 2003) where the incidence peaks in the 7th and 8th
decades. All studies previously conducted indicate that CRC risk is at its peak
between the ages of 40 and 60, but that the risk before the age of 40 is
considerable, and perhaps to begin colorectal screening at the age of 25 is
justifiable34.
Interestingly, females were significantly more frequently found to be mutation
negative than mutation positive (p<0.0005). However, no other phenotypic
characteristics appeared to separate the males from the females in both the
mutation positive and mutation negative groups. Data cleaved to date show that
male mutation carriers have a lifetime colorectal cancer risk of 74% or more, but
whilst female mutation carriers have half this risk, it is still many times higher than
in the general population and still warrants the same intensive screening as that
suggested for males33.
Sixty-three percent of the mutation positive patients had CRCs located in the
proximal region of the colon compared to only 21% proximally located CRCs in
the mutation negative individuals. These observations are consistent with those
made by Lynch et al.35 where 70% of the CRCs in HNPCC patients occurred
proximal to the splenic flexure.
The frequency of extracolonic manifestations were similar to reports previously
made36,37, with endometrial cancer representing 38% of the extracolonic cancers
observed. Lifetime endometrial cancer risk is 42% or more, with some evidence
that risk is elevated in MSH2- compared to the MLH1-mutation carriers and with
highest incidence between age 40 and 6033. Other ECMs observed were cancers
of the stomach, ovary, breast, liver, oesophagus, skin, adrenal gland and renal
cell cancer. There is much evidence that MMR mutation carriers are at elevated
risk from ovarian, gastric, urologic tract, small bowel and hepatobiliary tract and
for brain tumours36,38. For a number of ECM types it has been suggested that
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significant inter-family variation in risk exists31,36,29 and for some, intracultural and
secular variations in cancer risk are observed39.
As expected, in agreement with previous documentation, mutation positive
patients had a significantly higher prevalence of synchronous and metachronous
CRCs compared to mutation negative individuals (p<0.05)11.
Such a study of genotype-phenotype correlations, involving one population, of
Swiss individuals, has its plus and minus points. Variations possibly introduced
via cultural and environmental differences39 are minimised, although at the same
time, only a limited proportion of all known mutations occurring in the disorder is
represented. However, here we can conclude that the use of phenotypic features
such as age of CRC diagnosis, CRC location, the presence of ECMs and the
occurrence of syn-/metachronous CRCs, can be used to make a distinction
between mutation positive and mutation negative individuals and hence aid
clinicians in the prioritisation of patients for mismatch repair gene mutation
screening and genetic counselling.
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Chapter IV
Evaluation of referral criteria and screening
procedures in the identification of HNPCC patients
A draft of a scientific paper prepared for publication.
Abstract
Hereditary nonpolyposis colorectal cancer (HNPCC) is an autosomal dominantly
inherited cancer predisposition syndrome essentially caused by germline
mutations in DNA mismatch repair (MMR) genes. This study aimed to (i) assess
the phenotypic and molecular differences between patients belonging to different
referral criteria groups, and (ii) determine the diagnostic accuracy of the criteria
and screening procedures employed in identifying individuals with mismatch
repair (MMR) gene alterations. A consecutive series of 222 unrelated Swiss
patients, referred because of clinically suspected HNPCC, were assigned to
either the Amsterdam Criteria I/II (AC), the restricted (ie. minus ACI/II) Bethesda
Guidelines (rBG) or the Neither Criteria (NC) group. Individuals were screened
for MMR gene alterations applying microsatellite marker analysis,
immunohistochemistry, direct DNA sequencing and RT-PCR/protein truncation
test. Statistical evaluation involved the Chi-square, Fischer exact or Student’s t-
test, with all probabilities reported as two-tailed Ps, considering a P of <0.05 to
be statistically significant. Of the referred patients, 37% fulfilled the AC, 34% the
rBG and 29% the NC group. MSI analysis established the stability status of 95%
of the tumours; 41% MSI and 59% MSS. Fifty-seven percent of the MSI tumours
stemmed from the AC, 24% from the rBG and 18% from the NC group (p<0.01).
Eighty-three percent of the unstable tumors had gene alterations whilst in
comparison 95% of the stable tumors were gene alteration negative (p<0.01).
Gene alteration positive tumors were more frequently unstable than gene
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alteration negative tumors (p<0.001), and were more often proximally located
(p<0.02). Of the screening methods employed, immunohistochemistry proved to
be the most sensitive and specific of all screening procedures with sensitivity and
specificity values equal to 1 for both hMLH1 and hMSH2 gene alterations. The
BG were of superior sensitivity and diagnostic accuracy compared to AC I/II
alone, in identifying patients with MMR gene alterations. Notably, individuals
belonging to the NC group displayed a later age at diagnosis of colorectal
cancer, although still occurring significantly earlier than in the general population.
In addition their tumors were predominantly MSS, pointing to a genetic
predisposition unrelated to mismatch repair deficiency. Based on the evaluation
of the different screening techniques employed in this study, the following
diagnostic approach should allow optimal identification of individuals with MMR
gene alterations: (1) Testing for MSI combined with immunohistochemical loss of
MMR proteins as initial screening methods and (2) subsequent mutational
analysis of the positively scored individuals encompassing both a DNA and a
mRNA-based technique.
Introduction
Hereditary nonpolyposis colorectal cancer (HNPCC) is an autosomal dominantly
inherited cancer predisposition syndrome which leads mainly to the development
of colorectal carcinoma (CRC) at an average age of 45 years (1-3). It is believed
to account for 2 to 5% of the total CRC burden (4). Colorectal tumors from
HNPCC patients are predominantly located proximal to the splenic flexure, often
occur syn- and metachronously, and patients display enhanced survival from
CRC in comparison to matched controls (5-7). In addition, a defined spectrum of
extracolonic tumors is associated with the disease, primarily endometrial
carcinoma (8).
In 60-70% of HNPCC kindreds the disease is caused by germline mutations in
one of the DNA mismatch repair (MMR) genes, hMSH2, hMLH1, hMSH6, hPMS1
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or hPMS2 which function as “guardians of the genome.” Inactivation of the MMR
system through mutation of one of its components consequently leads to
genomic instability, as evidenced by microsatellite instability (MSI). MSI can be
observed in 75 to almost 100% of CRCs stemming from HNPCC patients (9).
Approximately 11-38% of sporadic CRC also display genomic instability in
conjunction with a somatic mismatch repair (MMR) defect, mainly due to
promoter hypermethylation of hMLH1 (10).
Originally drawn up to identify the genes responsible for HNPCC, and exclusively
focusing on a family history of CRC, the so-called Amsterdam criteria (ACI) were
recently extended to also include endometrial, small bowel and upper renal tract
cancers (Amsterdam criteria II, ACII) (11,12). In parallel, the Bethesda guidelines
(BG) were set up to define which colorectal tumors should be tested for MSI in
order to identify HNPCC patients in the general population (13).
Only limited data are available however, which assess the value of the different
referral criteria in combination with MSI testing and the various mutation
screening methods applied. By studying a consecutive series of 222 unrelated
patients, referred to the Medical Genetics department because of clinically
suspected HNPCC, this survey aimed to (i) assess the phenotypic and molecular
differences between patients belonging to different referral criteria groups, and
(ii) determine the diagnostic accuracy of the criteria and screening procedures
employed in identifying individuals with mismatch repair (MMR) gene alterations.
Patients and Methods
This study investigated 98 unrelated Swiss patients who were referred to the
Medical Genetics department by the consulting physician due to an observed
familial clustering of colorectal cancer (CRC) or young age at diagnosis of CRC.
Informed consent was obtained from all individuals studied and following
assessment of a detailed personal and familial history, patients were assigned to
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one of the following referral criteria groups: the Amsterdam Criteria I (ACI) which
are defined as follows; 1) three or more relatives with histologically verified CRC
one of whom is a first-degree relative of the other two; 2) CRC involving at least
two generations; 3) one or more CRC cases diagnosed before the age of 50
years; and 4) familial adenomatous polyposis must be excluded (14). The
Amsterdam Criteria II (ACII) differ from the ACI only in that they encompass a
defined spectrum of additional HNPCC associated cancers (cancer of the
endometrium, small bowel, ureter or renal pelvis) (12).
The Bethesda Guidelines (BG) are fulfilled if any of the following criteria are met:
1) individuals with cancer in families that fulfill the Amsterdam Criteria; 2)
individuals with at least 2 HNPCC related cancers, including synchronous and
metachronous CRC (endometrial, ovarian, gastric, hepatobiliary or small-bowel
cancer or transitional cell carcinoma of the renal pelvis or ureter); 3) individuals
with CRC and a first degree relative with CRC and/or HNPCC related
extracolonic cancer and/or a colorectal adenoma; one of the cancers diagnosed
at age <45 years, and the adenoma diagnosed at <40 years; 4) individuals with
CRC or endometrial cancer diagnosed at <45 years; 5) individuals with right-
sided CRC with an undifferentiated pattern on histopathology diagnosed at age
<45 years; 6) individuals with signet-ring CRC diagnosed at <45 years; 7)
individuals with adenomas diagnosed at age <40 years (15). In order to clearly
distinguish the referral groups and avoid double classification of patients, only
patients that did not fulfill the ACI or ACII but otherwise complied with the BG
were included in the so-called restricted Bethesda Group (rBG). Patients fulfilling
neither the AC nor the rBG constituted the Neither Criteria (NC) group.
All patients were investigated as anonymous cases and the results of the various
analyses were assessed by at least two reviewers independently.
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DNA Extraction
Genomic DNA was isolated from EDTA blood using the methods previously
described by Miller (16). In short, 10ml blood were mixed with 30ml EL buffer
(55mM NH4Cl, 10mM KHCO3, 1mM EDTA, pH7.4) and left on ice for 15 minutes.
The lysate was centrifuged at 2000rpm for 10 minutes and washed twice with EL
buffer. The resulting pellet of intact lymphocytes was resuspended in NL buffer
(10mM Tris.HCl, pH8.2, 400mM NaCl, 2mM Na2EDTA, 1% SDS and 200g/ml
protein K) and subsequently incubated at 37°C overnight. The following day, 1ml
of 6M NaCl was added, the mix was vigorously shaken and then centrifuged in
order to remove cellular proteins. The supernatant containing DNA was
transferred to a fresh tube and the DNA precipitated with ethanol. The final DNA
pellet was washed with 70% ethanol, dried briefly and resuspended in 1ml of TE
buffer (10mM Tris.HCl, pH 7.5, 0.7m EDTA).
Tumor DNA was isolated from formalin fixed, paraffin embedded tissue using the
QIAMP DNeasy Tissue kit and according to the suggested protocol of the
manufacturer (Qiagen, Switzerland). After verification of the tumor cell content
(>70%) of HE stained tumor specimen, 10x 5-8m thick tumor sections were cut
from each paraffin block. Lysis of the tissue was completed overnight with
Qiagen buffer, Proteinase K and an incubation temperature of 55°C. The
samples were then washed twice with Qiagen wash buffer and the DNA finally
eluted in 200 l elution buffer provided.
RNA Extraction:
RNA was isolated from EDTA blood using a Qiagen RNeasy Mini Kit and the
protocol supplied by the manufacturer (QIAGEN, Switzerland). A maximum of
1x107 cells were disrupted in 350l lysis buffer and homogenized, in order to
shear genomic DNA and reduce viscosity of the lysate. 250l 100% ethanol was
added to the mixture before the sample was applied to the RNeasy spin column.
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RNA was absorbed by the column membrane and contaminants were washed
away with Qiagen buffers. Subsequently, total RNA was eluted from the column
with 50l RNase-free water.
MSI Analysis:
For MSI analysis, matched normal (ie. leukocyte-extracted) and tumor DNA were
investigated using a panel of 14 microsatellite markers in two stages. Initial
screening consisted of microsatellite markers BAT 25, BAT 26, D10S197,
D18S58, D2S123, D5S346 and MFD15. In cases where none or only one of the
markers was unstable an additional set of markers were employed to detect low
degree instability: BAT 40, D18S69, D19S210, D22S257, D3S1265, D4S243,
and MYCL1.
PCR amplifications were performed with approximately 100ng of genomic DNA
and 200ng of tumor DNA, in a total volume of 50l, using a Hybaid Omn-E
Thermocycler (Catalys AG, Wallisellen, CH); 94°C-3mins for 1 cycle, 94°C-20
secs, 56°C-30 secs, and 72°C-45secs for 35 cycles, and 72°C-5mins for 1 cycle.
Subsequently, PCR products were loaded onto an ABI PRISM 310 Genetic
Analyser using the POP4 polymer (PE Applied Biosystems, USA), a HEX, TET,
FAM and TAMRA matrix, and the GENESCAN software for analysis. Although
experiments were repeated several times, PCR amplification was not possible in
9 tumor specimens. These patients were therefore omitted from further study. In
addition, another 2 patients, with an MS-Stable status, were eliminated from the
study since their tumor content was below 70% and thus too low for reliable
assessment of MSI status. MSI was allocated with respect to the number of
microsatellite markers displaying allelic expansions or contractions. Assessment
was based on the recommendations of the NCI workshop on microsatellite
instability (17): >30% of the investigated loci unstable were classified as being
MSI-High (MSI-H), >0% and <30% unstable loci MSI-Low (MSI-L) and no
unstable microsatellite loci defined MSI-Stable (MSS). Loss of heterozygosity
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(LOH) was defined as a >50% reduction in relative intensity of one allele
compared to the other.
Protein Truncation Test (PTT):
Three micrograms of total RNA were reverse transcribed into complementary
DNA with 2l of random primer, 1.5l of Rnasin 10000U/l, 10l of 5x Buffer (1x
buffer: 10mM/L Tris, 50mM/L KCl, and 0.2mg/ml BAS, pH 8.5), 5l of 10mM
dNTPs (Promega Corporation, WI, USA) and 3l Reverse Transcriptase 600U/l
(Gibco, Maryland, USA). The procedure was completed by heating the samples
for 2 hours at 37°C. Polymerase chain reaction (PCR) amplifications were
performed in 50l total volumes, containing the following: 100ng cDNA, 0.2U Taq
(Gibco/PWO, Gibco USA/Boehringer Mannheim, USA), 2.5M each dNTP, 5mM
MgCl2, 10x reaction buffer (1x buffer: 10mM/L Tris, 50mM/L KCl, and 0.2mg/ml
BAS, pH 8.5) and 0.5M each primer. PTT primer sequences for hMLH1 and
hMSH2 were taken from Luce et al. (18) and used to amplify each gene into two
overlapping segments of 1.2 and 1.3 kb, and 1.7 kb and 1.3 kb, respectively. The
cycling conditions were as follows: 94°C-4 min. for 1 cycle, 94°C-45 secs,
55/56°C-1 min. (for hMSH2 and hMLH1, respectively), and 72°C-150 secs for 45
cycles, and 72°C-10 mins for 1 cycle on a Hybaid Omn-E Thermocycler (Catalys
AG, Wallisellen, CH). The banding patterns of the PCR products were primarily
assessed on a 1.4% agarose gel. Subsequently, the PTT was run by adding 4l
PCR Product to 6l PTT Mix (200l TNT T7 coupled Reticulocyte Lysate System,
8l RNasin, 16l TNT reaction buffer, 16l 35S-Methionine) and heating for 60
mins at 30°C. The reaction was stopped with 10l of 1x sodium dodecyl sulfate
(SDS) sample buffer. Subsequently, the products were loaded onto a 12% SDS-
polyacrylamide gel and run for 110 mins at 35mA. The gels were then fixed (10%
glacial acetic acid, 30% methanol) for one hour and dried for 45 minutes at 80°C
before exposure on a Biomax film (Kodak, Rochester, NY).
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IHC
Four micrometer serial sections from paraffin blocks were mounted on silanized
slides, deparaffinized and rehydrated. Antigen retrieval was obtained by heating
the sections in a pressure cooker at 120°C for 2 min in 10mM citrated-buffered
solution (pH 6.0). DAKO peroxidase blocking reagent and goat serum were
sequencially used to suppress nonspecific staining due to endogenous
peroxidase activity and nonspecific binding of antibodies, respectively.
Incubations with primary monoclonal antibodies were performed as follows: anti-
hMSH2: 24 hours at 4C with Ab NA26 (Oncogene Research), 1µg/ml; anti-
hMSH6: 2 hours at RT with Ab G70220 (Transduction Laboratories), 4µg/ml; anti-
hMLH1: 1 hour at RT with Ab 13271A (PharMingen), 1.2 µg/ml; anti-hPMS2: 24
hours at 4C with Ab 65861A (PharMingen), 3 µg/ml. After washing, anti-mouse
secondary antibodies conjugated to peroxidase labelled polymer (DAKO
EnVision+kit) were applied for 30 min at RT, and the peroxidase activity was
developed by incubation with 3,3‚diaminobenzidine  (DAB) chromogen solution
(DAKO). Sections were then counterstained slightly with hematoxylin.
Sequence Analysis
Exon specific primer pairs (sequences as reported by Kolodner (19,20) were
used to amplify the 16 exons of hMSH2 and the 19 exons of hMLH1, including
the respective exon-intron boundaries, from genomic DNA. Fifty microlitres of
PCR reaction mixture contained 100ng of genomic DNA, 0.5M each primer,
2.5M each dNTP, 5mM MgCl2, 10x reaction buffer, and 0.2U Taq polymerase
(Qiagen, Switzerland). The reaction parameters were; 94°C-3 mins for 1 cycle,
94°C-30 secs, 53°C-30 secs and 72°C-45 secs for 35 cycles, and 72°C-3 mins
for 1 cycle, for a Hybaid OmnE Thermocycler (Catalys AG, Wallisellen, CH). The
sequencing reaction was completed using the Thermosequenase Sequencing Kit
(Amersham Pharmacia, Switzerland). PCR amplicons were diluted 1:3 and
enzymatically purified with shrimp alkaline phosphatase and exonuclease I
(Amersham Pharmacia, Switzerland). The purified PCR products were run
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through a cycle sequencing reaction with primers labeled with an infrared dye;
T7-IRD800 and SP6-IRD-800 for forward and reverse sequencing, respectively.
Cycle sequencing parameters were 95°C-3min. for 1 cycle, 95°C-30 sec. 55°C-
30 sec. and 72°C-1min. for 30 cycles. The resulting products were loaded onto a
6% denaturing polyacrylamide gel and analysed on a LiCor 4000L automated
DNA Sequencer (LiCor, Lincoln, NE).
Statistical Analysis
Statistical comparison of patients’ features, encompassing referral criteria,
phenotypic characteristics (sex, age at diagnosis of CRC, tumor location,
extracolonic cancers and degree of differentiation), MSI and mutational status,
was performed using the Chi-square and Fisher exact test for categorical
variables, or Student’s t-test for continuous variables, with all of the probabilities
reported as two-tailed Ps, considering a P of <0.05 to be statistically significant.
To assess the value of the referral criteria and the screening methods employed
calculations for sensitivity, specificity, false positive and negative rates as well as
diagnostic accuracy were performed according to Jaeschke, Guyati and Sackett
(21).
Results
Of the consecutive series of 222 patients, 82 (37%) fulfilled the Amsterdam
Criteria I/II (ACI and ACII; 76 ACI and 6 ACII) and 76 (34%) complied with the
restricted Bethesda Guidelines (rBG) (Table 1). Sixty-four (29%) of the patients
studied fulfilled neither the AC nor the rBG due to exceeding the age limit (>50
and >45 years of age at diagnosis, respectively) and were hence assigned to the
Neither Criteria group (NC).
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Phenotypic Features
As depicted in Table 1, the male to female distribution of the 222 cases was
relatively evenly balanced with 44% men and 56% women. If subdivided
according to referral criteria however, a statistically significant difference was
observed, with women being more prevalent in the rBG (42%) group compared
to the AC (35%) and the NC (23%; p<0.05 and p<0.01, respectively).
Consequently, all statistical comparisons were performed for each sex separately
to account for possible gender bias; unless stated otherwise, the statistically
significant findings were sex-independent.
REFERRAL CRITERIA
Total Amsterdam
Criteria
rBethesda
Guidelines
Neither
Criteria
SEX: Female 124 43 52 29
Male 98 39 24 35
TUMOUR
LOCATION:
Proximal 121 40 48 33
Distal 81 36 26 19
Not Colon
Cancer
20 6 2 12
ADDITIONAL
CANCERS:
Syn-/ meta-
chronous CRC
19 9 7 3
Extracolonic
Cancer
27 13 9 5
none 176 60 60 56
TOTAL: 222 82 76 64
Table 1. Phenotypical features of a consecutive series of 222 patients suspected
of having HNPCC, and subdivided according to referral criteria.
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The average age at diagnosis differed significantly (p<0.01) between all 3 referral
criteria groups, being 47 years (±11.6 SD; range 25-79, median 45) for AC, 38
years (±9.2 SD; range 19-68, median 38) for rBG and 59 years (±12.4 SD; range
31-90, median 57) for NC patients (Figure 1).
Figure 1: The age distribution of 222 HNPCC suspected patients according to
referral criteria (Green bars: Amsterdam Criteria I/II, Blue bars: restricted
Bethesda Guidelines and Red bars: Neither Criteria).
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Overall, colorectal cancers (CRC) were most commonly located in the sigmoid
colon (31%), followed by the rectum (19%), the transverse (15%) and ascending
colon (14%), the coecum (8%) and descending colon (4%). The CRC site did not
differ significantly among the 3 referral criteria groups, although
adenocarcinomas in the rBG group tended to occur more frequently in the distal
part of the colorectum compared to those of AC and NC groups (63% vs 48%
and 52% respectively; p=0.08). The histopathological properties of the tumors
were consistently similar among the 3 groups with the majority of AC, rBG and
NC tumors being moderately well differentiated (66%, 66% and 56%,
respectively).
Microsatellite Instability
Tumors from 212 (95%) of the 222 referred patients were available to determine
MSI status. The group displayed nearly identical phenotypical properties when
compared to the initial study population (data not shown). Overall, 41% (n=87) of
the patients were found to be microsatellite unstable (MSI) and 59% (n=125) MS-
Stable (MSS). Fifty-seven percent of the 87 MSI tumours stemmed from the AC,
25% from the rBG and 18% from the NC group (p<0.01). Of the MSS tumours,
24%, 42% and 34% were from AC, rBG and NC patients, respectively.
The phenotypic features of the 212 patients with CRCs investigated to date for
MSI, are depicted in Table 2. CRCs coming from the AC group were significantly
more frequently found to be unstable (54%) when compared to those from the
rBG (26%) or the NC (20%) group (p<0.01). MSI CRCs were more often
proximally located compared to MSS cancers (60%, vs 26%, respectively;
p<0.01). Although not statistically significant, patients with MSI CRCs tended to
have a higher prevalence of syn- and metachronous colorectal and extracolonic
cancers (19% and 13%, respectively) compared to those with stable tumours
(12% and 2%, respectively; Table 2).
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MICROSATELLITE INSTABILITY STATUS
Total MSI MS-Stable
REFERRAL
CRITERIA:
Amsterdam
Criteria
80 50 30
rBethesda
Guidelines
73 21 52
Neither
Criteria
59 16 43
SEX: Male 95 45 50
Female 117 42 75
TUMOUR
LOCATION :
Proximal 80 49 31
Distal 116 33 83
Not Colon
Cancer
16 5 11
ADDITIONAL
CANCERS:
Syn-/ meta-
chronous
CRC
19 16 3
Extracolonic
Cancer
26 13 13
none 167 58 109
TOTAL: 212 87 125
Table 2. HNPCC suspected patients according to the MSI-status of their
colorectal cancer, and the phenotypic features related.
No association between MSI status and the degree of CRC differentiation was
observed, although this may reflect an ascertainment bias with the majority
(74%) of all CRCs investigated being moderately well differentiated. Fourteen
(6%) CRCs (7 ACs, 5 rBGs and 2 NCs) were mucinous in appearance, with 72%
of these being MSI 28% and 28% MSS. These patients did not however,
phenotypically significantly differ from the ones with non-mucinous CRCs.
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A panel of 14 markers was used in order to ascertain the MSI status of 56 (26%)
of the tumours investigated. The mononucleotide repeat markers BAT26, BAT25
and BAT40 proved to be the most sensitive markers for detecting MSI, predicting
high-level microsatellite instability in 100%, 96% and 96% (31/31, 30/31 and
30/31), With similar sensitivity, MFD15 and D2S123 detected MSI-H in 87%
(20/23) and 86% (24/28), respectively. Six percent of the analysed tumours
proved to have an MSI-L status. These were most efficiently detected with
BAT26, which displayed novel alleles in 80% (4/5) of the MSI-L CRCs. The
remaining markers presented sensitivity values between 20 and 40% in the
detection of low degree MSI. Due to the sensitivity and specificity of the BAT26
microsatellite marker, subsequent screening of HNPCC families was done by
employing BAT26 only. Hence, BAT26 analysis alone was employed for the
assessment of MSI in the remainder of the tumours studied (n=156, 74%).
respectively.
hMLH1/hMSH2 gene alteration screening
All 87 patients with MSI tumours, as well as 10 patients with MSS tumours but a
positive family history of nonpolyposis CRC (6 AC, 2 rBG and 2 NC), were
enrolled in mutational analysis encompassing at least 2 out of 3 different
screening methods, direct DNA sequencing (n=54), RT-PCR and the protein
truncation test (PTT) (n=25), as well as immunohistochemical detection of
mismatch repair proteins hMLH1, hMSH2, hMSH6 and hPMS2 (n=92).
Mismatch repair gene alterations were observed in 82%, 74% and 67% of
patients fulfilling the AC, rBG and NC, respectively. Overall, 77% (75/97) were
found to have either an hMLH1 or an hMSH2 gene alteration, of which 96% were
microsatellite unstable. Nine frameshift mutations (single base pair ins/del) were
identified, as well as 21 base substitutions and 14 larger deletions (2bp-3 exons)
(Table 3).
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GENE/
EXON
DNA CHANGE AMINO ACID
CHANGE
REFERRAL
CRITERIA
FAMILY
NUMBER
hMLH1
2 1995 G>A G67R AC 1652
2 184 C>T Q61X rBG 1900
3 292 G>C G98R AC 2047
4 341 C>G T117R AC 434
4 1050 C>T T350M AC 1936
5 IVS4-2 A>G splice acceptor site AC 1500
7-9 Exons 7-9 del frameshift AC 1806
10 811-815delTCCTT frameshift AC 1805
10 IVS9-4/791-
5delTTAGATCGT
frameshift AC 1834
13 1490 insC frameshift AC 1754
13 1490 insC frameshift rBG 1902
13 1490 insC frameshift NC 1906
13 1410-1413 Del
AAAG
frameshift BG 1917
15 1731 G>A splice donor site AC 1801
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15 1690-1693delCTCA frameshift rBG 1808
16 1896 Del G frameshift AC 1033
16 1946-1848 Del AAG K616 Del AC 2151
16 1946-1848 Del AAG K616 Del AC 1848
16 1846-1848delAAG K616del rBG 1760
16 1852 A>T K618X BG 1956
16 1896+1 G>T splice donor site AC 2048
17 1976 G>C A658P AC 1921
18 IVS18+1 G>T splice donor site AC 1813
19 IVS18-2A>T splice acceptor site AC 1121
19 IVS18+1 G>T splice donor site AC 1831
hMSH2
2 261-262delTT frameshift rBG 1820
3 388-389 Del TC frameshift AC 1097
5 942+3 A>T splice donor site BG 2170
5 942+3 A>T splice donor site BG 1893
7 1148 C>T R383X AC 1587
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7 1165 C>T STOP AC 2025
7-8 Exons 7-8 del frameshift AC 1817
7-8 Exons 7-8 del frameshift AC 1835
10 1576 Del A frameshift AC 1846
10 1576 delA frameshift NC BItalia1
11 1740 G>T E580X AC 1642
11 IVS11+2 T>C splice donor site AC 1807
12 1787-1789 AAT Del frameshift AC 1383
12 1853delC frameshift rBG 1886
12 1760-1 G>A splice acceptor site AC 1989
14 2261delC frameshift AC 1827
15 2503 A>G N835D AC 1991
16 2740 G>T E914X AC 1841
16 2646 del A frameshift NC BItalia9
Table 3: List of hMLH1 and hMSH2 germline mutations identified (AC:
Amsterdam Criteria, rBG: restricted Bethesda Guidelines and NC: Neither
Criteria)
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Of the 87 patients with unstable colorectal tumours, mismatch repair gene
alterations were observed in 88%, 81% and 69% of patients fulfilling the AC, rBG
and NC, respectively (Table 4). Eighty-one percent were found to have either an
hMLH1 (n=43, 60%) or an hMSH2 (n=29, 40%) gene alteration.
Table 4: hMLH1/ hMSH2 gene alteration status in 87 patients with unstable
colorectal tumours.
The phenotypic properties between gene alteration positive and negative, MSI
patients, e.g. age at diagnosis (41.5 years ±14.49SD and 46.6 years ±16.33SD,
respectively; p=0.17) were consistently similar. Extracolonic manifestations
(ECMs) were observed in both the gene alteration positive and gene alteration
GENE ALTERATION STATUS
Total MLH1 MSH2 negative
REFERRAL
CRITERIA:
Amsterdam
Criteria
50 25 19 6
rBethesda
Guidelines
21 10 7 4
Neither
Criteria
16 8 3 5
SEX: Female 42 24 8 10
Male 45 19 21 5
TUMOUR
LOCATION:
Proximal 49 27 18 4
Distal 38 16 11 11
ADDITIONAL
CANCERS:
Syn-/ meta-
chronous CRC
16 13 3 0
Extracolonic
Cancer
13 6 5 2
none 58 24 21 13
TOTAL: 87 43 29 15
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negative patients, although the risk of ECMs appeared to be higher in association
with a gene alteration. Gene alteration positive patients displayed ECMs in the
endometrium (n=5, 8%), the skin (n=1, 2%), the adrenal glands (n=1, 2%) and in
the stomach (n=1, 2%). Gene alteration negative patients had ECMs of the
endometrium (n=1, 7%) and the stomach (n=1, 7%). Interestingly, only gene
alteration positive patients had a history of synchronous or metachronous CRCs
(23%).
In contrast to the patients with unstable tumours, in 70% (7 out of 10) of the
individuals with a positive family history but MSS tumours, no gene alteration
could be determined (p<0.01). The average age at diagnosis was 50.4 years
(±10.9SD). No extracolonic carcinomas or synchronous or metachronous
cancers were observed. Two of the three mutation positive, MSS, patients were
males, aged 48 (AC) and 59 (NC), with colorectal carcinomas of the sigma and
coecum, respectively. Interestingly, they shared the same mutation in hMLH1;
1490 inserted C. The third mutation positive, MSS, patients was a 39 year old
female, classified by AC. She had a CRC of the sigma and harbored a mutation
in hMSH2; exons 7-8 deleted.
Sensitivity and Specificity of referral criteria and diagnostic methods to
identify MMR gene alterations
Referral Criteria: The AC and the BG (which encompass AC and rBG) were
able to correctly identify 46 and 63 of the 72 patients with MMR gene alterations
corresponding to sensitivity values of 0.64 and 0.88, respectively. However, they
also classified 10 (45%) and 12 (55%) of the 22 mutation negative patients,
leading to false positive rates of 0.45 and 0.75, respectively. The overall
diagnostic accuracy for the AC and the BG amounted to 0.60 and 0.72,
respectively.
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Microsatellite Instability Analysis: Out of 87 patients with an unstable CRC 72
(83%) were subsequently established as gene alteration positive. Among the 10
MSS cases with a positive family history, three (30%) patients, 2 ACI and 1 NC,
were found to harbor hMLH1 and hMSH2 gene alterations. Overall, microsatellite
instability analysis displayed a sensitivity value of 0.96 in identifying individuals
with MMR gene alterations, and a false positive rate of 0.65. The overall
diagnostic accuracy amounted to 0.83.
Immunohistochemistry (IHC): Tumours from 95 patients could be screened for
the presence of the mismatch repair proteins immunohistochemically, and
verified by RT-PCR/PTT and/or direct DNA sequencing. Seventy-four (78%)
stained negative for either hMLH1 or hMSH2 (44 hMLH1, 30 hMSH2) whilst in 21
(22%) tumours (14 MSI, 7 MSS) all MMR proteins were present. Among the 10
MSS tumours studied, 2 (20%) showed loss of hMLH1 and 1 (10%) a loss of
hMSH2. None of the investigated samples subjected to IHC showed loss of
hPMS2 or hMSH6. IHC resulted in sensitivity and specificity values equal to 1 for
both hMLH1 and hMSH2 gene alterations.
Direct DNA sequencing: Through direct DNA sequencing, 54 patients could be
analysed. A total of 39 (72%) patients (37 MSI and 2 MSS) were established as
having a germline mutation in either hMLH1 or hMSH2, 38 (97%) of which were
confirmed by a second analysis technique, IHC and/or RT-PCR/PTT. In the
remaining 15 patients (all MSI) no mutation could be identified, all of which were
cross-validated by IHC and/or RT-PCR/PTT. Eleven (73%) of these patients (all
MSI) appeared to be falsely established as mutation negative by direct DNA
sequencing; in all 11 patients (5 hMSH2 and 6 hMLH1) the combined results of
IHC and RT-PCR/PTT point to the presence of large, exon-spanning deletions or
insertions which are currently under investigation. In the remaining 4 (27%)
patients (2 AC, 1 rBG, 1 NC) the negative sequencing results correlated
successfully with results cleaved from both RT/PTT and IHC. Both MSS cases (1
AC, and 1 NC) subjected to sequencing proved to be mutation positive for
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hMLH1; both harbouring a 1490 inserted C. The direct DNA sequencing method
thus had an overall sensitivity of 0.78 (0.79 and 0.76 for hMLH1 and hMSH2,
respectively), with no false positive results and a diagnostic accuracy of 0.80.
RT-PCR/protein truncation test (PTT): Through RT-PCR/PTT, 25 patients
could be screened for aberrant splice transcripts, large genomic
deletions/insertions and truncated proteins. Twenty patients (80%) displayed
altered amplification or translation products in hMLH1 or hMSH2, all of which
were agreed with results cleaved in parallel investigations by IHC and
sequencing. Among the 5 gene alteration negative patients, RT-PCR/PTT
yielded a false positive results for 1 (20%) patients. Overall, the RT-PCR/PTT
method had a sensitivity of 0.95, with no false positive results and an overall
diagnostic accuracy of 0.96.
Discussion
This study investigated a consecutive series of 222 Swiss patients with clinically
suspected HNPCC with the aim to (i) assess the phenotypic and molecular
differences between patients belonging to different referral criteria groups
(Amsterdam Criteria I/II (AC), Bethesda Guidelines (BG) and Neither Criteria
(NC)), and (ii) to determine the diagnostic accuracy of the individual referral
criteria and screening procedures employed, in identifying individuals with
mismatch repair (MMR) gene alterations.
The referral criteria groups, being evenly represented in the overall study
population, differed significantly (p<0.01) in average age of colorectal carcinoma
(CRC) onset, due to age at diagnosis being a key criterion for the AC and BG.
Still, with an average age at diagnosis of 59 years (being 9 and 14 years later
than AC and rBG patients, respectively), NC patients developed CRC 13 years
earlier than the general population (Swiss Cancer Registries’ Association
database, 1996; p<0.01), and 33.3% of these MSS NC patients had a family
history of colon carcinoma, hence, indicative of a genetic predisposition rather
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than a sporadic event. Except for the 16 NC patients with unstable tumors, 2 of
which were found to have mismatch repair (MMR) gene alterations, NC tumors
were predominantly microsatellite stable (73%; p<0.01) and for these the
underlying genetic defect(s) is likely to be unrelated to MMR deficiency.
Microsatellite instability (MSI) was observed in 63% of AC tumors out of which
88% were found to have MMR gene alterations. Encompassing both the AC and
rBG, the BG increased the MSI tumour detection by an additional 29% (21 MSI
tumours) and the MMR gene alteration detection by 26% (12 hMLH1 and 7
hMSH2).  In agreement with previous reports (22) proximally located colon
tumors displayed significantly (p<0.01) more often an MSI status. In addition,
patients with MSI CRCs had the highest frequency of synchronous and
metachronous cancers, with endometrial carcinomas representing the most
frequent extracolonic tumor manifestation (23). Mononucleotide repeat markers
were the most sensitive in detecting MSI, which is consistent with data from other
groups (9). However, despite its high sensitivity and specificity in this study, and
recent reports that BAT26 has been studied as the sole microsatellite marker,
caution needs to be applied as MSI-H tumors have been described that do not
display instability at the BAT26 locus (24). While our results for BAT25 and
BAT40 are in agreement with previous reports stating that MSI-L tumors often
lack instability at mononucleotide repeats, BAT26 was successful in detecting
instability in 80% of the MSI-L CRC (9,25). Among the other microsatellite
markers used in this survey, MFD15 and D2S123, located intragenic of BRCA1
and hMSH2, respectively, and with the ability to detect complex repetitive
sequences as well as dinucleotide runs, were more sensitive than non complex
markers with (CA)n repeats only.
Mutational screening, encompassing direct DNA sequencing, RT-PCR/Protein
Truncation Test (PTT) and immunohistochemical analysis, identified 83% of
patients with unstable tumors to have an hMLH1 or hMSH2 gene alteration,
compared to 8% of patients with microsatellite stable CRC (p<0.01), which is
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consistent with previous observations that 70-100% of unstable tumors from
HNPCC patients carry germline mutations in hMLH1 and hMSH2(26). The
mutation spectrum observed in this study corresponds with results published by
the International Collaborative Group on HNPCC, showing 80% (71%) of hMSH2
and 63% (65%) of hMLH1 germline mutations in HNPCC patients to be either
nonsense or frameshift mutations (27). In 4% of patients somatic inactivation of
hMLH1 due to promoter hypermethylation is likely to be responsible for the
observed MSI. In 8% of patients no MMR gene alteration could be identified by
any of the 3 screening methods, including immunohistochemical analysis of
hMSH6 and hPMS2.
Comparison of MMR gene alteration-positive and –negative patients did not
show any statistically significant phenotypic differences, with the exception that,
and in accordance with research by Lindblom, tumors with an hMLH1/hMSH2
alteration were more often proximally located than gene alteration negative
tumors (p<0.02) (28).
Assessment of the diagnostic value of the referral criteria clearly demonstrated
that the Amsterdam Criteria alone identified considerably less patients with MMR
gene alterations than combined with the additional inclusion criteria (in particular
no. 4, inclusion of individuals with CRC or endometrial cancer at age <45)  from
the Bethesda Guidelines. Albeit in the same time increasing the number of false
positive results, the overall diagnostic accuracy was improved by 12%.
Microsatellite instability as a pre-screening method proved to be highly predictive
(83%) in identifying individuals with MMR gene alterations, displaying equally
accurate results for unstable tumors in general (MSI-H and MSI-L) and MSI-H
alone, the importance of which has been previously demonstrated by Aaltonen et
al. on unselected CRC patients (2). Notably, 4 out of 22 (18%) AC patients and 2
out of 14 (14%) NC patients with microsatellite stable tumors was found to harbor
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an hMLH1 alteration, highlighting the need for caution when applying MSI
analysis as the sole pre-screening method.
Comparison of the 3 screening procedures applied in this study compiled strong
evidence that only a combined approach, incorporating immunohistochemical
analysis as well as a DNA and a mRNA-based screening method, is able to
reliably identify individuals with MMR gene alterations. This is on one hand due
to the shortcomings of each technique (eg. failure of IHC and PTT to detect
missense mutations and of direct DNA sequencing to identify large, exon-
spanning deletions / insertions as well as hypermethylation of the hMLH1
promoter) and on the other hand a consequence of the diverse mutational
spectra and the lack of “hot spot” regions in hMLH1 and hMSH2. It appears that
more focused investigations (assessment of promoter hypermethylation, linkage
analysis) are warranted only subsequently to the combined approach.
In conclusion, this study of a consecutive series of 222 patients, clinically
suspected of HNPCC, established the Bethesda Guidelines as more sensitive
and of higher diagnostic accuracy than the Amsterdam Criteria I/II alone in
identifying patients with mismatch repair gene alterations. Notably, a third set of
individuals, was observed, which did not fulfill either referral criteria; these
patients displayed a markedly later age at diagnosis of colorectal cancer (mean
59 years), though still occurring significantly earlier than in the general
population, and the tumors were predominantly microsatellite stable, pointing to a
genetic predisposition unrelated to mismatch repair deficiency. Based on the
evaluation of the different screening techniques employed in this study, we
propose the following diagnostic approach to optimally identify MMR gene
alterations in individuals clinically suspected of having HNPCC: (1) Testing for
microsatellite instability and immunohistochemical loss of mismatch repair
proteins should be used as initial screening methods and (2) subsequent
mutational analysis of the positively scored individuals should encompass both, a
DNA and a mRNA-based technique.
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Chapter V
Evidence for genetic anticipation in hereditary non-polyposis
colorectal cancer
Submitted as a scientific paper to the Gastroenterology journal
Abstract
Hereditary non-polyposis colorectal cancer (HNPCC) is an autosomal dominantly
inherited colorectal cancer predisposition syndrome caused by germline
mutations in DNA mismatch repair (MMR) genes, predominantly hMLH1 and
hMSH2. Thus far, only limited data exist on the occurrence of genetic anticipation
in HNPCC, i.e. the earlier age at diagnosis of colorectal cancer (CRC) in
successive generations. Performing nonparametric, distribution-free statistical
analyses, we investigated 55 parent-child pairs (PCPs) diagnosed of colorectal
cancer and coming from 21 Swiss HNPCC families with characterised MMR
germline mutation (15 in hMLH1 and 6 in hMSH2). The overall median age at
diagnosis was 43 years (interquartile range (IQR)=14), with incidence ages
ranging from 18 to 62 years. Descendants of HNPCC patients (median age at
diagnosis 39 years, IQR=12) were found to be diagnosed of CRC significantly
earlier than their parents (47 years, IQR=10), with the median of the paired age
difference amounting to 8 years (IQR=15; p<0.0001). Birth cohort effects could
be excluded since the same, statistically significant age difference was also
observed in the oldest offspring birth cohort (birth year <1916; p=0.01). Genetic
anticipation appeared to be more pronounced when the disease allele was
transmitted through the father than through the mother (median age difference 11
versus 4 years, respectively; both p<0.01).
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Genetic anticipation appears to occur in HNPCC kindreds with identified MMR
gene mutation. If confirmed in larger, ideally prospective studies, these results
may have important implications for genetic counselling and clinical management
of HNPCC families.
Introduction
Hereditary non-polyposis colorectal cancer (HNPCC) is an autosomal dominantly
inherited colorectal cancer (CRC) predisposition syndrome, exhibiting a high
penetrance (80-85%) and accounting for 2 to 10% of the total CRC burden 1.
HNPCC patients typically present with, mostly right-sided, CRC at early age
(mean age 45 years) and often develop syn- or metachronous CRC. Besides
CRC the tumour spectrum also includes cancers of the endometrium, stomach,
small bowel, ovary, ureter/renal pelvis, brain, hepatobiliary tract, and skin.
HNPCC is caused by mutations in DNA mismatch repair (MMR) genes (hMSH2,
hMLH1, hMSH6, hPMS2, hPMS1, hMLH3), with hMLH1 and hMSH2 accounting
for more than 90% of all germline mutations identified. Following inactivation of
the wild-type allele in the tumour, MMR deficiency ensues leading to genetic
instability as exemplified by the occurrence of microsatellite instability due to
replication errors at short repetitive DNA sequences.
The disease shows considerable inter- and intrafamilial phenotypic heterogeneity
among hMLH1/hMSH2 mutation carriers. Despite harbouring identical MMR
gene mutations, disease severity and age at diagnosis often vary significantly
between family members. In this context genetic anticipation, a "phenomenon in
which the age of onset of a disorder is reduced and/or the severity of the
phenotype is increased in successive generations" 2 has been put forward to
occur in HNPCC. Thus far, only limited and controversial data are available on
this issue, ranging from single case reports to few systematic investigations in
HNPCC families 3-6. In this study, we examined 21 Swiss HNPCC kindreds with
identified hMLH1 or hMSH2 germline mutation for the occurrence of genetic
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anticipation with regard to the age at diagnosis of CRC in parents and their
descendants (first-degree kinship).
Subjects and Methods
Out of 46 Swiss HNPCC families with an identified MMR gene mutation in
hMLH1 or hMSH2, registered between 1990 and 2001 either at the Research
Group Human Genetics, Division of Medical Genetics, Department of Clinical and
Biological Sciences, Basel, or at the Unit of Genetics, Institut Central des
Hôpitaux Valaisans, Sion, Switzerland, 26 (57%) unrelated families were suitable
for the study with complete phenotypic information being available from medical
and histopathological records on gender, year of birth, age at diagnosis, tumour
type and the occurrence of additional (extracolonic) tumours.
The 26 families harboured either a pathogenic hMLH1 (n=18) or an hMSH2 (n=8)
germline mutation. Out of the 126 individual patients 91 parent-child pairs (PCPs)
were created, each consisting of an affected parent and an affected child.
Twenty-two parents had more than one child (range: 2 to 5 children) and 14
descendants had themselves affected children included in this study (see Figure
1 with pedigree examples). In 145 (79.7%) hMLH1/hMSH2 mutation carriers, the
first tumor diagnosed was a colorectal one compared to 37 (20.3%) patients with
an extracolonic tumour. For the study only PCPs with children and parents
affected with colorectal cancer  (21 families; n=55) were analysed. The PCPs
were treated as related data for the statistical analysis. Written informed consent
was obtained from all individuals alive.
Statistical analysis
Nonparametric, distribution-free tools were applied for statistical analysis.
Related data were compared applying the Wilcoxon matched-pairs signed-ranks
test (referred to as paired Wilcoxon test). Independent data were compared with
the Mann-Whitney U test. The disproportions of gender frequencies were
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analyzed with the Binomial test. The median and the IQR were used instead of
the mean and the standard deviation, respectively. The significance level was set
to <0.05 (5%). All statistical tests were applied in their two-sided form. The
software-packages used for the statistical analysis were “RS/1” (Research
System 1), version 6.1 (Brooks Automation) and “StatXact”, version 4 (Cytel
Software Corporation).
Results
To assess the occurrence of genetic anticipation in HNPCC, 55 PCPs, both
affected with CRC, coming from 21 Swiss HNPCC kindreds with identified
hMLH1 (n=15) or hMSH2 (n=6) germline mutations were examined. The PCPs
encompassed 52 (62.7%) male and 31 (37.3%) female patients. Twenty-four
(28.9%) patients had developed metachronous cancers (range 1 to 4 tumours)
encompassing those of the colorectum (n=15; 62.5%), small intestine (n=2;
8.3%), stomach (n=1; 4.2%) and other sites (n=6; 25%). Median age at diagnosis
did not significantly differ between genders, neither in parents (p=0.42) nor in
descendants (p=0.23).
The overall median age at diagnosis was 43 years (IQR=14), with incidence ages
ranging from 18 to 62 years (Figure 2a). Taking the median of the paired age
differences, descendants (39 years, IQR=12) were diagnosed 8 years earlier
than their parents (47 years, IQR=10.0), the difference being statistically
significant (paired Wilcoxon test, p < 0.0001), with 76%, 9% and 15% of
descendants being diagnosed at an earlier, same and later age, respectively
(Table 1). Moreover, the paired age difference was more marked if the parents
had developed CRC at later age (Figure 2b).
Comparison of the median age at diagnosis according to the gene mutated found
descendants with an hMLH1 germ-line mutation to be diagnosed statistically
significantly earlier than those with an hMSH2 mutation (38 versus 43.5 years,
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p<0.05) in contrast to parents (47 versus 48 years, p=0.91), respectively.
Similarly, PCPs with an hMLH1 mutation displayed a significant median of the
paired age difference (p<0.01). The median of the paired age difference in
hMSH2 PCPs with colorectal cancer did not reach statistical significance,
possibly owing to the small sample size (n=14; p=0.12; Table 1).
When subdividing PCPs according to parental transmission, sons and daughters
who inherited the disease allele from their father showed a significantly increased
median age difference of 11 years (p<0.001) compared with 4 years in children
who had inherited the germline mutation from the mother (p<0.01; Table 2).
Importantly, median age at diagnosis did not significantly differ between mothers
(45 years, IQR 14) and fathers (47 years, IQR 10; p=0.5).
In order to test if the observation of apparent anticipation could reflect a birth
cohort bias of ascertainment we grouped the PCPs according to the birth year of
the children and created 3 birth cohorts: 1) those born before 1916 (n=9), 2)
between 1916-1936 (n=20) and 3) those born after 1936 (n=24). As depicted in
Table 3, the median of the paired age difference remained statistically significant
in the first (15 years; p=0.01) and third cohort (9 years; p=0.001). In the second
cohort the median age difference amounted to 5 years but hardly missed
statistical significance (two-sided p=0.06).
Discussion
In this study we provide significant evidence for genetic anticipation in 55 parent-
child pairs (PCPs) coming from 21 Swiss HNPCC kindreds with characterised
hMLH1 or hMSH2 germline mutation. Compared to the parents, descendants
developed colorectal cancer (CRC) eight years earlier, in particular if the parents
had developed cancer at later age.
Besides the first report on HNPCC by Warthin in 1925, only four studies deal in
detail with the occurrence of genetic anticipation in this syndrome, i.e. the
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progressive decrease in age of onset of CRC in successive generations.
Although three investigations did observe anticipation in HNPCC kindreds
fulfilling the Amsterdam Criteria I (ACI), they cannot be directly compared with
our study since i) no statistical tests were applied, ii) investigations were done
either before the actual discovery of the genes responsible 3, 6 or afterwards, but
without molecular genetic characterization 4. The fourth study by Tsai et al.
analysed a total of  67 ACI-positive PCPs (38 families) with hMSH2 and hMLH1
germline mutations characterised in 14 (7 families) of them 5. However, they
could not detect any difference in mean age at diagnosis between generations in
neither of the subgroups analysed. This apparent contradiction to our findings
could be due to the small sample size (14 compared to 55 PCPs in our study)
leading to a type II error (failure to reject the null hypothesis). In addition, the
comparison might be hampered by differences in the way data were collected
and the time window analysed.
In contrast to the findings by Tsai et al. 5, a possible birth cohort bias of
ascertainment could not be confirmed in our study group (Table 3): the median of
the paired age difference remained statistically significant in the youngest as well
as the oldest birth cohort (9 years, p<0.001, and 15 years, p<0.01, respectively)
and just failed significance in the middle birth cohort (5 years, p=0.06). On the
other hand, PCPs with cancers other than CRC (n=36),  excluded from the
original study, revealed a clear birth cohort effect (data not shown).
Intriguingly, genetic anticipation in our study population was more pronounced if
the disease allele was transmitted through the father than through the mother
(9.5 vs. 4 years paired median age difference, respectively; Table 2 and Figure
1). This finding does not appear to be due to differences in median age at
diagnosis between fathers and mothers which were similar (47 vs. 45 years;
p=0.5). It remains to be seen, however, whether this apparent parental
transmission effect is merely due to ascertainment bias or may actually reflect a
true biological phenomenon. If so, it is tempting to speculate that this effect is
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related to differences in male and female gametogenesis, in particular given the
greater number of cell divisions during spermatogenesis and continuous
replication throughout adulthood. Given the data implying hMLH1 in the meiotic
recombination process 7, 8 and in analogy to genetic anticipation observed in
trinucleotide repeat disorders like Huntington’s disease 9, it could be
hypothesized that mismatch repair (haplo)insufficiency in the germline could lead
to anticipation via low level repeat instability.
Despite the evidence for genetic anticipation presented here, there are several
caveats to this retrospective study. First of all, we cannot exclude an
ascertainment bias since our study population represents a highly selected group
of patients. In particular, a selection bias might have resulted from under-
representation of “younger parent-older child” pairs in which the parent had died
before producing a “complete” family. Furthermore, the significant difference in
age at diagnosis of CRC observed between the generations could i) reflect
changes in environmental factors such as dietary and life style habits, ii) be due,
at least in part, to earlier and better diagnosis progressively over time and/or iii)
greater awareness/anxiety in descendants. It is therefore mandatory that these
findings are confirmed in larger, ideally prospective studies on HNPCC kindreds.
This could also allow to assess the occurrence of genetic anticipation for other
HNPCC related tumours, particularly endometrial cancer.
In summary, we have presented significant evidence for genetic anticipation to
occur in HNPCC families harbouring MMR gene mutations, with descendants
being diagnosed of CRC 8 years earlier than their parents. Intriguingly, this effect
seemed to be more pronounced if the disease allele was transmitted through the
father. If our findings on genetic anticipation in general and on paternal
transmission in particular are confirmed, they may have important implications for
genetic counselling and clinical management of MMR gene mutation carriers and
their offspring.
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General Discussion:
This thesis has focused on genotype-phenotype correlations in two hereditary
colorectal cancer syndromes, hereditary nonpolyposis colorectal cancer
(HNPCC) and familial adenomatous polyposis (FAP) in an attempt to optimise
the selection criteria for affected individuals, to establish the sensitivity and
specificity of different screening methods, to investigate a relatively new gene
associated with a multiple colorectal adenoma and carcinoma phenotype and to
assess the role of a modifier gene locus on chromosome 1p33-36. All
investigations aimed ultimately to aid clinicians in their selection of patients for
different genetic screening programs and give them guidelines for optimal
genetic testing, hence helping them maintain an overview on the best
surveillance and prevention strategies and genetic counselling schemes.
The preliminary step towards the diagnosis of a hereditary cancer syndrome is
the compilation of a detailed account of the family history of cancer (Polednak,
1998). The pedigree should concentrate on all types of cancer and their location;
the family member’s age at cancer onset; any pattern of multiple primary
cancers; any association with phenotypic features that may be related to cancer,
eg. colonic adenomas; and whenever possible records of pathological findings.
Such a combination of information frequently identifies a hereditary colorectal
cancer syndrome in the family, should it exist. Molecular genetic investigations
can then produce clarification of the diagnosis, and determine the presence of a
germline mutation in the family (Vogelstein et al., 1998; Eng et al., 2001).
On establishing the diagnosis of a hereditary colorectal cancer syndrome, the
proband’s high risk relatives should be informed. Genetic counselling and DNA
testing should be offered and in attempts to reduce morbidity and mortality,
surveillance measures may be instigated depending on the nature of the disorder
(Lynch et al., 1999).
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Genetic counselling is of high importance to a patient with a clear familial form of
colorectal cancer. The family concerned should be updated on the details
regarding the genetic risks of cancer at specific sites; the available options for
surveillance and management; and the necessity for genetic testing (Lynch et al.,
2001; Aktan-Collan et al., 2000). It is advised that counselling is conducted face-
to-face, although sessions may include multiple family members (Lynch et al.,
2001). However, the outcome of mutational analysis should be revealed to a
patient on a one-to-one basis (Lynch et al., 1999).
Hereditary Nonpolyposis Colorectal Cancer (HNPCC):
The consistently accurate identification of HNPCC families continues to be a
problem despite knowledge concerning the genetic basis of the disease (Scott et
al., 2001). At a meeting of the International Collaborative Group (ICG) on
HNPCC in 1990, the Amsterdam Criteria (AC) were introduced for the uniform
identification of hereditary colorectal cancer patients for genetic screening and
surveillance programs (Vasen et al., 1990). Originally drawn up to identify the
genes responsible for HNPCC, and exclusively focusing on a family history of
CRC, the AC were recently extended to also include endometrial, small bowel
and upper renal tract cancers (Amsterdam criteria II, ACII) (Vasen et al., 1991;
Vasen et al., 1999). In parallel, the Bethesda guidelines (BG) were set up to
define which colorectal tumors should be tested for MSI in order to identify
HNPCC patients in the general population (Rodriguez-Bigas et al., 1998).
Considering the value of these criteria it is surprising that only limited data are
available which assess their sensitivity and specificity, especially in conjunction
with MSI testing and various other mutation screening methods. Through the
investigation of 222 unrelated patients, referred to the Medical Genetics
department because of clinically suspected HNPCC, this thesis reports on the
phenotypic and molecular differences between patients belonging to different
referral criteria groups, and the diagnostic accuracy of the criteria and screening
procedures employed in identifying individuals with mismatch repair (MMR) gene
alterations.
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Of the referred patients, 37% fulfilled the AC, 34% the rBG and 29% the NC
group. Fifty-seven percent of the MSI tumours stemmed from the AC, 24% from
the rBG and 18% from the NC group (p<0.01). Eighty-three percent of the
unstable tumors had gene alterations whilst in comparison 95% of the stable
tumors were gene alteration negative (p<0.01). Gene alteration positive tumors
were more frequently unstable than gene alteration negative tumors (p<0.001),
and were more often proximally located (p<0.02). This study proved the BG to be
of superior sensitivity and diagnostic accuracy compared to AC I/II alone, in
identifying patients with MMR gene alterations.  This observation is in
accordance with previous reports stating that the Bethesda Guidelines (excluding
the AC) can identify an additional 20% of the HNPCC families which have a
condition related to MMR gene mutations (Buerstedde et al., 1995; Wijnen et al.,
1998; Heinimann et al., 1999). Furthermore, as a result of assessing the different
screening procedures the following diagnostic approach should allow optimal
identification of individuals with MMR gene alterations: (1) Testing for MSI
combined with immunohistochemical loss of MMR proteins as initial screening
methods and (2) subsequent mutational analysis of the positively scored
individuals encompassing both a DNA and a mRNA-based technique.
A combination of methods is necessary due to the inadequacies of each
technique eg. failure of IHC and PTT to detect missense mutations and of direct
DNA sequencing to identify large, exon-spanning deletions / insertions as well as
hypermethylation of the hMLH1 promoter, (Aaltonen et al., 1998) and on the
other hand a consequence of the diverse mutational spectra and the lack of “hot
spot” regions in hMLH1 and hMSH2 (Moslein et al., 1996; Liu et al., 1996;
Salovaara et al., 2000).
Whist familial adenomatous polyposis has had numerous genotype-phenotype
correlations made and described (Lynch et al., 1996, 1998, 2003; Brensinger et
al., 1998) no such relationships appear to have been made for HNPCC.
However, subtle associations have been reported describing possible histological
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variances between hMSH2-mutated tumors and hMLH1-mutated tumors in
HNPCC (Shashidharan et al., 1999) and some clinical differences that may exist
(Vasen et al., 1999), but to complicate matters further, previous reports also
suggest that the phenotype in HNPCC varies from individual to individual
(Watson et al., 2001).
This thesis aimed to further characterize the phenotype of HNPCC patients by
comparing MMR gene mutation carriers to gene alteration negative. Mutation
positive patients were found to be on average 3 years younger than mutation
negative individuals at the time of their CRC diagnosis. Mutation positive patients
had CRCs located more frequently in the proximal region of the colon compared
to the mutation negative individuals (p<0.0001). In addition, a higher prevalence
of extra colonic manifestations was observed and more syn-/metachronous
CRCs were found, in mutation positive compared to mutation negative patients
(p<0.03 and p<0.05, respectively).
Using the HNPCC referral criteria as a basis, AC and BG, and subsequently
phenotypic differences such as those established in this and other studies,
namely age at CRC diagnosis (Watson et al., 2001), CRC location (Lynch et
al.,1999), the occurrence of syn-/metachronous cancers (Gryfe et al., 2000), and
the presence of extracolonic manifestations (Watson et al., 1993; Lin et al., 1998)
families or individual patients can be identified and offered genetic testing for
genes associated with HNPCC. Better classification of the mutation negative
group could lead to the identification of additional genes associated with this
disorder.
Familial Adenomatous Polyposis (FAP):
In a significant subset, 20-50%, of clinically diagnosed FAP patients an APC
germline mutation cannot be identified, giving rise to the so-called APC-negative
individuals (Armstrong et al., 1997; Giardiello et al., 1997; van der Luijt et al.,
1997). Characteristically, a later age at diagnosis is observed and 50% of APC-
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negatives have fewer than 100 colorectal polyps. In addition, extracolonic
manifestations (eg. polyps of the upper gastrointestinal tract, desmoids,
osteomas) are less frequently detected. Several reasons could stand for the
failure in world-wide efforts to identify germline mutations within the APC gene of
FAP patients. No individual method for mutation detection is sensitive enough for
all types of gene alteration. Only a combination of several different screening
techniques results in a good detection rate. Furthermore, since current mutation
analysis has little focus on the regulatory regions of the APC gene or quantitative
tests of
APC gene expression there is a lack of understanding in these areas. And finally,
few cases of FAP genetic linkage to the APC locus have been described
suggesting that other genes may be responsible for the development of FAP or
may lead to a similar clinical phenotype (Stella et al., 1993; Tops et al., 1993).
In light of results from recent studies, implicating biallelic germline mutations in
the base-excision-repair (BER) gene MYH with a multiple colorectal adenoma
and carcinoma phenotype, this thesis reports on the investigation conducted to
further correlate MYH germline mutations with APC-negative individuals and
establish any genotype-phenotype correlations. Thirteen from 65 individuals were
identified as MYH mutation carriers, 7 of which had biallelic mutations. Aside
from previously reported mutations, 3 apparently novel gene alterations were
established. No specific somatic APC mutations were observed although loss of
heterozygosity of APC was observed in 3 patients with biallelic MYH mutations.
In addition, 2 biallelic mutation carriers also harboured KRAS oncogene
mutations in exon 1. The phenotypical characteristics of all patients investigated
were similar, although biallelic MYH mutation carriers had a higher prevalence of
colorectal cancers diagnosed, compared to the monallelic mutation carriers and
the mutation negative individuals. Further distinctions in phenotype have been
made by other research groups and hence recommendations can be made for
genetic testing and surveillance based on numbers of colorectal adenomas
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(Jones et al., 2002; Sieber et al., 2003) and with the observed increased
frequency of G to A somatic APC transversions (Al-Tassan et al., 2002). Number
and histology are indeed the indicators in the detection of many colorectal cancer
predisposition syndromes (Enholm et al., 2003) although it is still clearly apparent
that more experience should be derived to entitle a more profound understanding
of the natural history of MYH-associated colorectal neoplasia.
FAP displays considerable inter- and intr-familial phenotypic heterogeneity, which
represents a major problem in genetic counselling of APC mutation carriers.
Such phenotypic heterogeneity in FAP patients cannot be solely related to the
variety of different APC gene mutations. Other genetic factors can modify
disease expression as illustrated by numerous mouse models of FAP (Dietrich et
al., 1993; MacPhee et al., 1995).
The Min mouse model indicated a putative disease modifier locus on
chromosome 4, which is syntenic to human chromosome 1p35-36 (Dietrich et al.,
1993). The recent identification of germline MYH mutations, mapped to the 1p33-
34 region, in multiple adenoma and carcinoma patients, points to a possible role
as a disease modifier in FAP. This thesis documents a study where fine-mapping
of the critical region, as well as mutation analysis of the MYH gene, were
performed on a large Swiss FAP kindred (no.1460). These investigations allowed
the significant exclusion of the 1p33-36 region as a modifier locus and MYH as a
modifier gene for extracolonic disease in this FAP family. The results indicate
that linkage analysis of further putative candidate regions is necessary to identify
a disease modifier locus in FAP which will prove critical in establishing genetic
risk and thus improved accuracy in genetic counseling of FAP patients.
In conclusion it can be said that morbidity and mortality from FAP and HNPCC
can be reduced once the patients’ familial or hereditary risk is determined and a
complex program of cancer surveillance and management is undertaken (Burke
et al., 1997; Jarvinen et al., 2000; Ramsey et al., 2001). Prevention will be
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improved by the identification of the responsible germline mutation in a family,
hence confirming the risk. Advances in technology in cancer screening and the
identification of biological markers of cancer susceptibility, eg. microsatellite
instability, and also specific germline testing, will also aid physicians in achieving
cancer prevention targets. In addition, molecular genetic research on hereditary
forms of colorectal cancer must continue and strive to search for new mutations,
novel genes, and even modifier genes, in these heterogeneous disorders.
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Appendix I
Optimization of the denaturing high performance liquid
chromatography (dHPLC) protocol for use in the screening of
patients with suspected hereditary non polyposis colorectal
cancer (HNPCC)
This procedure was optimised for use in the Human Genetics Lab
by Anna M Russell
Introduction
Hereditary non polyposis colorectal cancer (HNPCC) is an autosomal dominantly
inherited cancer predisposition with at least 5 genes associated to the risk of
patients developing cancers of the colon, rectum, endometrium, small bowel and
urinary tract1. These include hMLH12, hMSH23, hMSH64, hPMS1 and hPMS25. In
more than 90% of HNPCC families with identified germline mutations, hMLH1
and hMSH2 are accountable for the disease (http://www.nfdht.nl). The most
sensitive mutation detection technique is considered to be direct DNA
sequencing. However, sequencing of the 35 exons of hMLH1 and hMSH2 proves
to be technically demanding, time consuming and expensive6.
In the detection of sequence variations in disease genes, high sensitivity is
fundamental. The most widely employed mutation scanning techniques in
laboratories today range from relatively simple methods eg. single-strand
conformation analysis (SSCP) and heteroduplex analysis, to the more complex
procedures such as direct sequencing, protein truncation test (PTT) and
denaturing gradient gel electrophoresis (DGGE)7. SSCP and heteroduplex
analyses tend to lack sensitivity, whilst the more sensitive methods are often
labour intensive, expensive and time consuming. For the optimal detection of
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mutations in large numbers of DNA fragments, the scanning methods should be
sensitive, non-hazardous, relatively inexpensive and fully or at least semi-
automated to minimise time and labour costs. To satisfy clinicians and their
patients, such techniques should also have a rapid turnover time. The above
criteria seem to be fulfilled by the recently established denaturing high
performance liquid chromatography (dHPLC) method, developed primarily as a
pre-screening method in the identification of sequence variations in a number of
disease genes.
dHPLC is based on the detection of heteroduplexes in short segments of DNA by
ion-reverse phase high performance liquid chromatography8. Partial heat
denaturation within an acetonitrile gradient leads to the separation of the DNA
strands, resulting in the formation of hybrid wild type/mutant heteroduplexes.
These heteroduplexes have a reduced column retention time and hence an
altered mobility compared to their homoduplex counterpart. The most obvious
advantages of the dHPLC method include low cost, the use of automated
instrumentation and the speed of the analysis (5 minutes per sample).
This technique has been successfully employed in the detection of mutations and
polymorphisms in the Y chromosome9, exons from the factor IX and
neurofibromatosis type 1 genes10, rearranged transforming (RET), cystic fibrosis
transmembrane conductance regulator (CFTR) and phosphatase and tensin
homologue on chromosome 10 (PTEN) genes11, BRCA1 and BRCA212,13,14 and
hMLH1 and hMSH215,16. The sensitivity of dHPLC for hMLH1 and hMSH2
mutation detection has been previously described by Holinski-Feder et al15 to be
approximately 97%.
Due to the previously stated advantages of the dHPLC method, the sensitivity
reported for the detection of mutations in genes related to the HNPCC syndrome,
and the relatively large number of colorectal cancer patients whom this rapid and
inexpensive technology may benefit, including those in our research cohort
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suspected of HNPCC but proving to be mutation negative after screening was
complete, we decided to optimise the protocol for dHPLC for use in our lab.
I was able to develop the dHPLC protocol for the following genes and DNA
segments; hMLH1, hMSH2, hMSH6, and hMYH genes, the APC mutation cluster
region and the promoter regions of hMLH1 and hMSH2.
Methods
i) The WAVE System Hardware:
Powering Up the WAVE System:
- Each hardware module should be powered up in the following order:
-    Interface
-    Pump
-    Chiller
-    Autosampler
-    Oven
-    UV detector
-    Degasser
- With the L7200 Autosampler, the chiller module MUST be powered up
             BEFORE the Autosampler
- Each module performs a self-initialisation and one of the following
            messages should appear:
-    D-Line System is not ready
-    E5
- NB 1: If these messages do not appear, the module is not in D-Line
            (communication mode). Switch off all hardware modules, in reverse order
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            ie. Degasser to Interface, and switch on again. Also check all connecting
            cables at the back of each hardware module for loose wires/plugs.
Powering up the WAVE System computer and WAVEMAKER Software:
-    Press the power button on the computer to start
-    Press CTRL + ALT + DEL simultaneously for the LOGIN window to appear
-    In the User Name field type ADMINISTRATOR. Leave the Password field
     blank
-    On the desktop Transgenomic folder, double click the D-7000 HSM icon
-    Click on the hardware status button on the left side of the screen: 
-    Click the Initialise button on the toolbar
-    WAVEMAKER Software initialises each of the systems' modules. The
     following values should appear in the hardware boxes, after 2-3 minutes, if all
     components have been properly connected and turned on:
-    Interface Module:  D-7000
-    Autosampler :  L-7250
-    Pump A :  L-7100
-    Pump B :  /
-    Pump C :  /
-    Oven :  L-7300
-    Detectors :  L-7400
-    If these values do not appear, do as previously ie. NB 1,  and repeat the
     Initialisation step
-    Once all components are confirmed and values appear correctly on the
    hardware status dialog box, click OK and close the HSM software
Preheating the Oven:
-    Press the SET MONIT button on the keypad of the oven
-    Press the UP/DOWN arrows to set the temperature to 50°C
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WARNING: Failure to preheat the oven before commencing buffer flow may
result in damage to the DNASep Cartridge
Purging the Pump:
-    The pump should be purged daily
-    Open the drain valve on the front right of the pump, anticlockwise
-    Manually set the pump to purge the lines by pressing MANUAL SET on the
     L7100 keypad. Enter the following percentages: B 33%, C 0%, D 33%. Line A
     will automatically be set at 34%
-    Enter 0.9 ml/min for pump flow rate and an upper pressure limit of 3600 psi.
-    Press ENTER
-    Press PUMP ON/OFF to start the pump
-    Press PURGE
-    Continue purging until all air bubbles have been eliminated from the eluant
     lines; 1-5 minutes
- Switch off pump and close drain valve again
Equilibrating the System/DNASep Cartridge:
-    Ensure the oven temperature is greater than 40°C before starting the buffer
     flow through
-    Press the MANUAL SET button on the autosampler keypad to set the
      following conditions: Buffer A 50%, Buffer B 50%, flow rate 1.5 ml/min and
      3600 psi
-    Press the PUMP ON/OFF button on the keypad to start the pump
-    Allow the system to equilibrate for 10 minutes
-    Longer equilibrium times, eg. 40-60 mins are necessary for DNASep
     Cartridges that have been stored, new columns, after Active CleanTM flush or
     if the buffer bottles have run dry.
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NB. If the buffer bottles have been left to run dry, equilibrate until the Sample and
Reference numbers displayed on the UV Detector are similar ie. within 10-20
units of eachother
Priming the Autosampler:
-    The Autosampler can be primed during the purging step to save time
-    Press the WASH button on the Autosampler 3-15 times, until all air is
     removed from the syringe inlet  line
NB.  The Autosampler should be primed before the beginning of every project. If
the Autosampler is not primed, inconsistent injections, loss of intensity or air
spikes may be detected in the chromatograms.
ii) Setting up Methods:
Mutation Detection Analysis using the Rapid DNA Option:
1.   Open the WAVEMAKER Software main window
2. Click the App. Type button
3. Select the Mutation Detection button
4. Select the Rapid DNA check box
5. Click the Apply button
6. Click the Sequence button. The DNA sequence page appears
7. In the sequence box, enter the DNA sequence of the DNA sample to be
investigated. This can be copied and pasted from a word file. NB. ensure the
sequence includes the primer and T7/SP6 sequences. See Tables 1- 6 for
sequences used in our analyses for
      the MLH1, MSH2, MSH6, and MYH genes, the APC mutation cluster region
      and the  MLH1 and MSH2 promoter regions
8. Click the apply button. The Oven Temp field on the Navigator Bar is
automatically updated
9. Click the Gradient button. The gradient page appears
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10. Verify that the entries in the Gradient Parameters area are appropriate. If any
changes need to be made check the Edit Table box and enter the desired
values. Ensure the Stop Equilibrate Time is set to 3 minutes and the Flow
Rate is 1.5 ml/min
11. If any changes are made, click the Apply button
12. Save method. You must make and save a separate method for each exon of
each gene, under File, Save Method
13. Give the method name as: Gene, exon and temp.
14. At least 2 temperatures for each exon should be run in order to incorporate all
melting domains. A second temp. can be set as follows:
-    Carry out steps 2-6 as previously stated
-    Click the Melting button. The Melting Domains page appears
-    The first temp. you set should be automatically shown as you click the
     Calculate buttons
-    In the first temperature box, change the value to be ca.3°C more. The melting
     domain graph should change accordingly
-    In the Oven Temp. field on the Navigator Bar change the temp. to the value
     you have chosen as your second analysis temperature. Click on any other
     field  in the Navigator bar to have this change accepted
-    Continue with steps 9-13 as previously stated
-    See Tables 7–12 for the melting temperatures we set for our use in analysing
     the exons of MLH1, MSH2, MSH6, and MYH genes, the APC mutation cluster
     region and the MLH1 and MSH2 promoter regions
Creating a Project:
-    Open the WAVEMAKER Software main window
-    Click the App. Type button
-    Select the Mutation Detection button
-    Select the Rapid DNA check box
-    Click the Apply button
-    Select the Sample Table tab. The Sample Table appears
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-    Review the Vial, Volume, Injection, Sample Name and Method fields on the
     Sample Table. All other fields can be left blank and are filled automatically
-    Set up at least 2 blank samples to give the column and the oven enough time
     to reach equilibrium. Two rows in the sample table with the same, following
     values:
-    Vial =  1
-    Volume =  0
-    Injection =  1
-    Sample Name =  Blank
-    Method =  Mutation
-    The Vial field should correspond to the position on the 96 well plate ie.
      Sample 1 = Vial 1 on the Sample Table = Well A1 on the 96 plate
Sample 2 = Vial 2 on the Sample Table = Well B1 on the 96 plate
Sample 3 = Vial 3 on the Sample Table = Well C1 on the 96 plate etc
-    The Volume field should be set to 5 to allow an uptake of 5l from each
sample
-    The Injection field should be set to 1 to permit only one injection per sample
-    The Sample Name field should contain all details concerning the sample
      being run. The details stated here will be the only ones related to the
      chromatogram in the results section. Hence , it is important here to state the
      sample name, gene, exon and run temp.
-    The Method field should correspond to the sample exon being analysed. Go
      to File on the menu bar and open method. A copy of the method is made in
      the project's folder and can be selected from Meth. Name column drop-down
      list. The Sequence field will be automatically filled and will relate to the
      method file selected
-    When the Sample Table is complete, select File from the menu bar. Select
     Save Project As and type the name of the project in the File Name field
-    Click the Save button. Samples cannot be run until the project has been
     saved
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-    If the Samples are already loaded into the autosampler, click Run Samples to
      begin the analysis
III) Viewing Results:
To View Chromatograms:
-    On the results table, click on the sample row for which you want to view a
      chromatogram
-    If you want to view all chromatograms in a subset, select the Show All check
     box above the assigned subset
-    To fine-tune chromatogram displays, click the right mouse button on the
     displayed chromatogram and select Chart from the menu. Chart details, axes
     and off-set values can be changed
Configuring and Printing Reports:
-    Select File from the menu bar
-    Select Print Report. The report window appears and allows you to select
     which page of information to display or print
-    Click the Build Report button
-    If you want to print the report, click the Print button on the top of the Report
     Preview area. Select the appropriate options and click OK. The report prints
-    If you do not wish to print the report, click Cancel
IV) Shutting Down the WAVE System:
Shut Down for 2-4 Days:
-   When the WAVE system is not in use, it is important not to shut down the
    system completely but keep the pump running at a very low flow rate
-   The column can be maintained for 2-4 days by pumping the column at a flow
    rate of 0.05 ml/min with 50% Buffer B
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Shut Down for More than 4 Days:
-    Place all buffer lines in Solution D
-    Flush the system, including the column, for 30 minutes
-    Remove the column and close the black screws
-    Place the black union into the position of the removed column
-    Now shut down the system top to bottom ie.Degasser to Interface
V) Trouble Shooting:
1. NO PEAK:
 Failure of the PCR reaction: repeat PCR
 Air in the syringe: wash syringe at least 15 times
 Failure of syringe to take up sample: watch the syringe when either
washing or whilst it is taking up sample. If no sample is taken up, check
the syringe seal and replace if necessary. Also, check the syringe is tightly
screwed into place. If this doesn't solve the problem, replace syringe
 Check the syringe is going to the correct Z value within the sample tube:
96 well plate = 35
PCR tube       = 32
2. HIGH SPIKES DURING BLANK RUN
 Air in the syringe: WASH syringe at least 15 times
 Air in the system: run buffers 1 by 1, 100% through the system for 2-5
minutes. Then run A, B and D at 100% for 10 minutes. Continue until the
Reference and Sample values on the UV detector are roughly the same
ie. within 20 units of eachother
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VI) General Etiquette:
Please remember that we are using the lab space and equipment of
another research group. Hence, recycle empty cardboard boxes and empty
bottles in the room next to the 7th floor elevators.
All waste solutions should be taken to the waste solutions room on the 7th
floor (ask Anna or Jian for directions).
Tables of primers used in PCR amplification of genes and DNA segments:
MLH1
Exon
Sense Strand Primer 5I-3I Antisense Strand Primer 5I-3I
1 aggcactgaggtgattggc ctcacttaagggctacga
2 aatatgtacattagagtagttg gagtcaggacctttctctg
3 agagatttggaaaaatgagtaac cctgtgatgacattgt
4 aacctttccctttggtgagg gcctaggtctcagagtaatc
5 gattttctcttttccccttggg gtaaattgttgaagctttgtttg
6 gggttttattttcaagtacttctat gctcatacattgaacagttgctgagc
7 ctagtgtgtgtttttggc ggtggagataaggttatg
8 ctcagccatgagacaataaatcc ccatcacattattttggaac
9 caaaagcttcagaatctc ccactcacaggaaacacccacag
10 catgactttgtgtgaatgtacacc cagatgttctatcaggctctcctc
11 ggctttttctccccctccc cgtgagagcccagatttt
12a ctctccactatatatatatatata gcagcctctgagcaaac
12b gatggttcgtacagattcccg ctacctcctttattctgtaataa
13 tgcaacccacaaaatttggc ggttttggaaatggagaaag
14 tggtgtctctagttctgg gcagagctactacaacaatg
15 cccattttgtcccaactgg ctgaaatttcaactgatcg
16 catttggatgctccgttaaagc caaataaaatttccagccgggtg
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17 ggaaagcactggagaaatggg cggtacatgcatgtgtgctggaggg
18 taagtagtctgtgatctccg aaacggagatcacagactac
19 gacaccagtgtatgttgg catcccaacatacactggt
Table 1: Primers sequences used in the dHPLC analysis of hMLH1. Sense
strand primers and antisense strand primers also had the T7 and SP6 sequences
attached, respectively
MSH2
Exon
Sense Strand Primer 5I-3I Antisense Strand Primer 5I-3I
1 tcgcgcattttcttcaacc gcgtgctggggagggac
2 gaagtccagctaatacagtgc gagtagaaaaataaaaatgtgaag
3 gcttataaaattttaaagtatgttc ggagattccaggcctaggaaaggc
4 tttcatttttgcttttcttattcc gaaggatatttctgtcatat
5 ccagtggtatagaaatctt gggttaaaaatgttgaatgg
6 gttttcactaatgagcttgcc cccacatgattataccac
7 gacttacgtgcttagttg ccttcaactcatacaatatatac
8 atttgtattctgtaaaatgagatc gttatttttaaaaagcaaaggcc
9 gtctttacccattatttatagg ggaataattcttttgtct
10 ggtagtaggtatttatggaatac ccctaaatgctctaacatg
11 cacattgcttctagtacac gttctgaatgtcacctgg
12 attcagtattcctgtgtac gctttgtgggggtaacg
13 cgcgattaatcatcagtg gatagaaatgtatgtctctgtcc
14 taccacattttatgtgatgg gggaaacttactaccc
15 ctcttctcatgctgtccc gtttaacttagcttctctat
16 taattactaatgggacatt aaaatcccagtaatggaatgaaggta
Table 2: Primers sequences used in the dHPLC analysis of hMSH2. Sense
strand primers and antisense strand primers also had the T7 and SP6 sequences
attached, respectively
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MSH6
Exon
Sense Strand Primer 5I-3I Antisense Strand Primer 5I-3I
1 agatgcggtgcttttaggag agttggcttgaatgagtgca
2 tgccagaagacttggaattg ctgccatgtgtgtgtgtttg
3 gatggggtttgctatgttgc gaagaaagggggagggtgta
4a aatgaaaaacagtggctgca gcatttcatcagaaaccaag
4b ttaaaaggaaaagctctagg ggctttcctgaaattgcattt
4c attcatgaaaggcaactggg ggaaatctctcaaaggaaac
4d caagttttatttgaaaaagg gcagtgacattaaacaactt
4e aagcctatcaacgaatggtg cctgatttgactgtagaatt
4f ctctctgcagacaaaaaatcc gcttgttctcaggctttgat
5 ctgataaaacccccaaacga ggtgatcattttccaaacacag
6 ttgtgaaagttgttttagagtgcc aagctggagtgcaatggc
7 gcccagccaataattgcata actcaccattgtggcacaga
8 tgctaagcagactcgtgtag gctagcacatgtatcgctaa
9 attcggttttttgagaggg gg aagggatgatgcactatga
10 taaaaggggaagggatgatg tctgaatttaccacctttgtcaga
Table 3: Primers sequences used in the dHPLC analysis of hMSH6. Sense
strand primers and antisense strand primers also had the T7 and SP6 sequences
attached, respectively
MYH
Exon
Sense Strand Primer 5I-3I Antisense Strand Primer 5I-3I
1 tgaaggctacctctgggaag aggagacggaccgcaagt
2 ggctgggtctttttgtttca gggccacaacctagttcctt
3a ctgtgtcccaagaccctgat ttggtcgtaccagcttagca
3b agctgaagtcacagccttcc cacccactgtccctgctc
4 cctccaccctaactcctcatc aaagtggccctgctctcag
5 caggtcagcagtgtcctcat gtctgacccatgacccttcc
6 gtctctttctgcctgcctgt tcacccgtcagtccctctat
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7 cgggtgatctctttgacctc gttcctaccctcctgccatc
8 tcttgagtcttgcactccaatc aaagtgggggtgggctgt
9 gctaactctttggcccctct cacccttgttaccccaacat
10 ctgcttcacagcagtgttcc gacttctcactgccccttcc
11 acactcaaccctgtgcctct ggaatggggcttctgactg
12a cttggcttgagtagggttcg ggctgttccagaacacaggt
12b gagtggtcaacttccccaga cacgcccagtatccaggta
13 agggaatcggcagctgag gctattccgctgctcactta
14 aggcctatttgaaccccttg caacaaagacaacaaaggtagtgc
15 ccctcacctccctgtcttct tgttcacccagacattcgtt
16a ctacaaggcctccctccttc gctgcactgttgaggctgt
16b gccagcaagtcctggataat acatagcgagacccccatct
Table 4: Primers sequences used in the dHPLC analysis of hMYH. Sense strand
primers and antisense strand primers also had the T7 and SP6 sequences
attached, respectively
APC
MCR
Exon
Sense Strand Primer 5I-3I Antisense Strand Primer 5I-3I
1 tgcaaagtttcttctattaaccaa atttaggtgacactattctgcttcctgtgtcgtctg
2 ttcattatcatctttgtcatcagc atttaggtgacactattggaacttcgctcacaggat
3 gcagaaataaaagaaaagattggaa atttaggtgacactatctttgtgcctggctgattct
4 ctagaaccaaatccag cagact atttaggtgacactatgaacatagtgttcaggtgga
ctttt
5 agcgaaatctccctccaaaa atttaggtgacactatctggcaatggaacgactctc
6 cccactcatgtttagcagatg atttaggtgacactatgtttgtccagggctatctgg
7 tggaatggtaagtggcattat atttaggtgacactatcagcagtaggtgctttattttta
gg
8 tcctcaaacagctcaaacca atttaggtgacactatagcatctggaagaacctgg
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a
9 a agcaagctgcagtaaatgct atttaggtgacactatatggctcatcgaggctca
10 aagtactccagatggattttcttg atttaggtgacaqctatggctgctctgattctgtttca
11 atgcctccagttcaggaaaa atttaggtgacactattcaatatcatcatcatctgaat
catc
12 aaaaactattgactctgaaaaggac atttaggtgacactatggtggaggtaattttgaagca
Table 5: Primers sequences used in the dHPLC analysis of the APC mutation
cluster region (MCR). Sense strand primers and antisense strand primers also
had the T7 and SP6 sequences attached, respectively
Promoter Region Sense Strand Primer 5I-
3I
Antisense Strand Primer
5I-3I
MLH1 promoter region agtagccgcttcaggga ctcgtccagccgccgaataa
MSH2 promoter region gctgagtaaacacagaaa ctcctggttgaagaaaatgc
Table 6: Primers sequences used in the dHPLC analysis of the hMLH1 and
hMSH2 promoter regions. Sense strand primers and antisense strand primers
also had the T7 and SP6 sequences attached, respectively
Tables of melting temperatures used in dHPLC analysis
MLH1
Exon
Tm 1 °C Tm 2 °C
1 62.3 63.1
2 56.1 59.1
3 55.6 57.6
4 55.7 58.7
5 55.8 58.8
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6 56.1 58.1
7 56.0 57.0
8 53.8 57.8
9 56.9 57.9
10 58.6 59.0
11 57.7 62.7
12a 55.5 58.5
12b 59.5 60.5
13 57.7 59.7
14 58.1 59.1
15 56.7 57.7
16 57.5 59.5
17 58.0 60.0
18 56.8 59.8
19 55.5 58.5
Table 7: Melting temperatures (Tm°C) for MLH1 heteroduplex fragment analysis
MSH2 Exon
Tm 1 °C Tm 2 °C
1 65.7 66.1
2 55.0 56.0
3 57.4 59.4
4 50.6 53.6
5 53.1 57.1
6 55.5 58.5
7 54.2 57.2
8 54.7 57.7
9 56.4 57.4
10 55.9 57.9
11 55.0 56.0
12 56.0 59.0
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13 55.8 57.8
14 55.7 57.7
15 57.7 58.3
16 55.3 57.3
Table 8: Melting temperatures (Tm°C) for MSH2 heteroduplex fragment analysis
MSH6 Exon
Tm 1 °C Tm 2 °C
1 65.3 67.3
2 56.2 60.2
3 58.1 60.1
4a 57.7 58.7
4b 58.2 59.2
4c 57.6 58.6
4d 57.6 58.6
4e 56.8 57.8
4f 57.7 58.1
5 57.3 58.3
6 55.1 56.1
7 53.9 54.9
8 56.1 57.1
9 55.5 57.5
10 54.0 57.0
Table 9: Melting temperatures (Tm°C) for MSH6 heteroduplex fragment analysis
MYH Exon
Tm 1 °C Tm 2 °C
1 62.7 66.7
2 60.9 63.9
3a 61.7 62.7
3b 62.5 64.5
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4 61.4 62.4
5 61.7 63.7
6 60.4 63.4
7 60.7 64.7
8 61.1 66.1
9 60.9 64.9
10 61.5 65.5
11 62.2 64.2
12a 62.5 64.5
12b 62.1 65.1
13 63.6 65.6
14 59.6 63.6
15 59.6 63.6
16a 60.8 62.8
16b 56.3 61.3
Table 11: Melting temperatures (Tm°C) for MYH heteroduplex fragment analysis
APC Exon
Tm 1 °C Tm 2 °C
1 54.3 56.3
2 57.6 58.1
3 58.0 60.5
4 59.4 60.0
5 59.7 60.5
6 59.1 59.6
7 58.5 60.5
8 58.5 60.5
9 59.2 60.2
10 58.0 58.8
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11 56.1 57.9
12 55.5 57.8
Table 12: Melting temperatures (Tm°C) for APC mutation cluster region
heteroduplex fragment analysis
Promoter Region
Tm 1 °C Tm 2 °C
MLH1 promoter region 53.3 55.3
MSH2 promoter region 56.7 58.7
Table 13: Melting temperatures (Tm°C) for Promoter Region region heteroduplex
fragment analysis
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Appendix II
Optimization of the Laser Capture Microdissection (LCM)
protocol for use in the screening of patients with familial
colorectal cancer syndromes
This procedure was optimised for use in the Human Genetics Lab
by Anna M Russell
Introduction
A long standing hurdle for researchers in the field of cancer genetics is the
difficulty in characterising molecular changes that result during cancer
progression, where specific normal epithelial cells become premalignent cells
and then further transform into invasive and metastatic cancer (1 Liotta 2000). In
attempts to understand the molecular forces driving such an evolution,
comparisons are made between samples taken from the healthy appearing
epithelium, the premalignant cells, and the invasive carcinoma, all from the same
tissue sample, taken from the same patient. This enables fluctuations of
expressed genes or alterations in the cellular DNA to be correlated to the
transition from one disease stage to the next. However, for this to be
accomplished, it is desirable to sample pure cells in different stages of cancer
development without the contamination of neighbouring, non specific cells.
The procurement of pure cells from specific microscopic regions of tissue
sections is achievable by the method of Microdissection. Tissue samples are
heterogenous and complicated structures with many different cell types
interlocked in morphologic units with dense adhesive interactions with adjacent
cells, connective stroma, blood vessels, glandular and muscle structures,
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adipose cells, and inflammatory or immune cells. The diseased cells of interest
are surrounded by these heterogenous tissue compositions and epithelial cells,
precancerous cells or invading cancer cells may account for less than 5% of the
total volume of the tissue biopsy sample. Hence, microdissection is paramount to
the study of evolving tissue lesions in healthy tissues.
A new technology, known as Laser Capture Microdissection (LCM) was initiated
by NIH (2 Emmert-Buck, 1996) and subsequently commercially developed
through a Collaborative Research and Development Agreement (CRADA)
partnership with Arcturus Engineering Inc. (650-962-3020).
The theory behind LCM is very simple and has been developed to provide a fast
and dependable method of capturing and preserving specific cells from tissue,
under direct microscopic visualisation. A laser beam and special transfer film are
used to extract a microscopic homogeneous cellular subpopulation from its
complex tissue milieu. This subpopulation can then be compared with adjacent
interacting, but distinct, subpopulations of cells in the same tissue.
The LCM method affords a number of advantages.
1. Under microscopic direction it is possible to separate multiple identical
cells, and catapult only those cells of interest. The rest of the tissue
remains intact and ready for further dissection.
2. The elegance of this technique is that no tissue is destroyed in the
process. LCM operates by positive rather than negative selection. LCM
creates no chemical bonds to the targeted tissue that may alter
subsequent molecular analysis.
3. The morphology of the transferred cells is preserved and can be readily
visualised under the microscope.
4. Targeting precision of cells is 1m with the targeted spots as small as 3-
5m.
5. The user can capture from 1000-3000 shots on one transfer cap.
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6. Depending on the size of the cells the total number of captured cells can
be up to 6000.
7. As each shot takes less than a second to perform, a large number of pure
cells can be captured from a heterogeneous tissue sample in a very short
period of time.
However, it should be noted that the LCM method employs specialised,
expensive technology and requires training and practice for protocol optimisation.
Figure 1: The Laser Capture Microdissection system and methodology
Appendix II
191
A number of different molecular analyses have been conducted successfully on
cells procured by LCM. These include genomic analyses such as loss of
heterozygosity analysis, restriction fragment length polymorphism analysis, DNA
methylation analysis, fluorescence in situ hybridization, and comparative
genomic hybridization.
Gene expression analysis (ie. RNA analysis) has been achieved from LCM
samples using reverse transcription PCR, the construction of cDNA libraries and
differential hybridization on high density spotted nylon filters, glass microarrays,
and recently on high density oligonucleotide arrays after amplification of RNA.
Successful proteomic analysis has been performed by carrying out LCM in
conjunction with western immunoblotting, solid-phase sequential
chemiluminescent immunometric assay, and one dimentional and two
dimentional polyacrylamide gel electrophoresis (PAGE). See references for the
above application details.
With the LCM technique established in our laboratory for colorectal tumour tissue
samples, we aim to isolate pure microscopic clusters of cells from the colon and
rectum, in order to investigate the clonal evolution, both inter-tumoral and also
between patients.
Methods
Preparation of Slides for LCM: in flow cabinet:
1. Dip slides in 100% EtOH
2. Place the LCM membrane directly ontop of slide NB. to facilitate
membrane mounting without wrinkles, the membrane should be
smaller than the object slide and the slide should be wet with alcohol
3. With backing paper from the membrane, smooth out membrane
creases
4. Leave to dry well
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5. Apply glue (Entellan) to 2 opposite membrane edges (top + bottom of
slide). Use a pipette with tip
6. Leave to dry well
7. Apply ca. 20ul of poly-L-lysine to the membrane and spread carefully
with a pipette  tip NB. avoid any leakage underneath the membrane, as
this may result in problems with the LCM later.
Tissue Sectioning:
- Fix paraffin tissue blocks securely into the Microtome
- Cut tissue sections 10m thick
- Allow sections to settle in a heated waterbath (40°C)
- Transfer the sections from the waterbath onto the LCM pre-prepared slides
(see above)
- Smooth out the sections to remove wrinkles and aid adhesion to slides
- Allow to dry overnight at room temperature and in flow cabinet
- 
	 Some histopahthology labs use an adhesive in the water bath to
better adhere the tissue section to the slide, but this may result in
reduced LCM transfer of tissue. Also, baking the sample onto the
slide may bond it too strongly and prevent LCM transfer.
	 Careful attention should be given during sectioning to prevent
'carryover'. Carryover contamination of one specimen from another
or transfer of material from one region of a section to another can
lead to spurious results. The microtome used to cut sections should
be kept clean and excess paraffin and tissue fragments should be
wiped from the area with xylene between each block. Alternatively,
a fresh microtome blade should be used for each block.
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Tissue Staining:
Deparaffinization:
Xylene 2 x 30s
Ethanol absolute 1.5 min
Ethanol 96% 1.5 min
Ethanol 70% 1.5 min
Use a pipette to carefully wash away alcohol with dH2O (take care
not to wash dissolving glue from the membrane over the tissue
section)
Staining:
Toluidine Blue 10s
Rinse with water, again using a pipette
Fixation:
Ethanol 96% 30s
Ethanol 96% 30s
Ethanol absolute 30s
Ethanol absolute 30s
Allow sections to dry for at least 30 minutes (preferable overnight) at 37°C before
attempting LCM.
Laser Capture Microdissection:
1. The operator is able to view the tissue and select the desired microscopic
clusters of cells for analysis. This is done by drawing around the desired
cell(s) with the mouse pointer (Figure 1)
2. For laser microbeam microdissection the objective lens of the microscope
converges the laser light to produce extremely high density focal energy.
The focused laser beam induces a localised photodecomposition, without
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detectable heating, ablating the tissue in the narrow focal point without
damage to the surrounding tissue (Figure 2)
3. By increasing the light intensity and delivering a pulse of laser energy just
below the focal plane of the dissected specimen, the energy pulse
created, drives the specimen up and out of the section into a waiting
collection vessel (Figure 3)
4. By re-focusing the microscope lense, the catapulted cell(s) can be
visualised in the collection cap above the slide. If the tissue sample has
been stained and there is solution in the collection cap, it is possible that
the solution has changed colour with the dye, confirming the cell(s)
was/were successfully captured.
Table 1: Values for microdissection of 10 m sections of colorectal tumour tissue
stained with Toludine Blue and mounted on LCM membrane covered slides.
LCM Values on Software
Program
Values for cutting
colorectal tumour tissue
Values for catapulting
cell(s)
Cut Focus 80 micron diameters 70 micron diameters
Cut Energy 70 micron diameters 100 micron diameters
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Figure 1:
The operator views the tissue section (colorectal
tumour), under the microscope and selects the
desired cluster of cells to be catapulted
Figure 2:
The focused laser beam induces a localised
photodecomposition ablating the tissue in the
narrow focal point without damaging the
surrounding tissue. The desired cluster of cells
are ready to be catapulted.
Figure 3:
By increasing the light intensity and delivering
a pulse of laser energy just below the focal plane
 of the dissected specimen, the energy pulse created,
 drives the specimen up and out of the section into
 a waiting collection vessal.
*All actual pictures taken during optimization
procedure: well differentiated colorectal
carcinomas from the sigma.
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